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Women carry more than half the burden of HIV disease globally and this burden is even 
higher in sub-Saharan Africa (SSA). Young women, in particular, are at disproportionate risk 
of HIV infection in South Africa. Understanding risk behaviours and factors associated with 
ability to negotiate safe sex and condom use is one of the key elements in curbing the spread 
of HIV. Sexually transmitted infections (STI) and bacterial vaginosis (BV), which cause 
female genital tract inflammation, have been identified as key drivers of the HIV epidemic. 
This inflammation, which is also present in the absence of symptoms, is associated with 
increased susceptibility to HIV infection. Although syndromic management of symptomatic 
STIs or BV at the first encounter with a health care provider is an important public health 
measure, its effectiveness is minimised because a substantial proportion of individuals have 
either asymptomatic infections or fail to recognise signs and symptoms of STI and are 
therefore excluded.  
Most new HIV infections in SSA occur among young people and particularly among young 
girls. Prompt diagnosis of acute HIV infection (AHI) is critical and benefits the individual as 
well as providing opportunities for public health intervention. In South Africa, the majority of 
HIV infections are due to infection with HIV-1 subtype C for which there is limited data 
compared to subtype-B HIV-1 infections.  
The overall aim of this study was to assess the impact of BV, STIs, and associated genital 
tract inflammation on acquisition of HIV-1 subtype C infections; and evaluate the rate of 
subsequent disease progression in women.  




i. to investigate STIs and genital tract inflammation as risk factors for HIV infection in 
high risk women and adequacy of syndromic management;  
ii. to evaluate the challenges associated with diagnosing recently acquired (acute) HIV 
infection in a subtype C prevalent population;  
iii. and to evaluate the relationship between clinical disease progression and genital and 
or systemic inflammation in high-risk women who became infected with HIV.  
We assessed the adequacy of syndromic diagnosis of STIs, compared with laboratory 
diagnosis of STIs, and evaluated the association between STI diagnosis and the risk of HIV 
acquisition in a cohort of high-risk women. Genital cytokine profiles and the degree of 
inflammation associated with common STIs and bacterial vaginosis were assessed. The most 
common signs and symptoms of acute HIV infection (AHI) were described and a clinical 
algorithm to identify acute HIV cases was developed. We investigated rates of HIV disease 
progression of subtype C–infected South African women. 
Methods: 
The CAPRISA 002 study was a prospective cohort study established to examine the 
pathogenesis and natural history of HIV-1 subtype C infection and to describe the 
immunologic, virologic and clinical characteristics of acute and early infection in KwaZulu 
Natal, South Africa. A total of 775 high-risk women were screened for HIV infection, and 
245 HIV-uninfected women were enrolled into the study. At each monthly visit for a total of 
24 months behavioural and clinical data were collected.  Cervico-vaginal lavage (CVL) 
samples were collected at enrolment and at each six month follow-up visits and were tested 
for STI pathogens (including Chlamydia trachomatis, Neisseria gonorrhoeae, herpes simplex 
virus type 2 (HSV-2) and Trichomonas vaginalis) and bacterial vaginosis. Forty-two 




 All women received monthly HIV-1 antibody and RNA testing and were assessed for AHI. 
Signs and symptoms at the visit with HIV-1 antibody or HIV-1 RNA positive test were 
compared to HIV negative visits. Logistic regression identified clinical predictors of AHI and 
a model-based score was assigned to each predictor to create a risk score for every woman. 
All women who seroconverted were followed up for more than five years and monitored for 
HIV disease progression. Rapid disease progression was defined as CD4+ T cell count 
decline to <350 cells/µl within two years post-infection. Serial clinical and laboratory 
assessments were compared using survival analysis and logistic regression models. 
CAPRISA had established several cohorts of HIV negative women to determine the 
feasibility of establishing cohorts and sites for HIV biomedical prevention trials. Women 
seroconverting in these studies were referred to the CAPRISA 002 study for longitudinal 
follow-up for HIV post seroconversion.   
Results: 
In this study, the HIV-1 prevalence at screening was 59.6% (95% CI: 55.9% to 62.8%). 
During a total of 390 person-years of follow-up, 28 new infections occurred, yielding a sero-
incidence rate of 7.2 (95% CI:  4.5 to 9.8) per 100 person-years. A total of 62 participants, 
including seroconvertors from other CAPRISA cohorts, were enrolled into the acute HIV 
infection Women from the HIV-1 negative cohort generally demonstrated a high level of 
knowledge on HIV/AIDS, and 60.3% reported use of condoms. Reported condom use at last 
sexual encounter varied slightly by partner type (57.0% with steady versus 64.4% with casual 
partners; p = 0.36), whilst self-perceived ability to choose to use a condom was significantly 
lower with steady partners compared to casual partners (20.8% versus 53.9%; p=0.01).  
An important finding was that vaginal discharge was a poor predictor of laboratory-diagnosed 




pathogen had clinical evidence of a discharge (yielding a sensitivity of 12.3% and a 
specificity of 93.8%). CVL cytokine concentrations did not differ between women with 
asymptomatic or symptomatic STIs; and were elevated in women with either asymptomatic 
or symptomatic STIs compared to women with no STIs or BV. Women with chlamydia or 
gonorrhoea had the highest genital cytokine concentrations, with 17/42 and 14/42 of the 
cytokines measured in CVL being up-regulated compared with women with no infections, 
respectively. While BV was associated with elevated pro-inflammatory cytokine 
concentrations in CVL, women with BV had lower levels of chemokines and haematopoietic 
cytokines than women with no infections or BV. HSV-2 reactivation was inflammatory, but 
yielded a comparatively lower level of inflammation than Chlamydia or gonnorhoea. 
Trichomoniasis, despite being relatively common in this cohort, did not cause significant 
changes in genital tract cytokine concentrations compared to women with no infections or 
BV. Genital infections did not influence plasma cytokine concentrations, suggesting that the 
compartments were not linked with respect to cytokine responses. Although laboratory-
diagnosed STIs were associated with increased risk of HIV infection [hazard ratio, 3.3 (95% 
confidence interval, 1.5 – 7.2)], clinical symptoms were not.                                                                       
Of the women who became infected, factors predictive of AHI included age, 25 years (OR = 
3.2; 1.4 – 7.1), rash (OR = 6.1; 2.4 –15.4), sore throat (OR = 2.7; 1.0 – 7.6), weight loss (OR 
= 4.4; 1.5 – 13.4), genital ulcers (OR = 8.0; 1.6 – 39.5) and vaginal discharge (OR = 5.4; 1.6 
– 18.4). A risk score of 2 correctly predicted AHI in 50.0% of cases. The number of signs and 
symptoms correlated with higher HIV-1 RNA at diagnosis (r = 0.63; p = 0.001). The 62 
acutely infected women were identified at a median of 42 days post-infection (IQR = 34 – 
59). Mean CD4 count dropped by 39.6% at 3 months and 46.7% at 6 months post-infection in 
women with pre-infection measurements. CD4 decline to <350 cells/µL occurred in 31%, 




cells/µL in 69%, 79%, and 81% at equivalent time-points. Predictors of rapid progression 
were CD4 count at 3 months post-infection (hazard ratio [HR], 2.07; 95% confidence interval 
[CI], 1.31–3.28; P = .002), setpoint viral load (HR, 3.82; 95% CI, 1.51–9.67; P = .005), and 
hepatitis B coinfection (HR, 4.54; 95% CI, 1.31–15.69; P = .017). Conversely, presence of 
any of HLAB*1302, B*27, B*57, B*5801, or B*8101 alleles predicted non–rapid 
progression (HR, 0.19; 95% CI, .05–.74; P = .016). 
Discussion/Conclusion: 
This study showed that syndromic STI diagnosis, which is dependent on clinical signs of 
vaginal discharge, was poorly predictive of laboratory-diagnosed STIs or BV and missed a 
significant proportion of women with asymptomatic infections. However, the level of genital 
inflammation, as measured by cytokine concentrations in CVL, was similar in women with 
symptomatic and asymptomatic infections and therefore place women at increased risk for 
HIV infection. While laboratory-diagnosed STIs and the presence of inflammatory cytokines 
in the genital tract were associated with increased susceptibility to HIV acquisition, vaginal 
discharge was not. Chlamydial infection was associated with the highest genital cytokine 
concentrations, followed by gonorrhoea, HSV-2, trichomoniasis, and BV. In regions where 
HIV is prevalent and STIs are managed syndromically, targeted screening of populations at 
risk for STIs is critical and urgently needed. 
Recognition of signs and symptoms of AHI is important for early diagnosis of HIV infection. 
The proposed algorithm of risk-stratifying individuals for AHI provides a useful clinical tool 
especially in resource-limited settings where there are limited or no routinely available tests 
for AHI. However, validation of the algorithm on another cohort is needed to assess its utility 
further. Point-of-care HIV antigen or viral load testing is needed, to detect asymptomatic, 




This cohort showed high rates of rapid disease progression, with nearly half of these subtype 
C–infected women progressing to a CD4+ T cell count of below 350 cells/µL within 2 years 
of infection. Implementing 2013 World Health Organization treatment guidelines (CD4+ T 
cell counts less than 500cells/µL) would require most individuals to start antiretroviral 
therapy within 1 year of HIV infection. The economic and health systems planning 
implicated by these findings need to be explored and addressed to guide policy makers as 
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1.1 Introduction, Aims and Objectives: 
 
 
Sub-Saharan Africa continues to be the region most disproportionately affected by the HIV-1 
 
epidemic, hosting more than half the globally infected population and home to 70% of all new 
 
HIV infections reported in 2012 [1]. Until recently, the natural history of HIV disease was 
 
based extensively on published data from subtype B infections most prevalent in better 
 
resourced countries, with very limited information being available from subtype C HIV 
 
infections, the commonest clade causing >95% of infections in Southern Africa [2, 3]. The 
 
Sub-Saharan African (SSA) epidemic is predominantly heterosexually transmitted with young 
 
women bearing the brunt of the disease. Even though the HIV prevalence amongst young men 
 
and women (18 – 24yrs) declined by 42% between 2001 and 2012 in SSA, prevalence remains 
 
more than twice as high in young women compared to men in this region [1]. This dissertation 
 
describes the establishment of a cohort of women from Durban, Kwa-Zulu Natal Province, 
 
South Africa at high-risk of HIV infection [2]. Women who self-identified as sex-workers and 
 
those who reported to have had more than 3 sex partners in the 3 months prior to enrolment, 
 
were recruited. In these women, clinical, behavioural, immunological and virological factors 
 
that influenced risk of HIV infection and subsequent disease progression were investigated and 
 
detailed studies of the clinical course of HIV infection were conducted. Prior to the data 
 
generated from the cohort described in this thesis, limited data existed on factors that influenced 
 
HIV-1 subtype C acquisition, establishment of viral set-point and impact of set-point on disease 
 
progression, if any, in the South African population. 
 
 
The primary aim of this dissertation was to investigate the impact of sexually transmitted 
 
infections (STIs), bacterial vaginosis (BV) and genital tract inflammation on risk for HIV
9 
 
acquisition and rate of disease progression in subtype C infected women. The specific 
 
objectives of the study were: 
 
 
1. To investigate how STIs, BV, their clinical presentation and associated inflammation 
 
influenced the risk of HIV infection in women. 
 
2. To define a clinical algorithm for diagnosing acute HIV infection in this population, by 
 
defining the acute seroconversion syndrome. 
 
3. To describe clinical, immunological and genetic factors associated with HIV disease 
 






1.2 Thesis Framework: 
 
 
Chapter One: This chapter gives a brief introduction and rationale of the study, defining the 
 
aim and objectives. It also describes the framework of the thesis, summarising the objectives 
 
of each publication included in the thesis. 
 
 
Chapter Two: This chapter contains the literature review that informs the conduct of this 
 
study. It describes the relative risk for HIV infection and HIV disease burden seen in young 
 
females of countries where HIV subtype C predominates. The challenges associated with 
 
diagnosing STIs and BV, especially in females in poorly resourced communities, are explored 
 
as well as the impact of genital tract inflammation linked to these genital infections on 
 
acquisition of HIV. Described herein, is the importance of and complexities in diagnosing HIV 
 
during acute infection, while these women have high viraemia and are at increased risk of 
 
transmitting the virus to their sexual partners. The natural history of HIV-1 infection, including 
 
an evaluation of the number of infectious virions required to establish an infection, is discussed 
 





Chapter Three: This chapter contains the manuscript describing how the study cohort was 
 
established; the challenges associated with recruiting HIV negative cohorts in high prevalent 
 
settings and how this affects HIV prevention trials like HIV vaccines or microbicide studies 
 
(van Loggerenberg, Mlisana et al., PLoS One, 2009). This paper importantly sets the scene for 
 
the following manuscripts as it defines the methods used to enrol HIV-uninfected women, who 
 
were then followed longitudinally for HIV acquisition. A second manuscript defining the socio- 
 
behavioral characteristic of the cohort is included in this chapter (van Loggerenberg, et al., 
 
PLoS One 2012). All of the women who seroconverted in this study were confirmed to be 
 
infected with a subtype C strain of HIV. 
 
 
Chapter Four: The poor performance of syndromic management of STIs and/or BV in women 
 
at high-risk of HIV infection is presented in this Chapter (Mlisana et al., Journal of Infectious 
 
Diseases, 2012). The current WHO recommendation of managing STIs syndromically excludes 
 
a significant percentage of individuals who do not have clinical signs or symptoms. This paper 
 
astutely demonstrates how, even though asymptomatic, these women have evidence of genital 
 
inflammation as shown by raised inflammatory cytokines in cervicovaginal lavages, and are at 
 
higher risk of HIV acquisition. This paper on the sensitivity of syndromic management to detect 
 
STIs or BV in a setting of high HIV risk attracted an editorial comment which is included in 
 
the thesis, highlighting the importance of the findings. 
 
Chapter Five: This Chapter evaluated the genital cytokine profiles and the degree of 
 
inflammation associated with common STIs and BV (Masson, Mlisana et al., 2014). The genital 
 
cytokine profiles associated with distinct STIs and/or BV in women at risk of HIV infection 
 
are described. Asymptomatic genital tract infections were highly prevalent in this cohort, and 
 
were associated with significantly increased genital inflammatory cytokine concentrations, and 
 
a high HIV transmission or acquisition risk.
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Chapter Six: The high prevalence and incidence of STIs and BV in this population increases 
 
the risk of HIV acquisition. As acute HIV infection (AHI) is associated with non-specific signs 
 
and symptoms, diagnosis poses a challenge. However, diagnosis of acute infection is critical 
 
as these individuals are at greater risk of transmission to their sexual partners because of the 
 
high viraemia associated with acute infection. In this chapter, a scoring system is defined for 
 
use in poorly resourced countries with limited laboratory resources (Mlisana et al., PLoS One, 
 
2013). This clinical algorithm utilises commonly observed symptoms and signs at acute sero- 
 
conversion to identify clinical predictors of AHI using logistic regression analysis. 
 
 
Chapter Seven: In this chapter, the relationship between genital inflammation during AHI and 
 
the subsequent rate of disease progression was evaluated (Roberts, Passmore, Mlisana, et al. 
 
Journal of Infectious Diseases, 2012). Elevated genital tract inflammatory cytokine 
 
concentrations during earlier HIV infection were associated with higher viral set-points and 
 
lower CD4 counts at 12 months post-infection, suggesting that genital inflammation around 
 
the time of infection may influence the rate of disease progression as well their risk of acquiring 
 
HIV in the first place. The mechanisms underlying this effect on disease progression is 
 
suggested to be increased HIV target cell availability at the genital mucosa during infection. 
 
 
Chapter Eight: This chapter describes the rapidity with which disease progression occurred 
 
in this cohort of HIV infected women (Mlisana et al., 2014). The paper demonstrated how CD4 
 
counts declined by 39.6% during the first 3 months of infection and 46.7% by 6 months post- 
 
infection in this cohort of women who became infected with HIV. About one-third of these 
 
women (30.6%) reached a CD4 count of <350 cells/µl within 6 – 12 months of infection, 43.5% 
 
within 24 months, and 54.8% within 36 months post-infection, highlighting how rapidly this 
 





Chapter Nine: This is the conclusion chapter which places the findings from this study in the 
 
broader context, highlighting the important findings, limitations of the study as well as 
 
recommendations for further development or policy changes. 
 
 
1.3. Appendix 1: 
 
 
All the manuscripts that have emanated from this cohort are listed in this appendix, highlighting 
 











1. UNAIDS: 2013 Global Report: UNAIDS Report on the Global AIDS Epidemic. In: 
 
According to the UNAIDS’estimate the number of new infections in the region 
 




2. Harmelen JV, Ryst EVD, Loubser A, York D, Madurai S, Lyons S, Wood R, 
 
Williamson C: A predominantly HIV type 1 subtype C-restricted epidemic in 
 




3. Bredell H, Williamson C, Sonnenberg P, Martin DJ, Morris L: Genetic 
 
characterization of HIV type 1 from migrant workers in three South African gold 
 





























Chapter 2: Literature Review   
 
2.1 HIV-1 epidemic in sub-Saharan Africa  
Sub-Saharan Africa (SSA) continues to be ravaged by the HIV epidemic despite significant 
achievements in prevention and understanding its pathogenesis over the past three decades. In 
2012, an estimated 26.6 million HIV-1-infected individuals were in this region, which 
represents 67% of the global HIV burden and about 90% of the global infections in children 
under 15 years of age. In the same year, 1.8 million (67%) of the 2.7 million new HIV 
infections occurred in SSA [1]. Of the 1.9 million deaths estimated globally in 2012, 1.3 
million (68%) occurred in SSA [1].  
2.2 Disproportionately high rates of HIV in young women in SSA 
Women continue to bear the brunt of HIV disease, with young women in particular being the 
most severely affected. [2]. In SSA approximately 60% of HIV-1-infected individuals  are 
females [1] and young women (between the ages of 15 -24 years)  are at  >2-fold higher risk 
of infection compared to men in the same age group [1]. The peak prevalence of HIV in 
young women has typically been shown to occur 5 – 7 years earlier than their male 
counterparts [2, 3] (Figure 2.1). This disproportionate burden of HIV in women is likely to be 
linked to multiple factors, including gender disparities , cultural and sexual norms, intimate 
partner violence and abuse as well as poor socio-economic status seen in most African 
countries [4, 5]. Other factors thought to increase the risk of HIV infection amongst women 
in SSA include higher rates of sequential and concurrent sexual partnerships, vaginal 
insertion practices to enable dry sex by women and intergenerational sex [6-13]. The high 
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prevalence of HIV seen in adolescent girls and young women has been one of the significant 
factors that fuelled the epidemic in southern Africa [14-17].  
Whilst the HIV epidemic in sub-Saharan Africa is generalised, pockets of high risk 
populations exist, as seen with high pooled prevalence rates of 36.9% in female sex workers 
(FSWs) [18] and 3.8 times more infections seen in men who have sex with men (MSM) 
compared to heterosexual men [19]. A recent meta-analyses of HIV burden in FSWs showed 
an odds ratio estimate of 13.5 (95% CI 10.0–18.1) for a FSW to be HIV positive compared to  
women in similar age groups from the general population in low and middle income countries 
[18]. In addition to increased risk for HIV infection, FSWs who had become HIV-infected 
were more likely to be infected with more than one HIV variant concurrently (dual infection) 
and were more likely to experience more rapid disease progression [20, 21]. Although the 
prevalence of HIV infection in FSWs varies geographically, the behavioural and biological 
risk factors are similar as evidenced by persistently high numbers of sexual partners and high 
prevalence of sexually transmitted infections (STIs) with the associated reproductive health 



















Figure 2.1.  Age-specific HIV prevalence among men and women using data collected from national population 
based surveys in seven countries in southern Africa. Grey lines are for women and black lines for men. Pink and 
blue blocks indicate the age range of highest HIV burden in women and men per country, respectively. Red 





2.3 Sexually transmitted infections (STIs), bacterial vaginosis (BV) and risk of HIV 
infection  
Sexually transmitted infections (STIs) continue to present a major public health concern in 
both high and middle to low income countries, causing significant morbidity and mortality. In 
middle to low income countries, STIs and their complications are ranked in the top five 
disease categories for which adults seek health care [22]. BV, which causes the commonest 
type of vaginal discharge , results from an imbalance in the ecology of normal vaginal flora 
characterised by depletion of the hydrogen peroxide producing lactobacilli [23, 24]. 
Lactobacilli, by producing lactic acid, maintain the vaginal acidic pH which inhibits CD4+ T 
cell activation and therefore reduces the proliferation of HIV target cells in the vagina 
epithelium [25].  BV has been associated with an increased risk of HIV acquisition in HIV 
incidence studies with a risk rate of 1.61 (95 percent CI: 1.21, 2.13) and HIV seroprevalence 
ranging from was higher in most studies with BV positive women [26] The link between 
STIs and increased risk for HIV acquisition has been  well described [26], with the 
mechanism for this increased risk for HIV infection facilitated  through the disruption of 
genital epithelial barrier integrity (eg. genital ulcer diseases) or inflammatory modulation  or 
changes to the epithelium [27]. Studies in various populations of both women and men of 
varying sexual orientations at risk for HIV infection have shown increased STI prevalence 
with concomitant high prevalence of HIV infection [28-30]. Presence of STIs increases HIV 
infectiousness and susceptibility with risk estimates ranging from 2 to 23.5 as observed in 
multiple studies from different continents [28].  
STIs and BV increase the infectiousness of HIV-infected individuals and have been found to 
be the strongest determinate of the amount of virus being shed in genital secretions [31].  In 
the presence of STIs, localized genital inflammation is also known to significantly drive HIV 
shedding [32]. HIV viral load measurements in genital tract secretions from individuals 
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infected with an STI are higher than in persons without STIs, further increasing the risk of 
HIV transmission from an HIV-infected person to their uninfected partners [33, 34]. HIV 
levels in semen or genital secretions are directly linked to the number of white blood cells 
migrating to the genital tract [35]. The numbers of inflammatory cells  in the genital tract 
have been shown to be directly proportional to HIV infectiousness [33]. Gonococcal and 
chlamydial infections have been associated with increased leucocyte migration, and high 
levels of HIV shedding. BV has also been associated with as high as six-fold increase in HIV 
shedding [36]. 
2.4 Syndromic management of STIs and BV in southern Africa 
In SSA and other resource constrained settings within Africa and Asia, STIs are managed 
syndromically rather than by laboratory diagnosis of specific infections. Syndromic 
management is aimed at ensuring that patients presenting with signs and symptoms of STIs 
(commonly ulcers or genital discharge) receive high quality care at first point of contact 
without the delays of laboratory testing. This WHO approved approach has been simplified 
by use of easy-to-follow algorithms enabling primary healthcare nurses to manage these 
infections efficiently [37].  Syndromic management uses clinically distinct syndromes 
commonly associated with specific causative agents of STIs. Patient management includes 
therapeutic management for most pathogens producing the specific syndrome including 
education and counselling as well as condom provision and partner referral. Whilst clinical 
sign and symptoms of genital ulcers and urethritis in men with STIs are relatively 
straightforward and easily identified by patients, however, genital discharge in females is 
complicated by the fact that pathogens causing vaginal discharges differ from those that 
cause a cervical discharge higher up in the reproductive tract, and often discharges are 
undifferentiated by women from what they consider to be “normal” discharge.  Furthermore 
many women remain asymptomatic further complicating the management of STIs. A 
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speculum examination, which is not readily available in resource constrained health settings, 
is necessary for diagnosis of cervical discharge in order to distinguish between cervical and 
vaginal discharge. A meta-analyses of syndromic management studies showed that 
algorithms for the diagnosis and treatment of urethral discharge and genital ulcer disease in 
men performed better than those for women, with sensitivities or cure rates in men ranging 
from 87 to 99% for urethral discharge and 68 to 98% for genital ulcer disease [38]. The 
sensitivities for vaginal discharge algorithms ranged from 73 to93% among symptomatic 
women and much less in asymptomatic women (29-86%) [38]. For syndromic management 
to be effective, it relies on an individual or health care provider noting the presence of 
symptoms of an STI (discharge and/or ulcers) as well as patients presenting to a health care 
facility. A recent South African study showed a statistically significant increase in reporting 
of STIs by young HIV infected females compared to males [39]. Thus, early detection and 
appropriate management of STIs is of significant public health benefit and potentially 
impacting on HIV transmission and acquisition.    
By definition, syndromic management relies on the presence of symptoms of an STI. 
However, many STIs are asymptomatic with these asymptomatic infections being highly 
prevalent in communities with high HIV prevalence [39-41]. In a cohort study of MSM 
asymptomatic STI prevalence was around 14% with  more than 20 incident cases per 100 
person years of follow-up [41]. The associated risk factors in this cohort included young age, 
higher CD4 cell counts and the recreational use of marijuana.  Whilst some genital ulcers 
may be missed, the highest occurrence of asymptomatic infections are  seen in genital 
discharges with rates greater than 75% in females [42]. It has been demonstrated that even 
when STIs present asymptomatically, they continue to have serious health consequences. 
Undetected gonococcal and chlamydial infections in females, which would therefore be left 
untreated, increase the risk of pelvic inflammatory diseases (PIDs) and consequently risk for 
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ectopic pregnancies and infertility [43-45]. In addition to causing symptoms, like genital 
ulceration or discharge which increase susceptibility to HIV infection, STIs may be 
associated with sub-clinical manifestations, including up-regulated genital tract inflammatory 
cytokine responses [46, 47]. STIs are major causes of inflammatory cytokine upregulation 
and immune cell recruitment to the genital mucosa [48, 49].  
2.5 Alternatives to syndromic management of STIs and BV 
In comparison to syndromic management of STIs, aetiological diagnosis of STIs requires 
expensive laboratory equipment and well trained staff. Additionally, laboratory testing takes 
time to be performed and thus delays in the diagnosis and treatment of infected individuals 
[37, 50]. Since laboratory testing does not offer immediate results, transmission of STIs may 
persist while patients wait for their test results, and many patients do not return to the clinic 
for their results and remain untreated. In African studies of HIV testing, the return rate has 
been found to be as low as 37% in some areas [51].  
Rapid point-of-care (POC) tests have been under development for several years and have 
been successfully used for HIV and syphilis diagnosis. The Chlamydia Rapid Test (CRT) for 
Chlamydia trachomatis has shown promise in a single study, with a sensitivity of 80% and 
specificity of 99% compared to nucleic acid amplification (NAAT) testing technology [52]. 
However, in another study, the CRT had a sensitivity of only 41% [53]. Rapid NAATs 
combining both chlamydia and gonorrhoea testing have also been developed and show 
comparable predictive value to laboratory NAATs [54]. Very recently, a highly sensitive and 
specific rapid NAAT test for Trichomonas vaginalis was also been described [55]. However 
these tests require an onsite GeneXpert Platform or PCR machine and may have cost 




2.6 Population wide STI treatment as a tool to reduce HIV infection  
Several strategies for enhanced STI management, using population-wide syndromic 
management algorithms, have been tested to determine its effectiveness in reducing HIV 
acquisition.  However, with the exception of one successful syndromic management trial, 
these population-wide interventions (in which either improved syndromic management 
strategies were implemented or mass treatment of bacterial infections or therapy for HSV-2 
were performed) were found not to be effective in  reducing the rate of new HIV infections 
[17, 56-60].  In the first randomized controlled trial undertaken  in Mwanza, Tanzania HIV 
incidence was reduced by almost 40% in communities randomized to receive enhanced 
syndromic treatment for STIs [60, 61], suggesting that intensified STI detection and treatment 
strategies could  prevent HIV infection acquisition. In this trial, more than 12 thousand 
individuals from 12 communities were included, and followed for 2 years. Six of the 
intervention communities received enhanced STI syndromic management through active 
training of existing staff from local healthcare facilities in syndromic diagnosis and treatment 
of STIs; regular supply of drugs; regular supervisor visits and health education about STIs. 
The remaining 6 communities were part of the control group receiving the standard of care. 
At two  year follow-up, the rate of HIV infection was significantly lower in the intervention 
group compared to the control group (risk ratio: 0.58, 95% CI 0.42-0.79, p= 0.007) [60]. 
However, there were no differences in chlamydia and gonorrhoea infection rates among men; 
and STIs among pregnant women were unchanged, although the prevalence of newly-
diagnosed syphilis and male urethritis were lower in the intervention group [56]. 
Despite the promising results of the Mwanza trial, the two STI syndromic management 
interventions, implemented in Uganda and Zimbabwe, did not impact the rate of HIV 
acquisition [60, 62-64]. As a result, a growing skepticism about the value of STI treatment as 
an HIV prevention strategy currently prevails [65] whilst the importance of managing STIs 
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effectively cannot be underestimated. In Masaka, Uganda, nearly 100 thousand individuals 
were recruited from 18 communities and followed for 6 years between 1994 and 2000. The 
intervention in Uganda was similar to that in Tanzania and included training of health care 
workers in syndromic management of STIs, regular supply of drugs and supervision and 
health education about STIs. Although syndromic management reduced the incidence of 
active syphilis and gonorrhoea in this study, the incidence of chlamydia, genital ulcers, 
discharge and HIV-1 were unchanged [63]. Similarly, in Zimbabwe in which nearly 12 
thousand participants were included, implementation of syndromic management of STIs was 
not associated with reduced incidence of self-reported STI symptoms or HIV incidence [64].  
In an effort to improve on current syndromic STI treatment strategies, RCTs of periodic mass 
treatment of bacterial STIs and treatment for HSV-2 infection, however, did not demonstrate 
the effectiveness of these strategies in reducing HIV acquisition rates. In Rakai, Uganda, 
antimicrobial  treatment of STIs resulted in only a modest decline in the prevalence of some 
infections, and all STIs and BV were persistent and the prevalence of symptoms of STIs was 
similar in both the treatment and control groups [56]. It has been suggested that persistence of 
BV and STIs may be due to recurrence [66] or re-infection by partners outside of the 
intervention communities. Monthly antimicrobial treatment of bacterial STIs in Kenya 
resulted in a more substantial reduction in the prevalence of STIs, but did not influence HIV-
1 acquisition. HIV-1 infection was found to be associated with preceding N. gonorrhoea and 
C. trachomatis infections [57]. Treatment for HSV-2, which was highly prevalent in the 
participants of these studies, was not included in either the Uganda or the Kenya 
interventions and may have influenced HIV acquisition in these cohorts.  
The conflicting results of these trials might be explained by various factors. The population 
characteristics varied substantially.  At the time of conduct of the trials, the prevalence of 
HIV-1 in Tanzania was lower than the prevalence in Uganda, therefore the proportion of new 
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HIV- infections attributable to STIs may be lower in a more mature HIV epidemic, such as in 
Uganda [63, 67]. The Masaka trial was introduced at a more advanced stage in the Ugandan 
epidemic, when substantial behaviour change had already occurred, which could have 
accounted for marginal  or no effect of STI treatment on HIV incidence [63]. The higher 
prevalence of HSV-2 in Uganda may also have reduced the effect of STI treatment since 
acyclovir was not included in the treatment regimen [62, 63].  More intensive STI 
interventions are likely to be necessary to achieve a more substantial reduction in STI and 
HIV-1 infection rates, perhaps integration of both syndromic management strategies and 
mass treatment targeting both bacterial and viral STIs.  
More recently, Johnson et al. [67] modelled that 39% of heterosexually transmitted HIV 
infections in the early stages of South Africa’s epidemic could be attributed to  STIs; but that 
this has declined to 14% over time, partly as a result of increases in condom use and 
introduction of syndromic management protocols in the mid-1990’s, which substantially 
reduced the prevalence of curable STIs. In women, the proportion of HIV infections 
attributable to STIs was higher, with an estimated 50% of new HIV infections due to other 
STIs in 2010 [67]. In South Africa, syndromic management was estimated to have reduced 
adult HIV incidence by more than 6% between 1994 and 2004 [67].  
2.7 Female genital tract inflammation, inflammatory cytokines and their role in STIs 
and risk of HIV acquisition 
There is a considerable heterogeneity in an individual’s susceptibility to HIV infection during 
sexual transmission with some individuals remaining uninfected despite high levels of 
exposure [68]. The stratified epithelium of the female genital tract mucosa appears to provide 
an effective natural barrier to HIV infection, although this barrier is thought to be weakened 
by the presence of STIs which cause physical breaks (ulcers) in the barrier, or inflammation 
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[69].  Inflammation in the female genital tract has been identified as an important factor 
influencing risk of sexual HIV transmission and acquisition. Generally, inflammation is an 
essential innate process for control and/or clearance of infections but also an important 
mediator of tissue destruction [70, 71], and increased susceptibility to HIV infection [68, 72]. 
As part of this process, cytokines and chemokines, which are the main initiators of the 
inflammatory response, recruit immune cells from systemic circulation and activate these 
cells [73, 74]. Inflammatory cytokines that are involved in immune cell recruitment to the 
genital tract, or activation may increase risk for HIV infection, as HIV replication depends on 
the presence and density of immune cell targets, and the level of immune cell activation [75-
78]. Although the inflammatory response to tissue injury is important for STI clearance, 
destruction of infected epithelial layers occurs in the process, allowing STI-associated 
microbes to access deeper tissues but also easier passage for HIV across the mucosa. This 
results in an influx of highly-activated HIV target cells to the genital mucosa and the 
presence of a generalized pro-inflammatory milieu which is more conducive for HIV 
acquisition and transmission [79]. 
2.8 HIV transmission, acute HIV infection and natural history of infection 
HIV is transmitted through bodily fluids including semen, vaginal secretions; across the 
stratified squamous epithelium of the lower genital tract and the simple columnar epithelium 
of the endocervical canal, the transformation zone in females and the urethral simple 
epithelium, glans penis or foreskin in males [80, 81]. In females, CD4+ T cells and DC 
targets of HIV may migrate into the vaginal and ectocervical epithelium [82-84]. The main 
receptor that is used by HIV for host cell entry is the CD4+ T cell molecule [85]. All studies 
on sexual transmission have shown that new infections are established by viruses that use the 
CCR5 co-receptor for cell entry [86, 87]. Following genital mucosal transmission, 
experimental studies in macaques have shown that the simian immunodeficiency virus (SIV)   
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remains localized around the mucosa for the first 6 days before a productive systemic 
infection is established [88, 89]. 
Following infection, the clinical course of HIV infection has broadly been divided into three 
phases: the acute phase, chronic (asymptomatic) phase and the symptomatic phase of 
infection. A more detailed staging algorithm based on Feibig criteria has been used to further 
classify the acute (early) phases of HIV infection [90]. Fiebig staging proposes that the acute 
phase of HIV infection is further divided into 6 stages based on the emergence of host 
immune markers [91]. These stages are further defined in Figure 2.2.  
The acute phase of HIV infection is characterized by rapid growth and spread of the virus 
within the host cell lymphoid tissues in the absence of host adaptive immunity, which leads to 
high titres of HIV virus in plasma and substantial loss of CD4+ T cells in the blood. At this 
stage, viral RNA can be detected in blood and corresponds to Fiebig stage I. During this early 
stage of infection, HIV spreads to the lymphoid tissues and viral reservoirs are established 
throughout the body. HIV p24 (making up the viral capsid) can be detected in plasma at 
approximately day seven of infection although host immunity cannot yet be measured 
(corresponding to Fiebig stage II). After this, an expanded population of HIV-1 specific 
cytotoxic CD8+ T cells (CTLs) and HIV-specific binding antibodies develop and are 
measurable. Emergence of these HIV-specific adaptive immune responses have been 
implicated in bringing viral replication under control, and lowering the viral load to a steady 
set point [92]. At this stage, HIV gp120 and gp41 antibodies can be detected by ELISA 
(corresponding to Fiebig stage III). Fiebig stage IV (antibody positive by ELISA but negative 
by western blot), stage V (antibody positive by ELISA and western blot) and stage VI 




The asymptomatic or chronic phase of HIV infection is characterized by the establishment 
of viral “set point”, as a result of emerging host adaptive immune responses. Viral “set point” 
represents the sum of ongoing viral replication in the presence of this immunity and the 
ability of the host’s immunity to retard viral replication. The duration of this asymptomatic or 
chronic phase of infection varies from person to person and from country to country, with 
typical duration ranging from 5-15 years. Despite host adaptive immune responses against 
HIV, a steady yet slow decrease in CD4+ T cell numbers continues during chronic infection, 
ultimately resulting in exhaustion of both CD4+ and CD8+ T cells [93]. Although the typical 
duration of this asymptomatic phase of infection is <10 years, some HIV-infected individuals 
may have no AIDS-defining symptoms for longer than 10 years in the absence of 
treatment[94].  
The symptomatic phase or acquired immunodeficiency syndrome (AIDS) is characterized by 
a rapid decrease of CD4+ T cells, corresponding to a decline in HIV-specific T cell responses 
and rapidly increasing viraemia. In the absence of HAART, opportunistic infections usually 
appear leading to AIDS and death due to the collapse of host immunity [95] especially once 
CD4+ T cell counts decline to levels below 200 cells/ml blood. Since the introduction of anti-
retroviral therapy, the number of HIV-infected individuals who progress to this stage of 
infection is on the decline as more individuals improve CD4+ T cell counts improve with 
HAART. Although 61% of individuals who need HAART are currently receiving  treatment, 
and HAART rollout is increasing annually, most recent statistics report that 1.6 million 
people died of AIDS in 2012 [1]. 
In South Africa, 200 000 HIV-infected individuals died of AIDS in 2010 (UNAIDS, 2011). 
South African National Guidelines on antiretroviral therapy stipulate initiation of treatment 
once CD4+ T cell counts drop below 350 cells/ml except for pregnant women and TB 
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infected patients who are initiated on HAART irrespective of their CD4+ T cell counts (The 
South African Antiretroviral Treatment Guidelines, 2013).      
Figure 2.2. Typical clinical courses of HIV infection in humans. (A) Clinical course has broadly been divided 
into three phases: acute, asymptomatic and symptomatic infection phases. CD4+ T cell number (black line) 
drastically decreases during acute phase, rebounds slightly during the asymptomatic infection phase when host 
immunity emerges, achieving a relatively steady state. Viral loads (red line) increase during acute infection 
phase in the absence of host immunity, and decrease sharply when HIV-specific CTLs (blue line) and antibody 
responses emerge (green and turquoise lines, respectively). (B) Acute infection phase has further been divided 
into six Fiebig stages (I-VI) based on the detection of HIV-1 RNA, viral antigens and emergence of host 





2.9 Importance of diagnosing acute HIV infection 
The most common signs and symptoms of an acute HIV-1 infection include fever, fatique, 
morbilliform rash, headache, lymphadenopathy, pharyngitis, myalgia, arthralgia, aseptic 
meningitis, retro-orbital pain, weight loss, depression, gastrointestinal distress, night sweats 
and oral or genital ulcers [97, 98] . A maculopapular or morbilliform rash occurs in 40 to 80 
percent of patients with symptomatic acute HIV-1 infection [97]. These signs and symptoms 
appear within days to weeks after initial exposure and may last from a few days to more than 
10 days. Individuals in sero-discordant sexual relationships will have exposure to a person 
with known or possible HIV-1 infection and are presenting with signs and symptoms 
consistent with the diagnosis and history of exposure require an evaluation for acute HIV-1 
infection. The risk of transmission appears to be much higher in patients with acute or early 
HIV infection compared to those with chronic and established infection [99]. This is partly 
due to the high viraemia associated with acute infection. As the probability (per person) of 
transmitting  HIV-1 is closely associated with the viral burden in circulation, whenever there 
is a 10-fold increase in the viral load, the risk of transmission increases 2.5-fold [100].  
During this early phase, the virus replicates rapidly unhindered by the immune responses, 
which are often delayed, reaching peak vireamic levels of >10 million copies/ml [101, 102].  
Populations with relatively recently introduced  HIV-1 epidemics attribute most of their 
recent infections to transmissions from recently infected individuals, i.e. there are higher rates 
of forward transmission events with acute or early infections [103]. Socio-behavioural 
patterns play a critical role in the risk of transmission as higher rates of changes in sexual 
partners increase the risk of encountering a partner with acute HIV-1 infection. Multiple 
concurrent sexual partners also increase the transmission risk. A recent comprehensive study 
conducted in Lilongwe, Malawi, using both behavioural and biologic data, ascribed 38%  of 
HIV-1 cases to sexual exposure to individuals  infected within 5 months [103],  despite the 
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fact Malawi has a long-established epidemic. Studies in phylogenetically related isolates have 
further underscored the importance of acute HIV-1 infection by demonstrating  that more 
than half of the individuals  with newly diagnosed early HIV-1 infection in Montreal were  
infected with variants linkable through phylogenetic studies, suggesting the presence of 
transmission clusters, possibly due to individuals  with acute and early infection [103].  
2.10 Factors influencing the rate of HIV disease progression 
It has been established that viral, immunologic and host factors generally influences the 
course of HIV-1 infection. In the transition from acute to early chronic HIV infection, the 
high viraemia observed during seroconversion declines to a virologic set-point which has 
been described as being predictive of the rate of disease progression [21, 104, 105]. This 
virologic set-point is determined by host factors that modulate the course of HIV disease. The 
CD4+ T cell count is the most significant predictor of disease progression and patient 
survival [106-108]. Whilst the direct cytopathic effect of HIV-1 on CD4+ T cells contributes 
to the gradual depletion of these cells, there is enough evidence to show that there are other 
indirect effects of viral replication that facilitate this progressive depletion [109-111].    
Immune activation during HIV infection has been identified as a major contributor to HIV 
disease progression, and is the product of inflammatory responses to HIV-encoded Toll-like 
Receptor (TLR) ligands, microbial translocation and the homeostatic response to CD4+ T cell 
depletion [112, 113]. Cytokine profiles and mucosal inflammation in the genital tract during 
acute HIV infection are associated with lower CD4+ T cell counts and may thereby impact 
disease progression. We have previously shown that elevated levels of IL-1, IL-6, and IL-8 in 
the genital tract correlated with lower systemic CD4+ T cell counts during acute HIV 
infection [114]. A panel of HLA class 1 haplotypes has been demonstrated to be associated 
with different rates of HIV-1 disease progression [115, 116]. HLA* B35, B8, B45, and B53 
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have been associated with rapid progression, whereas HLA* B5701, HLA* B5703 and B27 
are strongly linked with delayed progression [117-119].  
The infecting HIV clade has also been associated with varying rates of disease progression. A 
study in East Africa showed that subtype D infected individuals had a shorter median to 
AIDS progression compared to subtype A infected [120-122]. Data from sub-Saharan Africa 
suggest rapid disease progression in this subtype C populated population [123].   
This study was therefore undertaken to investigate the impact of sexually transmitted 
infections (STIs), bacterial vaginosis (BV) and genital tract inflammation on risk for HIV 
acquisition and rate of disease progression in subtype C infected women. The clinical 
presentation of these STIs, including BV, their associated inflammation and how these 
influence the risk of HIV infection in high risk women was studied. The research presented 
also describes the clinical symptoms in acute HIV subtype C infection, which has been 
proposed to be useful to develop a clinical algorithm for rapidly diagnosing acute HIV 
infection in this population, by defining the acute HIV seroconversion syndrome. To further 
understand the long term trajectory of HIV subtype C infection, the clinical, immunological 
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Abstract 
Objectives: To describe the baseline demographic data, clinical characteristics and HIV-incidence rates of a cohort at high 
risk for HIV infection in South Africa as well as the challenges experienced in establishing and maintaining the cohort. 
Methodology/Principle Findings: Between August 2004 and May 2005 a cohort of HIV-uninfected women was established 
for the CAPRISA 002 Acute Infection Study, a natural history study of HIV-1 subtype C infection. Volunteers were identified 
through peer-outreach. The cohort was followed monthly to determine HIV infection rates and clinical presentation of early 
HIV infection. Risk reduction counselling and male and female condoms were provided. After screening 775 individuals, a 
cohort of 245 uninfected high-risk women was established. HIV-prevalence at screening was 59.6% (95% CI: 55.9% to 62.8%) 
posing a challenge in accruing HIV-uninfected women. The majority of women (78.8%) were self-identified as sex-workers 
with a median of 2 clients per day. Most women (95%) reported more than one casual sexual partner in the previous 
3 months (excluding clients) and 58.8% reported condom use in their last sexual encounter. Based on laboratory testing, 
62.0% had a sexually transmitted infection at baseline. During 390 person-years of follow-up, 28 infections occurred yielding 
seroincidence rate of 7.2 (95% CI: 4.5 to 9.8) per 100 person-years. Despite the high mobility of this sex worker cohort 
retention rate after 2 years was 86.1%. High co-morbidity created challenges for ancillary care provision, both in terms of 
human and financial resources. 
Conclusions/Significance: Challenges experienced were high baseline HIV-prevalence, lower than anticipated HIV- 
incidence and difficulties retaining participants. Despite challenges, we have successfully accrued this cohort of HIV- 
uninfected women with favourable retention, enabling us to study the natural history of HIV-1 during acute HIV-infection. 
Our experiences provide lessons for others establishing similar cohorts, which will be key for advancing the vaccine and 
prevention research agenda in resource-constrained settings. 
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As we move into the third decade of the AIDS epidemic, the 
need to increase and improve the research being conducted in 
some of the hardest hit areas of the developing world has become 
increasingly clear. These regions pose unique challenges for 
scientific research as they are typically resource-poor settings with 
minimal existing infrastructure and populations that are not well 
integrated into a formal health care system. In order to conduct 
effective research into the HIV  epidemic in southern Africa, it is 
critical to improve our ability to maintain longitudinal cohorts in 
the face of significant social, cultural, and logistical hurdles. 
In order to determine which host and viral factors during the acute 
and early phases of HIV-1 infection have a significant impact on the 
subsequent course of disease, the Centre for the AIDS Programme of 
Research in South Africa (CAPRISA) initiated the CAPRISA 002 
Acute Infection Study. This study will characterize HIV-1 subtype C 
viral load set point in heterosexual infection in South Africa, the role 
of specific T cell immune responses in the control of replication, and 
the relationship between viral set point, CD4+ T cell count trajectory 
and disease progression. 
The design of this study overcomes several limitations of 
previous acute infection studies. While several earlier studies used 
 






a large window period for identification of acute infection [1–5], 
others relied on patient recall of symptoms associated with acute 
retroviral syndrome [6]. Still other studies focused on one 
particular aspect of acute HIV infection, such as clinical signs 
and symptoms [7], without placing the clinical presentation in the 
context of virological and immunological responses. Furthermore, 
the majority of these studies were conducted in developed 
countries where both the context for the research and the viral 
subtypes are markedly different from those that are found in 
southern Africa and the developing world. The only prospective 
acute infection study that was conducted in Africa identified acute 
infections within a period averaging 1.1 months but was limited by 
its focus on clinical manifestations of acute infection [8]. As a 
prospective observational cohort study, this study will also provide 
a methodology for setting up and managing an observational 
cohort requiring frequent visits over an extended period of time 
against within a very challenging, resource-constrained environ- 
ment with participants who tend to be highly mobile and difficult 
to contact by conventional means. 
To our knowledge, this acute infection study will be the first in 
southern Africa to document acute infection in a prospective 
cohort with extensive follow-up on the natural history of HIV-1 
subtype C infection. The aim of this paper is to provide a 
preliminary description of the demographic and clinical charac- 
teristics of the cohort of HIV-uninfected participants, the 
challenges in administering the cohort, and some of the successful 
strategies employed to overcome these obstacles. This paper 
provides important information with respect to the establishment 
of high-risk cohorts for acute HIV  infection and other prospective 
observational studies. Establishment of cohorts in developing 
country setting have unique challenges which differ between 
locations and populations. Our cohort consists primarily of high 
risk HIV-uninfected women working as female sex workers, 
recruited from a large urban area. This cohort is of high potential 
impact as forms part of a larger acute infection study which 
measures virological, immunological and clinical events in acute 
and early infection. Results from this study are likely to provide 
valuable information to inform vaccine trials, as well as 
understanding host, immunological and virological correlates of 
disease progression in subtype C infection. This paper provides 
important information with respect to the establishment of high- 
risk cohorts for acute HIV infection and other prospective 
observational studies. 
 
Materials and Methods 
The CAPRISA 002 Acute Infection Study is being conducted at 
the Doris Duke Medical Research Institute (DDMRI) at the 
Nelson R Mandela School of Medicine of the University of 
KwaZulu-Natal in Durban, South Africa. The goal of this study is 
to identify acute HIV infection and, by prospectively following 
participants with acute infection, provide thorough information on 
the natural history of HIV-1 subtype C infection. 
 
Cohort Development 
Building on participatory research methods developed for 
earlier work in similar cohorts [9–11], a network of ten 
community liaison persons (CLPs) was established prior to 
initiation of the study to assist with study recruitment and 
retention efforts. Recruitment was based upon word-of-mouth 
and site visits by the CLPs. Initially we recruited directly within 
5 kilometres of the clinic site, but CLPs did bring women in 
from as far as around 45 kilometres (approximately 3 to 28 
miles). Most of the recruitment sites were associated with 
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transport links into the city, and so participants were able to 
access the existing system of public transport. Participants 
received reimbursement for time, effort and their transport 
expenses when they visited the clinic. We limited our 
recruitment radius so that no woman would have to use her 
own money. Women from the community who were at least 
18 years old and either self-identified as female sex workers 
(FSWs) or reported having had at least three partners in the 
3 months prior to recruitment were screened for participation in 
the study. Young women in urban South Africa are already at 
high risk for HIV infection [12], and our goal was to identify 
women who would theoretically be at the greatest risk of HIV  
acquisition. Women who were pregnant at the time of screening 
or who planned to travel away from the study site for more than 
3 months were excluded from participation. 
The screening procedure for identifying HIV-negative women 
consisted of voluntary counselling and testing (VCT) followed by a 
blood collection for rapid HIV antibody testing and urine 
collection for pregnancy testing. If the first antibody test 
(Determine: Abbott Laboratories, Tokyo, Japan) was negative, 
the participant was enrolled into the HIV-negative cohort. If the 
first antibody test was positive, a second rapid antibody test 
(Capillus; Trinity Biotech, Jamestown, NY, USA) was adminis- 
tered. Those with a two positive antibody tests were referred for 
HIV  follow-up care. Those with discordant antibody results were 
given a confirmatory HIV  enzyme immunoassay (EIA) (BEP 2000; 
Dade Behring, Marburg, Germany) and were either enrolled into 
the HIV-negative cohort or referred for HIV  follow-up care on the 
basis of those results. 
In order to maximize participant retention, the study visit 
schedule was thoroughly explained during the informed consent 
process and was re-emphasized at each study visit. Detailed locator 
information was collected and was reviewed at each subsequent 
visit and a secure participant-tracking database was established to 
facilitate visit scheduling and prompt follow-up for missed visits. 
Additionally, participants were compensated (100 South African 
Rand, ,$14USD, as approved by the ethics committee) for their 
transport to the study site and for their time at the clinic. 
To improve communication with the cohort, a web-based short 
message service (SMS) is used to send pre-approved cell phone text 
messages to willing participants. This system is used to remind 
participants who generally do not have access to fixed-line 
telephone services about their study appointments. The service is 
cost effective (0.33 South African Rand per message) and also 
provides an electronic record of all messages sent and whether or 
not they are received. 
If a participant misses a visit, the clinic nurse administrator 
attempts to call a participant for the first 3 days after the clinic 
visit. A SMS with the clinic contact number is also sent out on the 
second and third days. If these attempts at contact are unsuccessful 
by the second week, the study community liaison officer attempts 
person-to-person contact by travelling to the participant’s 
documented contact site as well as to the site from which the 
participant was originally recruited. 
In addition to the methods above, the study staff and 
community liaisons regularly communicate with the study 
community at large to increase awareness of HIV/AIDS and 
explain the purpose of HIV prevention research and the 
importance of completing research study visits. A Community 
Research Support Group (CRSG) comprised of the CLPs meets 
bi-monthly with study representatives to discuss and provide 
feedback on the progress of the study and to discuss challenges 
faced by the study team with regards to community and 
participant relations. 
 







The study protocol and informed consent documents were 
reviewed by the local ethics committees of the University of 
KwaZulu-Natal, the University of Cape Town, the University of 
the Witwatersrand in Johannesburg, and by the Prevention 
Sciences Review Committee (PSRC) of the Division of AIDS 
(DAIDS, National Institutes of Health, U.S.A.). The consent forms 
were translated into isiZulu and written informed consent is 
obtained at each stage of the study (screening, enrolment into 
HIV-negative cohort, enrolment into acute infection phase, and 
for sample storage). All women screened for participation, whether 
ultimately enrolled into the study cohort or not, receive HIV  pre- 
and post-test counselling, risk reduction counselling, male and 
female condoms, access to clinical care, and treatment for sexually 
transmitted infections (STIs). HIV/STI  risk reduction counselling, 
condom provision, and prevention education supplies are 
administered at each subsequent study visit. One-on-one counsel- 
ling was provided by a non-governmental organization which 
offered the same service in the public sector in the region, to be 
consistent with the services in the region. Overcoming one of the 
key challenges to doing HIV-related work in this context [11], 
participants who were HIV  infected during the study were referred 
to the CAPRISA Antiretroviral Treatment (CAT) programme 
where they were offered ongoing care, and treatment for HIV  
when clinically eligible. 
 
Study Visits and Procedures 
Once enrolled into the HIV-negative observational cohort, the 
participants underwent a baseline evaluation that included: a HIV  
behaviour risk assessment, a clinical evaluation, blood collection 
for routine laboratory assessment and HIV  status, and a specimen 
collection for sexually transmitted infection (STI) diagnosis. 
Following the baseline evaluation, participants in the HIV- 
negative cohort attend monthly follow-up evaluations for a 
maximum of 24 months. The monthly evaluations consist of a 
clinical evaluation, two HIV  antibody rapid tests, HIV  EIA, and 
pooled HIV-1 RNA testing (Amplicor v1.5: Roche Diagnostics, 
Rotkreuz, Switzerland). A urine dipstick is done on clinical 
suspicion of pregnancy, or if requested by the participant. In 
addition, a routine laboratory assessment, urinalysis, and STI  
screening are performed at 6-monthly intervals. 
Women from the HIV-negative cohort are diagnosed with acute 
HIV infection by (1) the detection of HIV-1 antibodies within 
5 months of a previously negative HIV-1 test; or (2) evidence of 
HIV-1 viral replication in the absence of HIV-1 antibodies. While 
women in this cohort were screened monthly allowing for rapid 
identification of acute infection, a 5 months window period was 
allowed to enable to recruit from other prevention cohorts where 
follow-up was only quarterly. Time of infection is defined as the 
mid-point between the last HIV  antibody negative test and the first 
HIV antibody positive test; or if a positive RNA PCR assay is 
available on the same date as a negative HIV EIA, the date of 
HIV infection is estimated at 14 days prior to the first positive 
RNA PCR assay. 
 
Staff Training and Infrastructure Development 
Given the extended scope and longitudinal nature of this study, 
CAPRISA was required to expand the size of the staff and the 
ability of the organization to manage a large cohort. After hiring 
additional clinicians, nurses, counsellors, and laboratory person- 
nel, all team members underwent extensive training in both good 
clinical practice (GCP) and in the particulars of this study with 
respect to the case report forms (CRFs) for documentation, the 
quality control plan, and Human Subjects Protections (HSP). 
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Furthermore, the capacity of the laboratory had to be increased to 
handle the large quantity of specimens related to the study. 
 
Data Management and Statistical Analysis 
All data is entered onto case report forms (CRFs) at the study 
sites and faxed into the CAPRISA Data Management Centre, 
using the DataFax system (Clinical DataFax Systems Inc., 
Ontario, Canada). This capability did not previously exist at site, 
and had to be implemented in order to collect the data for this 
study. Source documents and original CRFs are maintained on 
site while an electronic version of the CRF  is maintained by the 
Data Management Centre. Quality assurance and quality control 
are maintained and checked at specified intervals. All analyses are 
conducted using the SAS statistical package version 9.1 (SAS 
Institute, Cary, NC, U.S.A.). 
 
Results 
Establishing the Cohort 
Between August 2004 and May 2005, 775 women who were 
classified as high-risk either by self-identification as sex workers or 
self-report of more than three sexual partners in the previous 
3 months were screened for participation in the observational 
cohort. Recruitment was done at known FSW sites in the city, 
therefore the majority of these women (n = 193, 78.8%) were self- 
identified as sex workers. The cumulative number of women 
screened and enrolled over the entire 10-month period can be seen 
in Figure 1. 
Of the 775 women screened, 59.6% (95% CI 55.9%–62.8%) 
were found to be HIV-positive. The mean ages of the women who 
were screened and found to be HIV-positive and HIV negative 
were 29.3 years (range 16–58) and 34.2 years (range 18–58), 
respectively (p,0.001). The HIV  prevalence among the screening 
participants changed dramatically over time from 83% in the first 
month of screening to 17% in the last month of screening 
(Figure 2). 
Of the 313 women who were HIV-negative, 245 HIV-negative 
women were eligible and agreed to participate in the HIV- 
negative cohort. Exclusion criteria for women who were 
uninfected at screening were as follows: less than three sexual 
partners in the previous 3 months (n = 22), women who were 
pregnant at the time of screening (n = 16), women who planned to 









































Figure 2. HIV prevalence in participants screened for enroll- 




who were afraid of the testing procedures (n = 2). There were 
twenty-one women who were eligible following screening but 
never returned for enrolment into the HIV-negative cohort. 
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The demographic characteristics of the 245 women enrolled in 
the HIV-negative cohort are presented in Table 1. The mean age 
of the overall cohort was 34.3 years (range 18–58). Approximately 
42.0% of the cohort had 11 or 12 years of education or higher, 
33.5% had between 8 and 10 years of education, and 24.5% had 
an education level less than 8 years. 
The numbers of steady and casual partners reported by the 
women are listed in Table 2. Steady partners were defined as 
someone seen ‘‘most of the time, often over a period of time’’ while 
a casual partner was someone the women saw only occasionally or 
even only once (but not a client in the case of the FSWs). 
All of the women in the cohort have engaged in peno-vaginal 
intercourse; 34.6% and 25.4% of the cohort have engaged in anal 
and oral sex respectively. The mean age at sexual debut was 
17 years (range 12–26) and at the time of study enrolment the 
mean number of days since last sexual contact was 4.8 (range 1– 
45). While 58.8% of participants indicated that a condom was used 
at last sexual encounter, 13.9% and 34.3% of the women indicated 
that they were never able to insist on a condom being used with 
casual and steady partners respectively (Table 3). Additionally, a 
high proportion of the women (75.7%) provided economic support 
to adults (mean 0.9, range 0–7) or children (mean 2.8, range 0–14). 
Among the women who self-identified as FSWs, the median 
length of sex work was 3 years (range 1 month–31 years) and the 
median age at which the women began sex work was 26 years 
 
Table 1. Demographic characteristics of the HIV-negative observational cohort. 
 
Number (N = 245) Percent Number (N = 244) Percent 
Race/ethnicity Marital status 
Black 241 98.4 Single, no steady partner 10 4.1 
White 3 1.2 Married 16 6.5 
Indian 1 0.4 Divorced 3 1.2 
Widowed 3 1.2 
Education Stable partner 75 30.6 
. Grade 11 103 42.0 Multiple partners 135 55.1 
Grade 8–10 82 33.5 Separated 2 0.8 
, Grade 8 60 24.5 
(Note: where women refused to answer certain questions, the category total is less than the cohort total of 245.) 
doi:10.1371/journal.pone.0001954.t001 
 
Table 2. Sexual partner history for the 245 women in the HIV-negative observational cohort. 
 
Partners in the previous 3 months Lifetime partners 
Steady Casual Steady Casual 
# of partners reported   Number Percent Number Percent Number Percent Number Percent 
0 7 2.9 4 1.7 2 0.8 0 0 
1 158 65.6 14 5.9 9 3.7 0 0 
2–3 62 25.7 166 69.5 42 17.4 32 13.4 
4–6 8 3.3 33 13.8 80 33.1 31 13.0 
7–12 1 0.4 3 1.3 20 8.3 17 7.1 
.12 0 0 0 0 7 2.9 2 0.8 
Too many to remember 5 2.1 19 7.9 82 33.9 156 65.5 
Total 241 100 239 100 242 100 238 100 
(Note: where women refused to answer certain questions, the category total is less than the cohort total of 245.) 
doi:10.1371/journal.pone.0001954.t002 
 






Table 3. Ease of condom use with casual and steady partners, 
showing a trend towards ease of condom use with casual 
partners, and lower and inconsistent condom use with steady 
partners (Fisher’s exact test; p,0.001). 
 
Ease of Condom Use Casual (% and n) Steady (% and n) 
Never 13.9% (34) 34.3% (84) 
Sometimes 32.2% (79) 43.3% (106) 
Every Time 53.9% (132) 20.4% (50) 
doi:10.1371/journal.pone.0001954.t003 
 
(range 14–53 years). The median number of days performing sex 
work per week was 3 days (range 1–7 days) with a median of 2 
clients see per day (range 1–10), with a median of 2 clients (range 
0–30) seen in the previous week. 
 
Maintaining the Cohort 
Enrolment for the Phase 1 HIV-negative cohort began in 
September 2004 and the last participant was terminated in May 
2007. The retention rate for the HIV-negative cohort was 86.1%. 
Despite the high mobility and low socioeconomic status of this 
population, only 13 (5.3%) of the HIV-negative cohort were 
terminated because they could not be traced. Other reasons for 
termination included participant relocation (n = 13), inability to 
adhere to the study schedule (n = 4), participant withdrew consent 
(n = 4), and death due to causes unrelated to study participation 
(n = 5). 
As part of the study protocol, the women in the cohort received 
regular clinical examinations. Key baseline characteristics are 
summarized in Table 4. On enrolment into the cohort, the HIV- 
negative cohort had a mean body mass index (BMI) of 31.0 kg/ 
m
2
. Of the 245 participants, 121 (49.4%) had a BMI greater than 
30 kg/m
2
 (defined as obese) and a further 58 (23.7%) were 
overweight with a BMI between 25 and 30 kg/m
2
. Sixty-two 
participants (25.3%) had a normal BMI between 18.5 and 25 kg/ 
m
2
 and only five participants (2.0%) were underweight with a BMI 
less than 18.5 kg/m
2
. Despite the high prevalence of obesity in this 
cohort, hypertension was not common. The mean systolic blood 
pressure was 117 mmHg and the mean diastolic pressure was 
76 mmHg. Only 29 (11.8%) of the women had a systolic pressure 
greater than 140 mmHg or a diastolic pressure greater than 
90 mmHg. Moderate anaemia was relatively common in this 
population and 48 (19.7%) of the women had a haemoglobin less 
than 12 g/dL at study enrolment. 
On enrolment into the cohort and at 6-monthly intervals, these 
women underwent STI  screenings for Trichomonas vaginalis, Neisseria 
 
Table 4. Baseline medical characteristics of the HIV-negative 
cohort (n = 245). 
 
Mean (SD) Range 
Blood pressure (mmHg) 
Systolic 117 (15) 90–200 
Diastolic 76 (10) 55–110 
Body mass index (kg/m2) 31.0 (7.8) 17.2–54.5 
Hemoglobin (g/dL) 12.7 (1.3) 7.7–16.1 
Hematocrit (%) 37.3 (0.3) 25–46 
doi:10.1371/journal.pone.0001954.t004 
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gonorrheae, Chlamydia trachomatis, Mycoplasma genitalium, syphilis, and 
Herpes simplex virus-2. Overall, 29.4% of women were infected 
with an STI at baseline. This percentage increases to 62.0% if 
bacterial vaginosis is included. Further, while none of the women 
were pregnant on enrolment, there were 32 pregnancies in the 
cohort for an incidence of 8.5 per 100 person-years (95% CI 5.6– 
11.5). During this same period, there have been 5 deaths unrelated 
to study participation. Causes of death include: stab wound (1), 
clinically reported as idiopathic thrombocytopenia (1), and 
unknown (3). 
Finally, after 4784 monthly visits by 245 participants in this 
HIV-negative cohort, we identified 28 acute HIV infections. 
Twenty of the acute infections were among women who had self- 
identified as female sex workers and 8 of the acute infections were 
among women who had reported more than three partners in the 
preceding 3 months. The annual seroincidence after 390 person 
years was 7.2 per 100 person-years (95% CI 4.5–9.8). 
We investigated if the number of new HIV  infections reduced 
over time, which could be due to women who were most at risk of 
getting infected seroconverting early during follow-up or women 
reducing their risky behaviour over time and in response to 
repeated risk-reduction counselling. There was a significant trend 
over time in the rate at which women seroconverted (p- 
value = 0.0283), and this is graphically illustrated in Figure 3. 
 
Discussion 
This paper describes the recruiting strategies, screening 
methods, enrolment procedures and retention techniques for a 
cohort of high-risk South African women, consisting largely urban 
female sex workers, a typically transient and mobile population 
that formed the basis for the CAPRISA 002 Acute HIV  Infection 
study. We encountered numerous challenges over the course of 
establishing and administering the cohort and this paper aims to 
describe our strategies for overcoming these challenges. 
The first challenge was defining the inclusion and exclusion 
criteria for the cohort. The study design called for uninfected yet 
‘‘high risk’’ women so that we could theoretically maximize the 




















Figure 3. Percentage of acute HIV infections as a function of 
time in follow up (in days), showing a decrease in acute 
infections over time of follow up for the study. 
doi:10.1371/journal.pone.0001954.g003 
 






recruitment, we were confronted with cultural and social barriers 
to delineations within this population. While many women were 
involved in transactional sex of some form, they were often 
reluctant to identify themselves as FSWs. Transactional sex for 
money or goods with non-regular partners is common in this 
region and is often not explicitly described as commercial sex work 
[13]. Once these cultural taboos became apparent, our study staff 
made a concerted effort to ensure that transactional sex was asked 
about in an open and permissive manner. Close work with the 
CLPs, some of whom were self-identified FSWs, enabled the 
research team to systematize a non-judgmental approach. Future 
work in similar cohorts needs to take account of the fact that terms 
such as ‘sex worker’ or ‘client’ may be inappropriate, and that 
broader definitions that include multiple partners who provide 
material needs in exchange for sex should be included in 
behavioural risk assessments. 
The screening was made more difficult because of the high 
prevalence of HIV  (59.6%) in the screening population. This is an 
extremely high prevalence rate, even when compared with the 
reported prevalence rates of 13.3% for South African women, 
16.5% for the highly-burdened KwaZulu-Natal province, and 
33.3% for South African women between the ages of 25 and 
29 years [14]. The change in HIV prevalence rates over the 
course of screening was quite dramatic – from 83% to 17% – with 
the majority of uninfected participants identified in the final 
quarter of recruitment. The decline in prevalence over the course 
of screening could reflect a desire of women who were most 
concerned about their status to come first to the clinic for HIV  
testing, or for women who were most active in sex work to come 
forward first. Regardless, this discrepancy highlights the fact that 
cross-sectional surveys of seroprevalence can be a highly variable, 
or even unreliable, indicator of true prevalence and underscores 
the benefits of having an extended screening period with adequate 
numbers of screening participants. Enrolling participants over 
time from different populations with different risk profiles could 
bias the results of many studies. This variation is particularly 
significant for prevention studies where care should be taken to 
design the randomization process to equally distribute these 
differences with respect to time and intervention. For example, it is 
important to use blocked randomization to ensure that equal 
numbers of participants are enrolled at each stage of the trial into 
the different treatment arms. Accordingly, any trends over time in 
these studies must be interpreted with caution as these trends could 
be due to baseline differences in the participants. 
In our study there was a significant age difference between the 
HIV-positive women who were screened (mean 29.3 years) and 
the HIV-negative women (mean 34.3 years) who were enrolled 
into the study cohort. This difference may be a sign of the 
changing demographics of the HIV epidemic among high-risk 
women in South Africa and supports the view that the epidemic is 
being most acutely experienced by younger South African women. 
On the other hand, lower HIV  infection susceptibility, potentially 
(but controversially) associated with factors such as HLA alleles, 
partner-specific alloimmunity, reduced CD4+ T cell susceptibility, 
variability of cellular proteins involved in HIV-1 replication, host 
antiviral cellular proteins, or some related host genetic factor [15– 
23], may explain why some of the women have remained negative 
despite high-risk exposures and therefore remain uninfected 
although significantly older. That is, the women who are 
susceptible to infection are infected at an early age, leaving the 
less susceptible women as the core of the HIV-negative cohort. 
This trend is also supported by our finding that women who 
remain the in cohort are statistically less likely to seroconvert as 
follow-up progresses. Further research has been initiated to 
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examine some of these factors in the HIV-negative, high-risk 
women that remain uninfected at the end of their study follow-up. 
Another major challenge of working with this cohort of HIV-1 
negative women has been to reconcile the study goals of 
identifying acute infections with the ethical imperative to 
aggressively promote prevention. Prevention efforts in this cohort 
included the provision of male and female condoms along with 
monthly HIV  risk-reduction counselling. In spite of these efforts, 
the high rate of pregnancies and STIs in this cohort underscores 
the difficulty of prevention promotion in this population. Similar 
to vaccine or microbicide studies that intensively promote 
prevention, our experience is that some women will remain at 
risk for HIV infection in spite of the best efforts of the research 
team. 
Retention rates for the HIV-negative observational cohort have 
been extremely successful with close to 86% retention over the 
duration of follow-up. Given the highly mobile nature of this 
population, these rates are high and bode well for future 
microbicide and vaccine studies which could have even greater 
retention rates in light of the perceived benefits of the intervention 
to the participants. We believe that this success underscores the 
value of having a dedicated network of community liaisons and of 
making a coherent and concerted effort to engage the community 
on a structural level. Making use of all available contact 
mechanisms and channels, especially the cell phones and short 
message system technology, proved to be essential for maintaining 
follow-up in this highly mobile cohort in which fixed-line 
telecommunications access is not common. We have established 
the feasibility and utility of using these services to both remind 
patients about their study visits and to follow up with missed visits. 
Additionally, while the study’s CLP network was initially 
intended as an additional measure to assist with participant 
tracking and retention, we found that the designated CLPs were 
ultimately only effective in tracing women with whom they had 
pre-existing relationship or acquaintance. As the study progressed, 
the study staff would increasingly rely on friends and relatives to 
relay messages to participants. Other factors that have undoubt- 
edly contributed to the high retention rates include the monetary 
compensation for study visits, the regular counselling sessions and 
subsequent relationships formed with the counsellors, the 
distribution of condoms, and the knowledge that participants will 
be referred for STI treatment and other medical services as 
necessary. 
We have also presented here an overview of the demographic, 
behavioural, and clinical characteristics of this cohort. In 
reviewing the clinical profile of these women, while they are a 
relatively young population and would thought to be healthy, they 
have a number of comorbidities. The rates of hypertension 
(11.8%) are lower than reported rates for South Africa of 21.1% 
[24] but the cohort tended to be overweight or obese with a 
relatively high prevalence of anemia. The presence of these 
comorbidities will be important for the clinical management of 
these women and will need to be considered among HIV-infected 
South African women. They also have high rates of STIs and 
pregnancy despite intensive counselling and ready availability of 
prevention materials. Lastly, the non-study related deaths of five of 
the participants reveals that even HIV-uninfected women living in 
urban South Africa are at high-risk of death. As we continue to 
accrue longitudinal data on this cohort, we anticipate that these 
baseline characteristics will be expanded on, and specific results on 
anaemia during acute infection have been published [25]. 
The behavioural data provides an overview of the sexual history 
and potential exposures of this theoretically high-risk cohort, 
particularly the FSWs. A previous survey of sex workers in the 
 






KwaZulu-Natal province of South Africa found that women 
working at truck stops averaged 22 sex acts per week, with coitus 
occurring between two to ten times in a 24 hour period [9]. This 
earlier survey also found that peno-vaginal sex was the only 
practice reported, with strong cultural sanctions against anal and 
oral sex. The sex workers in this urban cohort appear to have 
customers with whom they engage in fewer acts but see more 
regularly, averaging just three clients per week, and are also 
engaging in anal and oral sex. Consequently, they have a very 
different risk profile than what had been anticipated based on the 
prior studies. This difference in risk behaviour has likely impacted 
the HIV  seroincidence in this cohort. Data are being analysed to 
determine the specific behavioural risk factors for HIV  infection in 
this cohort. 
The perceived ease of condom use in this cohort shows that 
women are significantly more likely to feel that they will be able to 
use condoms with casual partners than with their steady partners. 
This difference may explain why condom use has not led to a 
reduction in HIV  risk as these women are still vulnerable due to 
inconsistent condom use with their steady partners. This 
observation suggests that condom use may be associated with 
perceptions of trust; whatever the case, condom use is inconsistent 
at best in this population. The behavioural risk data collected at 
baseline will be analysed after the full 24 month follow-up period 
to see which factors are most predictive of HIV  acquisition in this 
cohort. 
Based on previous data, the projected annual sero-incidence for 
this high-risk population was 18.2% [9,12]. The actual seroinci- 
dence in this cohort has been 7.2% which is a little higher than the 
national seroincidence estimates of 6.3% for all South African 
women between the ages of 15 and 49 [14]. The risk of HIV  
acquisition in the context of the maturing South African HIV  
epidemic seems to be highly generalized. Hence, our designations 
of ‘‘high risk’’ are seemingly less relevant in retrospect and perhaps 
need not be considered as rigorously when designing future 
studies. Furthermore, unmeasured susceptibility factors may have 
disproportionately influenced the observed infection rate in this 
cohort of highly exposed individuals, where the women who were 
more susceptible had acquired HIV prior to screening for this 
study. Furthermore, our data support the notion that high-risk 
cohorts may yield fewer seroconversions over time, and that this 
attrition should be factored into the design of such cohorts. 
Women who remain in the cohort at the end of the follow-up, may 
represent a group enriched with host genetic resistance factors, 
and this is currently being explored as this group of woman has 
been recruited into a highly exposed persistently negative cohort 
for additional study. 
 
Conclusion and Significance 
To the best of our knowledge, this is the first prospective cohort 
to be assembled in southern Africa for a comprehensive analysis of 
the behavioural, clinical, and immunological characteristics 
associated with acute HIV infection. The methods, as well the 
challenges, of recruiting and successfully retaining a HIV-negative 
cohort have been described and can provide guidance for others 
wanting to assemble similar cohorts. Given the characteristics of 
our cohort, these experiences are particularly relevant to the 
recruitment and retention of cohorts of urban female sex workers 
in South Africa for HIV prevention and pathogenesis research. 
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The changing nature of the epidemic must be considered when 
recruiting high risk HIV-negative cohorts in prevention research, 
as demonstrated by the lower than anticipated seroincidence in 
this study. 
Understanding natural history of HIV  infection from as early a 
point following exposure to HIV  as possible is key for the design, 
development and targeting of new prevention interventions as well 
as for the treatment of advancing HIV disease. Understanding 
how to identify those most at risk for HIV  infection, whether this is 
due to high-risk behaviours, or due to the increased risk of 
infection due to high viral loads during acute or recent infection, 
or due to the increases risk conferred by concomitant sexually 
transmitted infections, has recently been suggested as the key 
concern for prevention science [26]. It is hoped that data from the 
Acute Infection study will contribute significantly to vaccine 
development by describing the natural history of HIV infection, 
the impact of host and viral factors during acute infection on viral 
load set point, as well as the impact of viral set-point on disease 
progression. Behavioural data collected before and after acute 
infection should assist in developing algorithms to identify those 
most at risk of infection. HIV screening algorithms [27] and 
clinical data collected during acute infection are potentially fruitful 
explorations of efficient and effective screening algorithms for 
identifying acute infection. These specific research areas will be 
addressed separately in publications from the CAPRISA 002 
Acute Infection Study Team. 
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Abstract 
Introduction: Young women are at disproportionate risk of HIV infection in South Africa. Understanding risk behaviors and 
factors associated with ability to negotiate safe sex and condom use is likely to be key in curbing the spread of HIV. 
Traditionally prevention efforts have focused on creating behavioral changes by increasing knowledge about HIV/AIDS. 
Methods: This was a cross-sectional analysis from a prospective observational cohort study of 245 women at a high-risk of 
HIV infection in KwaZulu-Natal, South Africa. 
Results: Participants demonstrated a high level of HIV/AIDS knowledge. Overall, 60.3% of participants reported condom use. 
Reported condom use at last sexual encounter varied slightly by partner type (57.0% with steady versus 64.4% with casual 
partners), and self-perceived ability to choose to use a condom was significantly lower with steady partners compared to 
casual partners (p,0.01). In multivariate analysis, women who had high school education were more likely to use condoms 
at their last sex encounter compared to those with only primary school education (RR of 1.36 (95% Confidence Interval (CI) 
1.06–1.75) and 1.46 (95% CI 1.13–1.88) for grades 8–10 and 11–12, respectively). Those who used condoms as a 
contraceptive method were twice as likely to use condoms compared to women who did not report using them as a 
contraceptive method. Greater perceived ability to choose to use condoms was associated with higher self-reported 
condom use at last encounter, irrespective of partner type (RR = 2.65 (95% CI 2.15–32.5). 
Discussion: Self-perceived ability to use condoms, level of formal education and condom use as a contraceptive were all 
significantly associated with self-reported condom use at last sexual encounter. These findings suggest that that gender 
inequality and access to formal education, as opposed to lack of HIV/AIDS knowledge, prevent safer sexual practices in 
South Africa. 
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Introduction 
In the South African province of KwaZulu-Natal, an estimated 
25.8% of all persons aged 15 to 49 years are HIV-positive. This 
prevalence rate is one of the highest in South Africa, a country that 
carries the highest number of HIV-infected persons in the world 
[1,2]. HIV is predominantly spread via heterosexual sex, with 
young women being the country’s most vulnerable population [1,3]. 
Traditionally prevention efforts have focused on creating 
behavioral changes (i.e. safer sexual practices) within the general 
population by increasing knowledge about HIV/AIDS. Studies in 
the United States and other developed countries have demon- 
strated successful reduction in HIV infection rates with educa- 
tional campaigns, while South Africa has continued to experience 
a rise in the prevalence of HIV  despite increased public knowledge 
and awareness of HIV/AIDS [1,4,5]. Recent reductions in HIV  
incidence in South Africa have instead been attributed to 
increased access to HIV treatment [6]. Additionally, several 
studies have found that improved access to information about HIV  
risk is not translating into an effective behavioral change in women 
at high-risk of infection [1,7,8,9,10,11,12,13,14]. Researchers have 
investigated the possible causes of this disconnect and one theory is 
that behavioral changed is impeded by the ‘social context’ of this 
community [15]. 
Reported level of condom use has been used as way of 
identifying and understanding barriers to behavioral change. 
 






Reported rates of condom use among sexually active populations 
in South Africa range from 32.8% to 78.4% [1,16,17,18,19, 
20,21]. In high-risk women, such as commercial sex workers, the 
rate of condom use is low [13,14,15]. The negative stigma 
associated with condoms, lack of female power in sexual 
relationships, threat of physical violence if condom use is 
requested, and financial incentives to forego condom use are all 
potential barriers to their use [3,7,11,12,13,14,15,20,22,23,24, 
25,26,27,28]. 
This investigation, as part of a larger behavioral study, focused 
on women at high-risk of contracting HIV/AIDS. It aimed to 
examine the impact of HIV/AIDS knowledge, as well as related 
sexual practices on self-reported condom use, and the influence 
these factors have on HIV  acquisition in a high-risk population. 
 
Methods 
This study was a cross-sectional analysis of baseline behavioral 
data gathered from women enrolled into a prospective observa- 
tional cohort study performed at the Centre for the AIDS 
Programme of Research in South Africa (CAPRISA), in Durban, 
KwaZulu-Natal Province, South Africa. This investigation, known 
as the CAPRISA 002 Acute Infection Study, began in 2004 to 
research the natural history of acute HIV  infection and associated 
risk behaviors in a cohort of high-risk women, 78.8% of who were 
self-identified sex workers. 
CAPRISA 002 study enrolled women . = 18 years of age who 
self-reported sex with more than three different partners in the 
previous three months, and who were HIV  antibody negative on 
screening with rapid tests (first with the Determine test (Abbott 
Laboratories, Tokyo, Japan) and, if positive, confirmed with a 
Capillus test (Trinity Biotech, Jamestown, NY, USA)). Discordant 
rapid HIV tests were resolved with a confirmatory HIV enzyme 
immunoassay (BEP 2000; Dade Behring, Marburg, Germany). 
More detailed information regarding CAPRISA 002 study 
methodology, including recruitment methods and eligibility 
criteria, is described elsewhere [29]. 
Prior to study initiation, the protocol and informed consent 
forms were reviewed and approved by the research ethics 
committees of the University of KwaZulu-Natal (E013/04), the 
University of Cape Town (025/2004), and the University of the 
Witwatersrand (MM040202). Consent forms and information to 
patients were available in English and were translated into isiZulu, 
the local language. Written informed consent was obtained at each 
phase of the study, including collecting the behavioral risk data 
and to store the study specimens. 
Participants completed a structured, in-person interview in 
either English or isiZulu (per participant preference) to identify 
their HIV  risk behaviors. Upon enrollment, demographic, locator 
information and laboratory samples were obtained from each 
participant who received HIV  pre- and post-test counseling, HIV  
and sexually transmitted infection (STI) risk reduction counseling, 
a behavioral risk assessment as well as a routine clinical evaluation. 
During the administration of the HIV/AIDS knowledge questions, 
participants were not prompted, but were asked to state their 
responses to the questionnaire administrator who ticked off the 
appropriate category according to the participant’s response. 
Responses were then labeled with a participant identification 
number and entered into a data collection system. Each 
participant was paid for her participation in the study as a means 
of reimbursement for their time and travel expenses. 
Descriptive and statistical analysis was performed using SAS 
software version 9.2 (SAS Institute Inc., Cary). Unadjusted and 
adjusted risk ratios, measuring the associations between the factors 
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of interest, were calculated using generalized estimating equation 
regression models with the log link function. Variables in the 
unadjusted model with a p-value less than 0.20, or variables 
deemed as important to adjust for, were fitted to the multivariate 
model. The McNemar test was used to assess differences in 




A total of 245 participants were enrolled in the study, the basic 
characteristics of whom are presented in Table 1. This was a 
cohort of high-risk women; 85.4% reported having 2–5 casual 
partners in the 3 months prior to enrollment and 78.8% self- 
identified as sex workers. Overall, 58.8% of women reported 
condom use at their last sexual encounter. 
All participants reported that they had heard of HIV/AIDS at 
the time of study enrollment and, overall, participants demon- 
strated a good level of knowledge of HIV  disease. These data are 
presented in Table 2. 
Participants were knowledgeable about how HIV/AIDS is 
spread; almost all participants listed vaginal sex as a risk factor, but 
considerably smaller proportion listed anal or oral sex. When 
asked about the risk of contracting HIV  via anal and oral versus 
penovaginal sex, slightly more than a third of participants 
answered that anal and oral sex carried more risk compared to 
vaginal sex. 
Similarly, there was high level of awareness how to prevent 
acquisition or transmission of HIV. Almost all of the participants 
listed condoms as an effective method, while only 39% and 30% 
indicated abstinence and staying faithful to one partner as an 
effective HIV  prevention method. Even though treatment was not 
widely available at the time of the interviews, the majority of 
participants knew that HIV could not be cured, while a similar 
proportion agreed that it could be treated. 
Sexual behavior data is presented in Table 3, and indicate that 
participants were much more likely to have had sex with a steady 
partner than a casual partner (defined as one seen only 
occasionally, or even once, that was not a sex work client) at last 
encounter (75.9% steady versus 24.1% casual). In the three 
months prior to enrollment, over 85% of participants reported two 
to five casual partners. With respect to total lifetime partners, 
54.1% reported more than five steady partners and 76.1% 
 
Table 1. Participant demographic characteristics. 
 
Mean age in years ±  SD                       34.2610.5 
High school education %  (n) 
- Primary                                      24.5% (60) 
- Secondary to 10
th
 grade                   34.3% (84) 
- Grades 11/12                                 41.2% (101) 
Partner status %  (n) 
- No partner                                   7.4% (18) 
- One partner                                  35.7% (87) 
- Many Partners                                57.0% (139) 
Race %  (n) 
- Black                                        98.4% (241) 
- Indian                                       0.4% (1) 
- White                                       1.2% (3) 
doi:10.1371/journal.pone.0030669.t001 
 






Table 2. HIV/AIDS awareness and knowledge. 
 
Have you ever heard of HIV/AIDS? %  (n) 
- Yes 100% (n = 245) 
- No 0% 
How is HIV/AIDS spread? %  (n) 
- Vaginal sex 99.6% (n = 244) 
- Contact with blood 94.7% (n = 232) 
- Anal sex 56.7% (n = 139) 
- Oral sex 51.8% (n = 127) 
- From mother to child 48.2% (n = 118) 
- Breastfeeding 10.6% (n = 26) 
- Touching someone 4.9% (n = 12) 
- Mosquito bites 4.5% (n = 11) 
- Sharing same cup 3.7% (n = 9) 
- Using public toilets 2.9% (n = 7) 
- Other 62.4% (n = 153) 
How can you prevent the spread of HIV/AIDS? %  (n) 
- Using condoms 99.6% (n = 244) 
- Avoid sharing razors 75.1% (n = 184) 
- Injections with clean needles 53.5% (n = 131) 
- Abstaining from sex 39.2% (n = 96) 
- Staying faithful 29.8% (n = 73) 
- Having good diet 2.0% (n = 5) 
- Other 35.5% (n = 87) 
If you have an STI, do you think you are more likely to get HIV/AIDS? 
%  (n) 
- Yes 71.8% (n = 176) 
- No 1.6% (n = 4) 
- Unsure 26.5% (n = 65) 
Do you think that HIV/AIDS can be cured? %  (n) 
- Yes 4.1% (n = 10) 
- No 91.4% (n = 224) 
- Unsure 4.5% (n = 11) 
Do you think that HIV/AIDS can be treated? %  (n) 
- Yes 95.1% (n = 233) 
- No 2.0% (n = 5) 
- Unsure 2.9% (n = 7) 
Risk of HIV acquisition by route 
Anal sex compared to penovaginal sex? %  (n) 
- Less risk 30.3% (n = 74) 
- Same risk 27.9% (n = 68) 
- More risk 34.0% (n = 83) 
- Don’t know 7.8% (n = 19) 
Oral sex compared to penovaginal sex? %  (n) 
- Less risk 23.9% (n = 58) 
- Same risk 33.3% (n = 81) 
- More risk 38.3% (n = 93) 
- Don’t know 4.5% (n = 11) 
doi:10.1371/journal.pone.0030669.t002 
 
reported more than five casual partners. Participants reported 
that they engaged in penovaginal sex an average of 10 times a 
month, with low levels of oral and anal sex. Approximately 80% 
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Table 3. Sexual behavior. 
 
Mean age at sexual debut 6 SD                       17.062.4 
Mean days since last encounter 6 SD                  4.664.6 
Last sex act partner type %  (n) 
- With casual partner                                24.1% (59) 
- With steady partner                                75.9% (186) 
Number of casual partners in the last 3 months %  (n) 
- 0–1                                              5.0% (12) 
- 2–5                                              85.4% (205) 
- .5                                             9.6% (23) 
Number of lifetime casual partners %  (n) 
- 0–1                                              0.0% (0) 
- 2–5                                              23.9% (57) 
- .5                                             76.1% (181) 
Number of steady partners (last 3 months) %  (n) 
- 0–1                                              68.4% (165) 
- 2–5                                              29.1% (70) 
- .5                                             2.5% (6) 
Number of lifetime steady partners %  (n) 
- 0–1                                              4.1% (10) 
- 2–5                                              41.7% (101) 
- .5                                             54.1% (131) 
Mean number of penovaginal sex acts per month 6 SD    10.266.7 
Mean number of oral sex acts per month % (n) 
- 0–1                                              79.9% (191) 
- 1–4                                              14.2% (34) 
- .4                                             5.9% (14) 
Anal sex acts per month 
- Never                                            66.8% (159) 
- Once or less                                      11.3% (27) 
- $2                                             21.9% (52) 
Douche after/between sex % (n) 
- Yes                                              9.4% (23) 
- No                                              90.6% (221) 
Proportion who ever had sex while drunk % (n)           26.9% (66) 
Proportion who use any contraceptives % (n)             79.9% (195) 
Proportion who use condoms % (n)                     60.3% (147) 
Contraceptives used: % (n) 
- Condom                                          32.0% (78) 
- Dual (condom+other)                       28.3% (69) 
- Non-condom                                      19.3% (47) 
- None                                            20.5% (50) 
Proportion using injectable contraceptives % (n)          27.9% (68) 
doi:10.1371/journal.pone.0030669.t003 
 
of participants reported that they used contraceptives, with 
60.3% listing condoms as a method of contraception. Impor- 
tantly, none of these baseline characteristics or sexual practices 
were found to be statistically associated with subsequent HIV  
acquisition. 
While frequency of contraceptive use was not assessed, condom 
use at the most recent sexual encounter varied depending on 
partner type (see Table 4). For example, 57.0% of participants 
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Table 4. Condom use. 
 
Condom used at last sexual encounter % (n) 58. 8% (144) 
- Steady partner at last sexual encounter: condom use % (n) 57.0% (106/186) Fisher’s exact 
- Casual partner at last sexual encounter: condom use % (n) 64.4% (38/59) p = 0.36 
Perceived ability to choose condom use with steady partner %  (n) 
- Never 35.0% (84) 
- Sometimes 44.2% (106) 
- Every time 20.8% (50) 
Perceived ability to choose condom use with casual partner %  (n) 
- Never 13.9% (34) 
- Sometimes 32.2% (79) McNemar 
- Every time 53.9% (132) p,0.01 
doi:10.1371/journal.pone.0030669.t004 
 
reported using a condom with a steady partner, compared to 
64.4% with a causal partner (p = 0.36). Perceived ability to 
negotiate condom use with casual partners was significantly higher 
compared to steady partners, with only 20.8% of participants 
saying they felt they could always use condoms with their steady 
partner versus 53.9% with casual partners (p,0.01). 
Several factors were associated with condom use at last sexual 
encounter. For example, self-perceived ability to choose to use 
condoms was associated with self-reported use both in 
univariate and multivariate analyses (see Table 5). In the 
multivariate model, women who believed they had a high 
degree of control over condom use (able to choose always or 
over half the time whether or not to use condoms) were more 
than twice as likely to have used a condom than those who 
reported never having the ability to choose or who felt they 
could only insist on using a condom less than half the time (RR 
2.21, 95% CI  1.79–2.72). 
Education level was significantly associated with condom use. In 
multivariate analysis, women with Grade 8 to 10 education were 
approximately 40.0% more likely to report using condoms 
compared to women with primary school education (p = 0.02); 
and those with Grade 11 to 12 education were about 50.0% more 
likely to report using condoms (p,0.01). Women who reported 
having no partner (single, divorced, widowed or separated) were 
1.39 times more likely (95% CI 1.01–1.90) to have used a condom 
at their last sex act compared to women who were in a stable 
relationship or married (p = 0.04). 
In univariate analysis, age was significantly associated with 
condom use, with older women being less likely to use condoms. It 
was no longer significant in the multivariate model, however, most 
likely because schooling was closely associated with age, with older 
women being less educated. Age was also associated with 
perceived choice or insistence on condom use; younger women 
reported being able to insist on condom use more often than older 
women. For every five year decrease in age, women were 1.03 
times more likely (95% CI 1.01–1.05) to insist on condom use 
(p = 0.01), adjusting for education level. 
Women who reported using condoms as a method of 
contraception were twice as likely to have used a condom at their 
last sex act compared to women who did not use condoms as 
contraception (RR 2.02, 95%CI 1.53–2.66, p,0.01). However, 
women who said they were using hormonal methods as a 
contraception method were no more likely to have used a condom 
at their last sex act compared to women who were not on 
hormonal contraception (p = 0.51). 
Discussion 
This study provides information about the behavioral charac- 
teristics, level of HIV  knowledge and predictors of condom use in a 
population of high-risk women in KwaZulu-Natal, South Africa. 
Specifically, this study illustrates that knowledge of HIV  and HIV  
transmission does not correlate with high condom use in this 
population. These behavioral risk data are also supported by high 
STI  and HIV  infection rates in this cohort over time [29]. Previous 
studies also illustrated that lack of HIV  specific knowledge does not 
explain low rates of condom use [7,8,11,12]. Of note, there was 
lower awareness of STI  and HIV  transmission risk with oral and 
anal sex, suggesting that this would be an important opportunity 
for more targeted education. 
In our cohort, an important finding is the higher reported efficacy 
of condom use choice at last sexual encounter with casual rather 
than steady partners. Similar observations were made in other 
studies from South Africa and the proposed explanations include 
concern about perceived lack of trust and threat to intimacy 
and commitment between steady partners [12,13,14,15,30]. This 
highlights the fact that negotiating condom use with steady partners 
is challenging as it may represent infidelity or, conversely, that non- 
use of condoms may signal trust. Ironically this means that steady 
sexual partnerships may represent greater risk of HIV  infection, for 
either partner. 
In our cohort, several factors were significantly associated with 
reported condom use during last sexual encounter. We found an 
association between education level and increased frequency of 
reported condom use, a result consistent with other studies that 
show an association between schooling and reduced levels of HIV  
risk, particularly in young women [31]. Our results also suggests 
that using condom for contraceptive purpose seems to be a more 
acceptable motivation, and women are more likely to use condoms 
in their sex acts if this is being done as the primary means of 
contraception. It remains to be seen whether or not use of 
hormonal contraception in this social context would undermine 
condom use. 
Importantly, we noted that women who perceived that they are 
able to make a choice about using a condom were twice as likely 
to report using one. It is therefore important to focus on female 
empowerment in sexual relationships. Previous literature suggests 
that encouraging self-agency and endorsing egalitarian gender 
roles in sexual relationships may have a positive impact on rates 
of condom use [22]. Similarly, a recent preliminary analysis from 
a randomized trial in South Africa has shown that interventions 
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Table 5. Perceived ability to choose to use a condom and predictors of condom use at last sexual encounter. 
 
Variable Univariate analysis Multivariate analysis 
%  with condom use at 
last sex act (n/N) Risk Ratio (95% CI) p-value Risk Ratio (95% CI)  p-value 
Ability to insist on condom use (number of times) 
- Less than half/Never 36.9% (58/157) 1.00 (reference) - 1.00 (reference) - 
- More than half/Always 97.7% (86/88) 2.65 (2.15–3.25) ,0.01 2.21 (1.79–2.72) ,0.01 
Age (by 5 year increase) 0.92 (0.88–0.97) ,0.01 0.99 (0.94–1.04) 0.69 
Age at sexual debut (by 5 year increase) 0.98 (0.78–1.24) 0.88 
Schooling 
- No schooling 28.6% (2/7) 1.00 (reference) - 
- Any schooling 59.7% (142/238) 2.09 (0.64–6.77) 0.22 
Highest level of school 
- Primary 43.3% (26/60) 1.00 (reference) - 1.00 (reference) - 
- Grade 8–10 63.1% (53/84) 1.46 (1.04–2.03) 0.03 1.36 (1.06–1.75) 0.02 
- Grade 11–12 64.4% (65/101) 1.49 (1.07–2.05) 0.02 1.46 (1.13–1.88) ,0.01 
Marital status 
- One partner 59.8% (52/87) 1.00 (reference) - 1.00 (reference) - 
- Many partners 56.1% (78/139) 0.94 (0.75–1.18) 0.59 0.92 (0.76–1.10) 0.36 
- No partner 72.2% (13/18) 1.21 (0.86–1.69) 0.27 1.39 (1.01–1.90) 0.04 
Last sexual partner 
- Steady 57.0% (106/186) 1.00 (reference) - 1.00 (reference) - 
- Casual 64.4% (38/59) 1.13 (0.90–1.42) 0.29 1.05 (0.87–1.26) 0.61 
Sex worker 
- No 69.2% (36/52) 1.00 (reference) - 1.00 (reference) - 
- Yes 56.0% (108/193) 0.81 (0.65–1.01) 0.06 0.96 (0.78–1.18) 0.69 
Ever had anal sex? 
- No 63.5% (101/159) 1.00 (reference) - 1.00 (reference) - 
- Yes 50.0% (42/84) 0.79 (0.62–1.00) 0.05 1.00 (0.82–1.24) 0.94 
Ever had oral sex? 
- No 59.9% (109/182) 1.00 (reference) - 
- Yes 54.8% (34/62) 0.92 (0.71–1.18) 0.50 
Ever had sex while drunk? 
- No 48.5% (32/66) 1.00 (reference) - 1.00 (reference) - 
- Yes 62.6% (112/179) 0.77 (0.59–1.02) 0.07 0.89 (0.72–1.10) 0.29 
Condom as contraceptive? 
- No 30.9% (30/97) 1.00 (reference) - 1.00 (reference) - 
- Yes 76.9% (113/147) 2.49 (1.82–3.39) ,0.01 2.02 (1.53–2.66) ,0.01 
Hormonal contraceptives? 
- No 60.0% (102/170) 1.00 (reference) - 
- Yes 55.4% (41/74) 0.92 (0.73–1.17) 0.51 
doi:10.1371/journal.pone.0030669.t005 
 
to empower a woman’s ability to negotiate condom use can lead 
to an increase in self-reported condom use at the last sex act 
[32,33]. 
Negotiating condom use for women in our cohort is further 
complicated by the social and cultural context in which these 
relationships are developed. For although, it has been shown that 
women have positive attitudes toward condom use [11], South 
African men are traditionally the decision makers, especially 
regarding issues of sexual practice [12,15,24,26,27,34,35]. There- 
fore, despite high levels of knowledge about HIV  transmission and 
prevention, some women are not able to protect themselves from 
infection. 
A strength of this study is the prospective design, with a 
relatively large cohort, and the high response rate with almost all 
participants responding to each question. These findings are thus 
important as they represent unique data for a large cohort of HIV  
negative women at high risk for HIV  infection, who had a broad 
range of risk factors, including both sex work and non-sex work 
partners. We believe these data contribute to greater understand- 
ing of the sexual networks and risk behaviors in this specific 
 






context. Furthermore, this level of data is particularly important in 
designing culturally relevant risk reduction counseling messages in 
the context of, for example, HIV  prevention studies. 
A limitation of the study is that the HIV knowledge and 
behavioral risk questionnaires were only administered at baseline 
in the HIV  negative cohort, limiting the analysis to cross-sectional 
data. For example, since data about factors associated with 
condom use are collected at a single time point, it is not possible to 
determine causality; prospective study would be needed to 
determine whether factors such as greater access to formal 
education would empower the woman to negotiate for condom 
use. Another notable weakness, shared by much behavioral 
research, is that the data are self-reported and therefore subject 
to reporting and recall bias. Attempts were made to minimize 
reporting bias by making the questions neutral and assuring 
participants of confidentiality. 
 
Conclusions 
Women at high-risk of HIV  infection were found to have had a 
high level of knowledge about HIV  acquisition and prevention of 
transmission. This indicates that education campaigns have 
reached women in need of this information. However, important- 
ly, knowledge about the high risk of transmission during anal sex 
was lacking. Future HIV/AIDS educational campaigns therefore 
need to include messages regarding the risk of transmission via 
anal sex. 
The self-perceived ability to choose to use condoms is 
significantly associated with reported condom use at last 
encounter, and furthers the argument that social barriers, 
particularly gender power imbalances in relation to sexual 
decision-making, as opposed to lack of knowledge, may be 
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influential factors preventing safer sexual practices in South 
Africa. This information highlights the importance of female 
empowerment in prevention efforts. In particular, and supporting 
this empowerment hypothesis, our data show that women who 
attained higher levels of formal education, and those who choose 
to use condoms for contraception, are more likely to report that 
they use condoms during sex. Our findings, from a unique cohort 
of women at high risk for HIV  infection with a range of partner 
types, suggest that focusing on ensuring higher levels of formal 
education in women and de-stigmatizing condom use, for example 
by emphasizing condom use as contraception, particularly among 
men who may view condom use for STI prevention as an 
indication of infidelity or a lack of trust, are essential components 
of HIV  prevention efforts and promoting safer sexual practices in 
this part of the world. 
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Background. Diagnosis and treatment of sexually transmitted infections (STIs) is a public health priority, 
particularly in regions where the incidence of human immunodeficiency virus (HIV) infection is high. In most 
developing countries, STIs are managed syndromically. We assessed the adequacy of syndromic diagnosis of STIs, 
compared with laboratory diagnosis of STIs, and evaluated the association between STI diagnosis and the risk of 
HIV acquisition in a cohort of high-risk women. 
Methods. HIV-uninfected high-risk women (n = 242) were followed for 24 months. Symptoms of STIs were 
recorded, and laboratory diagnosis of common STI pathogens was conducted every 6 months. Forty-two cytokines 
were measured by Luminex in cervicovaginal lavage specimens at enrollment. Human immunodeficiency virus 
type 1 (HIV-1) infection was evaluated monthly. 
Results. Only 12.3% of women (25 of 204) who had a laboratory-diagnosed, discharge-causing STI had clini- 
cally evident discharge. Vaginal discharge was thus a poor predictor of laboratory-diagnosed STIs (sensitivity, 
12.3%; specificity, 93.8%). Cervicovaginal cytokine concentrations did not differ between women with asymptom- 
atic STIs and those with symptomatic STIs and were elevated in women with asymptomatic STIs, compared with 
women with no STIs or bacterial vaginosis. Although laboratory-diagnosed STIs were associated with increased 
risk of HIV infection (hazard ratio, 3.3 [95% confidence interval, 1.5–7.2)], clinical symptoms were not. 
Conclusions. Syndromic STI diagnosis dependent on vaginal discharge was poorly predictive of laboratory- 
diagnosed STI. Laboratory-diagnosed STIs were associated with increased susceptibility to HIV acquisition, while 
vaginal discharge was not. 
 
Sexually transmitted infections (STIs) impose a major 
health burden, particularly in developing countries 
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such as South Africa, where the prevalence of 
human immunodeficiency virus type 1 (HIV-1) in- 
fection is high [1, 2]. In South Africa, most new 
HIV infections are sexually transmitted, and women 
are at higher risk of infection than men [3]. As STIs 
are associated with increased susceptibility to HIV in- 
fection, they have likely played a central role in facili- 
tating the spread of HIV [4–11]. STI management is 
thus a key issue in preventing HIV infection in coun- 
tries where both HIV infection and other STIs are 
prevalent. 
 










































Developing countries such as South Africa manage most 
STIs syndromically, on the basis of signs and symptoms [12]. 
Etiological diagnosis is expensive and time-consuming and re- 
quires laboratory equipment and suitably trained staff, whereas 
syndromic management is easily implemented and inexpensive, 
with immediate treatment available [12, 13]. However, because 
the STI syndromes used for diagnosis are nonspecific and 
because a large proportion of STIs are asymptomatic, under- 
treatment, and sometimes overtreatment, are pervasive [14–18]. 
In South Africa, asymptomatic infections occur in almost 50% 
of STI-infected women who do not seek care and therefore 
remain untreated [19]. Untreated STIs are associated with sig- 
nificant direct sequelae, including pelvic inflammatory disease 
(PID), ectopic pregnancy, and tubal factor infertility [20]. On 
the other hand, a significant number of women with conditions 
such as vaginal discharge resulting from a derangement of 
normal vaginal flora may be treated for STIs that they do not 
have. The costs associated with overtreatment include the finan- 
cial burden of supplying medicines, the potential development 
of antimicrobial resistance, and the social cost of misdiagnosis. 
Several studies have investigated the influence of different 
strategies for STI management on the risk of HIV infection. 
Population-wide treatment of bacterial infections or therapy 
for herpes simplex virus 2 (HSV-2) was found to be ineffec- 
tive at reducing HIV infection [21–25]. Two of 3 syndromic 
management interventions found no difference in HIV 
acquisition [26–29], suggesting that asymptomatic infections 
may play a role. In addition to causing visible clinical 
symptoms, certain STIs may be associated with subclinical 
manifestations, including elevated genital tract inflammatory 
cytokine responses [14, 30]. Although a direct association 
between genital tract inflammatory cytokines and suscepti- 
bility to HIV infection has not yet been demonstrated, 
previous studies have suggested that inflammatory cytokines 
may directly upregulate HIV replication in the genital 
tract by activating nuclear factor κB and by recruiting and 
activating various immune cells which act as targets for 
HIV infection [31–34]. Additionally, proinflammatory cyto- 
kines such as tumor necrosis factor α (TNF-α) may facilitate 
HIV infection by disrupting tight junctions between epitheli- 
al cells, reducing the integrity of this barrier [35–37]. 
The aim of this study was to establish the prevalence and 
incidence of STIs in a longitudinal cohort of HIV-uninfected 
women with multiple sexual partners in South Africa. The ad- 
equacy of syndromic management was evaluated by compar- 
ing clinical signs and symptoms to laboratory diagnosis of 
STIs. Inflammatory cytokine concentrations in cervicovaginal 
lavage (CVL) specimens were measured to determine whether 
women who had asymptomatic laboratory-diagnosed STIs 
also had subclinical inflammation that may facilitate HIV in- 
fection. Last, associations between STIs, cytokine concentra- 
tions, and HIV acquisition were investigated. 
MATERIALS AND  METHODS  
 
Study Design 
A total of 775 high-risk women were screened for HIV infec- 
tion, and 245 HIV-uninfected women were enrolled into a pro- 
spective observational cohort study, the CAPRISA 002 Acute 
HIV Infection study, which was conducted in Durban, South 
Africa [38]. Participants attended the clinic monthly for risk- 
reduction counseling, condom provision, and HIV testing. 
STIs were assessed at enrollment and every 6 months thereaf- 
ter. Acute HIV infection was diagnosed by detection of HIV 
RNA in the absence of HIV antibodies or on the basis of a 
reactive HIV antibody test within 5 months of a previously 
known negative antibody result. Laboratory diagnosis of STIs 
was conducted at enrollment and every 6 months thereafter. 
Ethics approval for the study was obtained from the University 
of KwaZulu-Natal and the University of Cape Town. Written 
informed consent was obtained from all participants. 
 
Laboratory Diagnosis of STIs 
A gynecological examination, including a speculum examination 
using an unlubricated sterile bivalve speculum, was performed 
at enrollment and every 6 months thereafter to visualize any cer- 
vical changes, and appropriate samples were collected from any 
suspicious lesions. Two vulvovaginal swab specimens were col- 
lected from the posterior fornices and lateral vaginal walls at 
each examination. Blood specimens were collected for serologi- 
cal testing for Treponema pallidum and HSV-2. All specimens 
were transported to the diagnostic laboratory (Medical Microbi- 
ology Laboratory, University of KwaZulu-Natal) within 1 hour 
of collection for same-day processing. One vulvovaginal swab 
specimen was rolled onto a glass slide for Gram staining for di- 
agnosis of bacterial vaginosis, using Nugents criteria. The 
second swab specimen was used to extract DNA for detection of 
Neisseria gonorrhoeae and Chlamydia trachomatis, using the 
BDProbe Tec ET polymerase chain reaction (PCR) assay 
(Becton Dickinson Microbiology Systems, United States), and 
for detection of Trichomonas vaginalis, Mycoplasma genitalium, 
and HSV-2, using an in-house PCR assay [39]. 
Genital ulcers were diagnosed as previously described, on 
the basis of PCR testing for T. pallidum, Haemophilus ducreyi, 
C. trachomatis (lymphogranuloma venereum types), and 
HSV-2 [40]. An impression slide of ulcers for microscopy was 
collected for the diagnosis of Calymmatobacterium granulo- 
matis, if suspected clinically. HerpeSelect-1 and HerpeSelect-2 
enzyme immunoassays were used to confirm genital herpes di- 
agnosis and to identify asymptomatic carriers. Syphilis screen- 
ing was done using the Becton Dickinson Macro-Vue RPR 
(rapid plasma reagin [RPR]) card test, and positive reactions 
were confirmed by the T. pallidum hemagglutination test 
(Omega ImmuTrep TPHA test). The RPR test was done on 
serum samples that were undiluted or diluted at ratio of 1:8. 
 










































Collection of CVL Specimens and Cytokine Measurements 
CVL samples for cytokine measurements were collected from 
study participants at enrollment into the study, as previously 
described [41]. Sterile normal saline (10 mL) was used to re- 
peatedly bathe the cervix. The fluid was allowed to pool in the 
posterior fornix, where it was then aspirated into a plastic bulb 
pipette. Samples were centrifuged, and the supernatant was 
stored at −80°C. CVL samples were not collected from men- 
struating participants, for whom sampling was postponed to 
the following week. CVL samples for cytokine analysis were 
available for a subset of 227 of 242 women who were included 
in this study, of whom 66 had ≥1 STI (excluding bacterial 
vaginosis and HSV-2 serology findings). Prior to cytokine 
measurements, CVL samples were prefiltered by centrifugation 
using 0.2 μm cellulose acetate filters (Sigma, United States). 
Concentrations of epidermal growth factor, eotaxin/CCL11, 
fibroblast growth factor 2, fms-like tyrosine kinase 3 ligand 
(Flt-3L), fractalkine/CX3CL1, granulocyte colony-stimulating 
factor (CSF), granulocyte macrophage CSF, growth related 
oncogene family (CXCL1-CXCL3), interferon α (IFN-α), in- 
terferon γ (IFN-γ), interleukin 1α (IL-1α), interleukin 1β 
(IL-1β), interleukin 1 receptor antagonist, interleukin 2 (IL-2), 
interleukin 3, interleukin 4, interleukin 5, interleukin 6 (IL-6), 
interleukin 7, interleukin 8 (IL-8)/CXCL8, interleukin 9, inter- 
leukin 10, interleukin 12p40, interleukin 12p70 (IL-12p70), 
interleukin 13 (IL-13), interleukin 15, interleukin 17 (IL-17), 
IFN-γ–induced protein 10/CXCL10, monocyte chemotactic 
protein 1/CCL2, monocyte chemotactic protein 3/CCL7, mac- 
rophage-derived chemokine/CCL22, macrophage inflammato- 
ry protein 1α/CCL3, macrophage inflammatory protein 1β/ 
CCL4, platelet-derived growth factor AA, platelet-derived 
growth factor AB/BB, RANTES/CCL5, soluble CD40 ligand 
(sCD40L), soluble IL-2 receptor α, transforming growth factor 
α, tumor necrosis factor α (TNF-α), tumor necrosis factor β 
(TNF-β), and vascular endothelial growth factor (VEGF) were 
measured using Human Cytokine LINCOplex kits (LINCO 
Research, MO), according to the manufacturer’s protocol. The 
sensitivity of these kits ranged from 0.01 and 18.3 pg/mL for 
each of the 42 cytokines measured. Data were collected using 
a Bio-Plex Suspension Array Reader (Bio-Rad Laboratories), 
and a 5-parameter logistic regression formula was used to cal- 
culate sample concentrations from the standard curves. Data 
were analyzed using BIO-plex manager software (version 4). 
Cytokine levels that were below the lower limit of detection of 
the assay were reported as the midpoint between the lowest 
concentration measured and zero. 
 
Statistical Methods 
Data was analyzed using SAS, version 9.2 (SAS Institute, Cary, 
NC), GraphPad Prism version 5 (GraphPad Software, San 
Diego, CA), and STATA (StataCorp, TX). Demographic and 
baseline behavioral characteristics are described overall and by 
STI and genital symptom profile at enrollment. The Fisher 
exact test and the Kruskal–Wallis test were used to compare 
characteristics between the groups. STI incidence was calculat- 
ed during follow-up for participants who were STI negative at 
baseline or for whom resolution of a previous infection 
allowed detection of a newly acquired STI. Sensitivity, specifi- 
city and positive and negative predictive values were calculated 
for STI diagnosis by discharge and genital ulcers, using labora- 
tory results as the true diagnosis. A Mann–Whitney U test was 
used to compare cytokine concentrations at enrollment in un- 
matched women with asymptomatic and symptomatic STIs 
and women with none of the assessed STIs. Hierarchical clus- 
tering was used to cluster women according to the relatedness 
of their cytokine expression profiles (Qlucore Omics Explorer). 
Principal component analysis (PCA) was used to simplify the 
data set and generate new variables (component estimates), 
which are representative of the unique and common variance 
of each of the included cytokines. P values were adjusted using 
a false discovery rate step-down procedure in order to reduce 
false-positive results when multiple comparisons were made 
[42]. The hazard ratios (HRs) for HIV infection were calculated 
using proportional hazards regression models with STIs as 
time-varying covariates. A multivariate proportional hazard 
model was also fitted, with adjustment for all laboratory- 
diagnosed STIs, clinical symptoms, and demographic and 
behavioral factors. Only STI infections diagnosed prior to the 
estimated date of HIV infection were included in the models 
predicting HIV infection. Demographic and behavioral factors 
associated with HIV risk will, however, be explored in more 
detail in a separate analysis. Participants lost to follow-up were 
censored at the last contact visit, while all other participants 




High Prevalence and Incidence of STIs in this Cohort of High 
Risk Women 
A total of 245 high-risk HIV-uninfected women were enrolled 
into this study and followed for up to 24 months. Of these, 
242 were included in the STI analysis, as 3 participants did 
not have preinfection data available. At enrollment, 57.0% of 
women reported having multiple “stable” partners, while 
35.7% had 1 stable partner or were married. However, most 
women (95.0%) reported having had >1 casual sex partner 
within the last 3 months, and 78.8% were self-identified 
female sex workers (Table 1) [38]. The prevalence of laboratory- 
diagnosed STIs at enrollment was high: 20.3% had T. vagina- 
lis, 5.4% had N. gonorrhoeae, 4.2% had C. trachomatis, 1.2% 
had M. genitalium, and 3.7% were HSV-2 positive on PCR. 
Of these, 25.3% of women received a diagnosis one of 1 STI, 
and 5.8% received a diagnosis of ≥2 STIs. HSV-2 antibodies 
were detected in 86.0% of the women, while the prevalence of 
 



















































(n = 245) 
or Symptoms 
(n = 83) 
Asymptomatic 
(n = 65) 
Symptomatic 
(n = 12)        P 
 
Education 
Primary school 60 (24.5) 18 (21.7) 14 (21.5) 2 (16.7) .7827 
Secondary school to grade 10 84 (34.3) 29 (34.9) 28 (43.1) 6 (50.0) 
Secondary school grade 11 and higher 101 (41.2) 36 (43.4) 23 (35.4) 4 (33.3) 
Marital status 
Single 18 (7.4) 9 (11.0) 6 (9.2) 0 (0.0) .1336 
Stable partner/married 87 (35.7) 32 (39.0) 22 (33.9) 1 (8.3) 
Many partners 139 (57.0) 41 (50.0) 37 (56.9) 11 (91.7) 
No. of casual sex partners in last 3 mo 
0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) .0475 
1 12 (5.0) 5 (6.2) 2 (3.1) 0 (0.0) 
2–5 205 (85.4) 73 (90.1) 51 (79.7) 10 (83.3) 
>5 23 (9.6) 3 (3.7) 11 (17.2) 2 (16.7) 
No. of steady sexual partners in last 3 mo 
0 8 (3.3) 1 (1.2) 5 (7.8) 0 (0.0) .0717 
1 157 (65.2) 59 (72.0) 35 (54.7) 10 (83.3) 
2–5 70 (29.1) 20 (24.4) 22 (34.4) 1 (8.3) 
>5 6 (2.5) 2 (2.4) 2 (3.1) 1 (8.3) 
No. who reported condom use at last sex act 144 (58.8) 54 (65.1) 36 (55.4) 8 (66.7) .4390 
Mean age in years (SD) 34.2 (10.5) 34.6 (9.7) 34.2 (11.5) 31.6 (8.0) .5974 
Mean age of sexual debut in years (SD) 17.0 (2.4) 17.1 (2.4) 16.4 (1.9) 16.4 (2.6) .2830 
Abbreviations: BV, bacterial vaginosis; STI, sexually transmitted infection. 
 
 
bacterial vaginosis was 52.7% (Table 2). During the study 
period, the incidence of any STI (excluding bacterial vaginosis 
and HSV-2 serology findings) was 26.7 cases per 100 person- 
years, and the incidences of T. vaginalis, N. gonorrhoeae, 
C. trachomatis, M. genitalium, and T. pallidum were 14.7, 3.3, 
4.8, 3.8, and 2.1 cases per 100 person-years, respectively. 
 
Most Women With Laboratory-Diagnosed STIs Were 
Asymptomatic 
Occurrence of genital ulcer disease and abnormal vaginal dis- 
charge was compared to laboratory diagnosis of STIs. Only 3 
participants presented with genital ulcers during the follow-up 
period, and none presented at enrollment. Each of these 
women tested positive for HSV-2 IgG antibodies prior to the 
ulcer episode. However, only one of these women tested posi- 
tive for HSV-2 by PCR after receiving an etiological diagnosis. 
The other 2 women were negative for all of the ulcer-causing 
organisms assessed (T. pallidum, H. ducreyi, C. trachomatis, 
HSV-2, and C. granulomatis). 
At enrollment, 15.3% of women presented with vaginal dis- 
charge, while only 1.5% and 4.8% reported vaginal discharge 
at their 6- and 12-month study visits, respectively (Table 2). 
Contrary to this, at enrollment 27.5% of women tested positive 
for a vaginal discharge–associated STI (T. vaginalis, N. gonor- 
rhoeae, M. genitalium, or C. trachomatis), with 18.5% and 
23.9% testing positive at their 6- and 12-month visits, 
respectively. 
Overall, only 34.3% of vaginal discharge incidents were 
accompanied by a positive laboratory test for ≥1 discharge- 
associated STI (Table 3). Meanwhile, a total of 87.7% 
laboratory-diagnosed STIs (discharge associated) had no ac- 
companying clinical symptoms. Assuming laboratory testing 
of the above STIs to be the reference standard, the presence of 
discharge for screening had a sensitivity of 12.3%, a specificity 
of 93.8%, a positive predictive value of 34.3%, and a negative 
predictive value of 80.2%. Therefore, only 12.3% of women 
with a confirmed laboratory-diagnosed STI would have been 
appropriately treated using vaginal discharge as an indicator 
for syndromic treatment. 
 
Asymptomatic Laboratory-Diagnosed STIs Were Associated 
With Elevated Genital Tract Inflammatory Cytokine 
Concentrations 
The concentrations of 42 cytokines were measured in CVL 
samples from study participants in order to determine 
whether women who had asymptomatic STIs also had 
 











































Table 2.  Prevalence and Incidence of Laboratory-Diagnosed Sexually Transmitted Infections (STIs) and Clinical Symptoms 
 
Prevalence, % (Proportion) 
 
Variable Enrollment (n = 242) 6 mo (n = 260) 12 mo (n = 189) Incidence, Cases/100 py (95% CI) 
 
Laboratory diagnosis 
HSV-2 serology 86.0 (208/242) 90.1 (183/203) 91.0 (171/188) 26.0 (11.2–51.2) 
HSV-2 PCR 3.7 (9/241) 1.5 (3/205) 2.2 (4/185) 4.1 (2.2–6.9) 
T. pallidum 2.9 (7/242) 3.0 (6/202) 1.6 (3/184) 2.1 (.8–4.3) 
BV 52.7 (127/241) 46.8 (96/205) 42.9 (79/184) 50.5 (40.9–61.6) 
T. vaginalis 20.3 (49/241) 13.2 (27/205) 17.3 (32/185) 14.7 (10.7–19.7) 
N. gonorrhoeae 5.4 (13/240) 2.0 (4/205) 2.2 (4/184) 3.3 (1.6–5.8) 
C. trachomatis 4.2 (10/240) 4.4 (9/205) 3.3 (6/184) 4.8 (2.7–7.7) 
M. genitalium 1.2 (3/241) 1.5 (3/205) 3.8 (7/185) 3.8 (2.0–6.5) 
Any STI (excluding BV and HSV-2 serology) 31.3 (75/240) 21.7 (44/203) 27.5 (50/182) 26.7 (20.8–33.7) 
1 25.3 (61/241) 17.6 (36/205) 24.3 (45/185) … 
>1 5.8 (14/241) 3.9 (8/205) 2.7 (5/185) … 
Clinical diagnosis 
Vaginal discharge 15.3 (37/242) 1.5 (3/203) 4.8 (9/189) 14.2 (10.6–18.5) 
Abbreviations: BV, bacterial vaginosis; CI, confidence interval; C. trachomatis, Chlamydia trachomatis; HSV-2, herpes simplex virus 2; Mycoplasma genitalium, 




subclinical genital inflammation. Cytokine concentrations in 
CVL specimens were compared in (1) women who tested neg- 
ative for all assessed STIs and bacterial vaginosis, (2) women 
who had vaginal discharge and tested positive for ≥1 STI 
(excluding bacterial vaginosis and HSV-2 serology findings), 
and (3) women who had no clinical symptoms but tested 
positive for ≥1 STI (excluding bacterial vaginosis and HSV-2 
serology findings; Figure 1A). The concentrations of IL-1α, 
 
 




Variable Clinical Symptoms + − Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
 
Any discharge-causing STI 
(including BV) 
 
Any discharge-causing STI 
(excluding BV) 
+               55      18          10.5               96.0            75.3         48.1 
−         468    433 
+               25      48          12.3               93.8            34.3         80.2 
− 179 723 
BV + 44 29 10.0 94.4 59.5 55.9 
− 398 504 
T. vaginalis + 20 54 13.8 93.5 27.0 86.2 
− 125 778 
N. gonorrhoeae + 5 68 17.9 92.8 6.9 97.5 
− 23 879 
C. trachomatis + 5 68 13.9 92.8 6.9 96.6 
− 31 871 
M. genitalium + 2 72 10.5 92.5 2.7 98.1 
− 17 886 
HSV-2 (by PCR) + 2 72 8.7 92.5 2.7 97.7 
− 21 882 
Abbreviations: BV, bacterial vaginosis; C. trachomatis, Chlamydia trachomatis; HSV-2, herpes simplex virus 2; Mycoplasma genitalium, M. genitalium; 
N. gonorrhoeae, Neisseria gonorrhoeae; NPV, negative predictive value; PCR, polymerase chain reaction; PPV, positive predictive value; T. vaginalis, Trichomonas 
vaginalis. 
 




































































Figure 1.  Cervicovaginal (CVL) cytokine profiles of women who did not have a sexually transmitted infection (STI), compared with women who had 
asymptomatic or symptomatic infections. A, Cytokine concentrations were measured in CVL samples that were available for 227 of 242 participants in 
this study. Women who did not have an STI, bacterial vaginosis (BV), or vaginal discharge (blue dots/blocks), women who had an asymptomatic STI 
(yellow), and women who had a symptomatic STI (orange) were clustered according to their genital cytokine concentrations. Only the cytokines that 
differed significantly between these groups after adjustment for multiple comparisons were included in this analysis. Abbreviations: Max, maximum 
standardized cytokine concentration measured; Min, minimum standardized cytokine concentration. B, Principal component analysis was used to group 
either (1) all cytokines or (2) cytokines that differed significantly between the groups into single components and generate estimates representative of 
each component. P values were adjusted for multiple comparisons, using a false discovery rate step-down procedure in order to reduce false-positive 
results when multiple comparisons were made. Adjusted (adj.) P values < .05 were considered statistically significant. 
 
 
IL-1β, IL-12p70, TNF-α, TNF-β, RANTES, Flt-3L, VEGF, IL- 
2, and IL-17 were significantly elevated in CVL specimens 
from women who had vaginal discharge and a laboratory- 
diagnosed STI, compared with women who had no STI or 
bacterial vaginosis, after adjustment for multiple comparisons 
(adjusted P values: .0043, .0016, .0016, .0152, .007, .0064, 
.0039, .014, .012, and .0294, respectively). Levels of 7 of these 
cytokines (IL-1α, IL-1β, IL-12p70, TNF-α, VEGF, IL-2, and 
IL-17), as well as levels of IL-8 and IL-13, were elevated in 
women who had ≥1 active STI but no clinical symptoms 
(adjusted P values: < .0016, < .0042, .012, .0027, .0429, .0115, 
.0204, .0084, and .0462, respectively). Cytokine concentrations 
did not differ significantly between women who had asymp- 
tomatic STIs and those with symptomatic STIs. It was found 
that women who had an STI, either symptomatic or asymp- 
tomatic, clustered separately from women who did not have 
an STI (Figure 1A). PCA was used to further reduce the com- 
plexity of the data set by defining new variables that were 
representative of either (1) the unique and common variance 
of each of the 42 cytokines assessed or (2) the variance of only 
those 12 cytokines that had significantly elevated levels in 
CVL from women who had an STI (Figure 1B). It was found 
that, although the groups of women were not clearly differen- 
tiated using the cluster of 42 cytokines, the estimates of a 
component including only the 12 significant cytokines were 
significantly higher in women who had either a symptomatic 
STI or an asymptomatic infection, compared with women 
who did not have an STI. Therefore, women who had asymp- 
tomatic STIs had subclinical inflammation that may increase 
their susceptibility to HIV infection. 
 
Asymptomatic Laboratory-Diagnosed STIs Were Associated 
With Increased Risk of HIV Infection 
Of the enrolled 245 HIV-seronegative participants, 28 became 
HIV infected, yielding an HIV incidence of 7.2 cases per 100 
women-years (95% confidence interval [CI], 4.5–9.8) [38]. As 
 










































Table 4.  Sexually Transmitted Infections (STIs) and Risk of Human Immunodeficiency Virus (HIV) Type 1 Infection 
 
Unadjusted Analysis Adjusted Analysis 
Variable HR (95% CI) P HR (95% CI) P 
Symptom 
Genital ulcers 0 … … … 
Discharge 1.04 (.24–4.58) .9594 0.59 (.12–3.00) .5283 
Laboratory diagnosis 
BV 2.04 (.90–4.63) .0892 1.69 (.71–4.06) .2375 
HSV-2 serology 1.30 (.31–5.52) .7234 2.12 (.43–10.50) .3558 
HSV-2 (by PCR) 1.96 (.26–14.59) .5108 1.42 (.18–11.44) .7426 
T. pallidum 0a … … … 
T. vaginalis 1.78 (.71–4.50) .2203 1.74 (.62–4.92) .2935 
N. gonorrhoeae 7.74 (2.82–21.24) <.0001 4.62 (1.34–15.93) .0154 
C. trachomatis 3.99 (1.19–13.39) .0250 0.90 (.18–4.63) .9006 
M. genitalium 4.49 (1.04–19.44) .0446 4.08 (.83–20.19) .0846 
Any STI (excluding HSV-2 and BV) 3.27 (1.49–7.21) .0033 … … 
No. of concurrent STIs (excluding HSV-2 and BV) 
1 2.93 (1.26–6.82) .0124 … … 
≥2 6.15 (1.72–22.03) .0053 … … 
The multivariate model adjusted for all laboratory-diagnosed STIs and clinical symptoms, as well as for demographic and behavioral factors (data not shown). 
Abbreviations: BV, bacterial vaginosis; C. trachomatis, Chlamydia trachomatis; HR, hazard ratio; HSV-2, herpes simplex virus 2; Mycoplasma genitalium, 
M. genitalium; N. gonorrhoeae, Neisseria gonorrhoeae; PCR, polymerase chain reaction; T. pallidum, Treponema pallidum; T. vaginalis, Trichomonas vaginalis. 




3 of these 28 did not have preinfection data, they were 
excluded from analysis. Among the STIs tested, N. gonorrhoeae, 
C. trachomatis, and M. genitalium were associated with HIV 
acquisition (Table 4). After control for demographic and beha- 
vioral factors, clinical symptoms, and other STIs, only N. 
gonorrhoeae remained significant (adjusted HR, 4.62 [95% CI, 
1.34–15.93]). The presence of any STI (excluding bacterial 
vaginosis and HSV-2 serology findings) was also significantly 
associated with HIV seroconversion (HR, 3.27 [95% CI, 
1.49–7.21]). Additionally, the number of STIs was predictive 
of HIV infection, with women who had 1 STI having a 
3-fold increased risk of acquiring HIV (HR, 2.93 [95% CI, 
1.26–6.82]), compared with women with no STI, and those 
who had ≥2 concurrent STIs had a 6-fold increased risk of 
HIV infection (HR, 6.15 [95% CI, 1.72–22.03]). HSV-2 sero- 
positivity, bacterial vaginosis, and vaginal discharge were not 
found to increase the risk of HIV acquisition. Genital ulcers 
were also not associated with increased risk of HIV infec- 
tion, although the prevalence of ulcers was low in this cohort 
(n = 3). 
Despite the long period between cytokine measurements in 
CVL specimens (at enrollment) and HIV infection (median, 
302 days prior to infection [range, 14–686 days]), several 
inflammatory cytokines were associated with risk of HIV 
infection, before adjustment for multiple comparisons. Eleva- 
ted concentrations of IL-1β, IL-6, IL-8, and sCD40L were 
associated with greater risk of HIV infection (HR [95% CI], 
1.25 [1.05–1.50], 1.28 [1.07–1.54], 1.39 [1.04–1.87], and 1.45 
[1.02–2.07], respectively, per 1 log10 pg/mL increase in cyto- 
kine concentration). Of these cytokines, IL-1β and IL-8 were 
elevated in women who had asymptomatic STIs, relative to 
women who had no STIs. 
 
DISCUSS ION  
 
The prevalence of STIs is generally very high in sub-Saharan 
Africa [1, 2], and these infections are associated with increased 
susceptibility to HIV acquisition and secondary transmission 
[4–11]. There is conflicting evidence regarding the use of syn- 
dromic management of STIs for reducing HIV incidence, and 
it is thought that this approach may underestimate STI preva- 
lence, as many infections are asymptomatic [26–29, 43]. The 
prevalence and incidence of laboratory-diagnosed STIs in this 
cohort were high; however, only 12.3% of women who tested 
positive for ≥1 STI had visible clinical symptoms. As a result, 
87.7% of STIs in this cohort of high-risk women would 
have been left untreated in a syndromic management setting. 
The presence of any laboratory-diagnosed STI was associated 
with a 3-fold increased risk of HIV infection, and this associa- 
tion was independent of clinical symptoms. The STI most 
significantly associated with HIV infection was N. gonor- 
rhoeae, increasing the risk of HIV infection by almost 5-fold. 
 










































No associations were found between abnormal discharge or 
genital ulcers and susceptibility to HIV-infection, although 
only a small proportion of women presented with ulcers in 
this study. Furthermore, HSV-1 was not tested for in this 
study but may be considered in future testing algorithms, 
given the increasing prevalence of this organism [44]. The 
prevalence and incidence of STIs were much higher than the 
values of approximately 50% reported in most studies. This 
might reflect a higher frequency of reinfection due to the 
higher number of partners in this cohort of mainly commer- 
cial sex workers. 
Genital tract inflammatory cytokine concentrations were 
similar in women who had symptomatic and asymptomatic 
laboratory-diagnosed STIs and were elevated in these women, 
relative to women who had no STIs, bacterial vaginosis, or 
symptoms. Previous studies have suggested that elevated 
genital tract inflammatory cytokine concentrations may facili- 
tate HIV transmission by directly upregulating HIV replica- 
tion, by recruiting and activating immune cell targets for HIV 
infection, and by disrupting tight junctions between epithelial 
cells [31–37]. Although confounded by the long interval 
between CVL cytokine measurements and time of HIV infec- 
tion and by the fact that women were treated for STIs in the 
period between enrollment and the time of HIV infection, we 
found that higher concentrations of inflammatory cytokines 
(IL-1β, IL-6, IL-8, and sCD40L) in CVL specimens were asso- 
ciated with increased risk of HIV infection, albeit weakly. This 
supports our finding that women who had no clinical symp- 
toms but had subclinical STIs were at increased risk of HIV 
acquisition, with N. gonorrhoeae remaining associated after 
adjustment for behavioral factors. Although this suggests that 
underlying genital tract inflammation may be a biological 
mechanism for HIV transmission in these women, it is also 
possible that the relationship between elevated inflammation 
and risk of HIV infection is indirect. Elevated cytokine concen- 
trations were found to be associated with STIs, which may be 
markers of high-risk sexual activity and thus increased risk of 
HIV infection due to behavior. 
The finding that clinically evident and syndromically 
managed STIs declined during follow-up while the prevalence 
of laboratory-diagnosed STI remained relatively high confirms 
that syndromic management does not address subclinical STI 
infections, which may contribute to genital inflammation and 
risk of HIV infection. This has important implications not 
only for HIV prevention strategies, but also for complications 
that are associated with untreated inflammatory STIs, includ- 
ing pelvic inflammatory diseases, ectopic pregnancy, and in- 
fertility [20, 30]. 
These data create a compelling argument for readdressing 
the STI management strategy in high-risk populations in 
which negotiating condom use is a challenge for women. 
Healthcare systems should include regular screening for STIs 
by means of laboratory testing in these groups rather than 
relying on symptoms only. The increased diagnostic power of 
PCR technology and the related potential to impact the risk of 
HIV acquisition could outweigh its high costs. This strategy 
would lead to treatment of greater numbers of STIs, reducing 
prevalence and incidence. Another diagnostic approach in un- 
derresourced areas would be to explore point-of-care STI 
testing as an alternative to laboratory testing. Some of these 
point-of-care tests have proven to be sensitive diagnostic tools 
in trials and would offer significant benefit in both rural and 
urban poor-resourced settings that do not have good access to 
a larger STI sentinel screening laboratory [45, 46]. 
Findings from this study and those from studies of other 
high-risk cohorts in South Africa [13] suggest that the current 
symptom-driven syndromic management system is untenable 
for high-risk populations and underscores the need for a para- 
digm shift in diagnosing STIs. Only when more effective STI 
treatment is achieved are we likely to see STI management 
playing a role in HIV prevention. 
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the Spread of HIV-1: Back to the Future 
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The transmission of human immunode- 
ficiency virus type 1 (HIV-1) depends on 
the infectiousness of the index case (ie, 
vector) and the susceptibility of the host 
[1]. The probability of the transmission 
event has been extensively studied [1–3], 
and the risk is often described as about 1 
in 1000 coital events [4]. However, large 
numbers of exposures like these are often 
derived from studies of stable, heterosex- 
ual, discordant couples [4, 5]. By defini- 
tion, the HIV-1–negative partners in 
these couples can be defined as “exposed 
and uninfected” at the time of enrollment. 
The transmission of HIV-1 is almost cer- 
tainly often more efficient than reflected 
in studies of couples and is likely en- 
hanced by amplifying factors [6]. 
Perhaps no other HIV transmission co- 
factor has attracted as much attention as 
sexually transmitted diseases (STDs). More 
than 20 years ago, Wasserheit and col- 
leagues described the transparent and om- 
nipresent relationship between classical 
STDs and HIV-1, coining this unfortunate 
marriage of pathogens “epidemiologic 
synergy” [7]. We subsequently showed that 
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infection with  Neisseria gonorrhoeae 
greatly increased shedding of HIV-1from 
the male genital tract in seminal plasma, 
offering a biological view of such synergy 
[8]. In recent years, however, interest in the 
relationship between STDs and HIV-1 has 
waned, primarily because it has proven 
nearly impossible to reduce the spread of 
HIV-1 through directed or empirical treat- 
ment of STDs [9]. 
In this issue of The Journal of Infec- 
tious Diseases, Mlisana et al [10] contrib- 
ute to this consideration. Because of the 
limited laboratory infrastructure in low- 
and middle-income countries, treatment 
of STDs in women often depends on the 
recognition of signs and symptoms of 
vaginal discharge, leading to empirical 
treatment with antibiotics [11, 12]. Syn- 
dromic management is important but 
often suboptimal since a substantial 
number of people using this method are 
over- or undertreated [11, 12]. 
Mlisana and colleagues [10] have 
further expanded our concerns about 
syndromic management. Two-hundred 
forty-two women at risk for HIV-1 in- 
fection were enrolled in a prospective 
cohort. Four things were measured: the 
presence or absence of a vaginal dis- 
charge, detection of ≥1 STD pathogens, 
vaginal cytokine concentrations, and 
HIV-1 acquisition. The results offered a 
stark reality for HIV-1 prevention and 
demonstrate yet again that STDs repre- 
sent a “hidden epidemic,” the title of a 
compelling Institute of Medicine report 
published more than a decade ago [13]. 
Only 12.3% of women infected with a 
pathogen that might cause a vaginal dis- 
charge had signs or symptoms of infec- 
tion. Women with STDs were >3-fold 
more likely to acquire HIV-1 than those 
who harbored no pathogens. Women 
with gonococcal infections, among the 
most inflammatory of the classical STD 
agents [14], had had an eye-opening 7- 
fold increased risk of HIV-1 acquisition, 
bringing us full circle to earlier reports 
[8]. Surprisingly, inflammatory cytokines 
were not significantly different in 
women with symptomatic STDs, com- 
pared with asymptomatic infections, al- 
though they were greater than in women 
with no STDs or with bacterial vaginosis. 
Passmore et al [15] have reported that 
some unique inflammatory cytokine 
profiles predict risk for HIV acquisition. 
How can we fit these observations 
into sensible HIV-1 prevention strate- 
gies? Padian et al [9] have provided an 
exhaustive summary of interventions de- 
signed to prevent HIV-1 transmission, 
emphasizing the general lack of preven- 
tion benefit with treatment of classical 
STDs. The failure of this approach, in 
my opinion, is not because STDs are not 
critically important. Rather, we are 
simply unable to treat the right infec- 
tions with the right drugs at the right 
times, and so the results of the interven- 
tions prove disappointing. Sadly, except 
for hepatitis B virus vaccine and HPV 
vaccine, STD vaccines are not available. 
 













































Where do we go from here? Mlisana 
and colleagues argue for more frequent 
STD testing, using point-of-care assays 
where possible. This recommendation 
stems directly from our inability to know 
which women have an STD, as demon- 
strated in their report. The problem, of 
course, is that missing healthcare infra- 
structure and high relative costs for STD 
testing led to syndromic management of 
vaginal discharge in the first place, and 
these limitations have not been resolved. 
Mlisana et al also indicate that in the 
absence of some other strategy, the am- 
plification of HIV-1 transmission by 
STDs—both infectiousness and acquisi- 
tion—will continue unabated. Perhaps 
ironically, this past year was filled with 
great optimism in HIV-1 prevention, 
leading The Economist to focus on “The 
End of AIDS” [16] and Secretary of State 
Hillary Clinton to describe an “AIDS- 
Free Generation” [17]. But the “hidden 
epidemic” [13] of classical STDs is squa- 
rely blocking optimal prevention of HIV-1 
transmission. These STDs—symptomatic 
or asymptomatic—simply cannot be 
ignored. As we commit to combination 
HIV-1 prevention, we must redouble our 
efforts to think of every possible way to 
recognize and treat classical STDs. Surely 
this problem is no more impossible to 
attack or less important than any other 
part of the HIV-1 pandemic. 
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ABSTRACT 
Objectives Sexually transmitted infections (STI) and 
bacterial vaginosis (BV) cause female genital tract 
inflammation. This inflammation, which is often present 
in the absence of symptoms, is associated with increased 
susceptibility to HIV infection. We aimed to evaluate 
genital cytokine profiles and the degree of inflammation 
associated with common STIs and BV. 
Methods HIV-uninfected women (n=227) were 
screened for BV, Chlamydia trachomatis, Neisseria 
gonorrhoeae, Herpes simplex virus type 2 (HSV-2), and 
Trichomonas vaginalis. Concentrations of 42 cytokines in 
cervicovaginal lavages and 13 cytokines in plasma were 
measured using Luminex. Changes in cytokine profiles 
were evaluated using Mann–Whitney U test, logistic 
regression and factor analysis. p Values were adjusted 
for multiple comparisons using a false discovery rate 
step-down procedure. 
Results Women with chlamydia or gonorrhoea had the 
highest genital cytokine concentrations, with 17/42 and 
14/42 cytokines upregulated compared with women 
with no infection, respectively. BV was associated with 
elevated proinflammatory cytokine concentrations, but 
lower chemokine and haematopoietic cytokine 
concentrations. HSV-2 reactivation was associated with 
lower levels of inflammation, while trichomoniasis did 
not cause significant differences in genital cytokine 
concentrations. Genital infections did not influence 
plasma cytokine concentrations. Although certain STIs, in 
particular chlamydia and gonorrhoea, were associated 
with high genital cytokine concentrations, only 19% of 
women with an STI/BV had clinical signs. 
Conclusions Chlamydia was associated with the 
highest genital cytokine levels, followed by gonorrhoea, 
HSV-2, trichomoniasis, and BV. In regions where HIV is 
prevalent and STIs are managed syndromically, better 
STI/BV screening is urgently needed, as certain infections 
were found to be highly inflammatory. 
 
INTRODUCTION 
Sexually transmitted infections (STI) and bacterial 
vaginosis (BV) are prevalent in South African women 




 The lower female 
genital tract is a unique, non-sterile environment 
that, while tolerant to allogeneic sperm, must 
respond rapidly to infectious agents.
3
 Inflammation is 
an immune process essential for microbial control 
and clearance that is initiated and sustained by cyto- 
kine production in response to pathogen recogni- 
tion.
4
 STIs are major causes of inflammatory 
cytokine upregulation and immune cell recruitment 
to the genital mucosa.
5–9
 Although inflammation can 
play an important role in STI clearance, it may also 
cause destruction of infected epithelial layers, allow- 





 Relatively few women spontaneously 
clear an infection without treatment, and STIs are 




 If untreated, STIs 
such as Chlamydia trachomatis, Neisseria gonorrhoea 
and Trichomonas vaginalis are associated with repro- 
ductive complications, including pelvic inflammatory 
disease (PID), ectopic pregnancy, miscarriage, 
preterm delivery and infertility.
13 
BV is a syndrome characterised by displacement of 
healthy vaginal flora, predominantly consisting of 





 While BV can upregulate 
genital proinflammatory cytokines, downregulation 







BV is also associated with sequalae including PID, 
preterm delivery and postpartum infection.
13 
STIs, BV and associated inflammation influence 
susceptibility to HIV  infection.
18–20 We have shown 
that  C. trachomatis,  N. gonorrhoeae  and 
Mycoplasma genitalium infections and elevated cer- 
vicovaginal lavage (CVL) concentrations of interleu- 
kin (IL)-1β, IL-6, IL-8 and soluble CD40L 
(sCD40L) were associated with increased risk of 
HIV  acquisition.
20
 Elevated cytokine concentrations 
in the genital tract may facilitate HIV infection by 
recruiting and activating HIV target cells, reducing 
epithelial barrier integrity and promoting HIV repli- 




The aims of this study were to evaluate whether 
common STIs or BV were associated with specific 
changes in genital cytokine profiles in women at 
high risk of HIV infection, and to compare the 
relative degree of cytokine production associated 
with each infection. 
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A cohort of 242 HIV-uninfected women at high risk of HIV  infec- 
tion was established in Durban, South Africa.
20
 For this study, 
CVLs were available from 227 women and plasma was available 
from 142 women. This study was approved by the University of 
KwaZulu-Natal and University of Cape Town Ethics Committees, 
and all participants provided informed consent. 
 
STI and BV diagnosis 
A gynaecological examination was performed and two vulvovagi- 
nal swabs were collected.
20
 Swabs were screened for C. tracho- 
matis, N. gonorrhoeae, M. genitalium, Herpes simplex virus 
(HSV) and T. vaginalis by PCR. BV was diagnosed by Gram stain- 
ing using Nugent’s criteria (score ≥7 indicating BV; 4–6 indicat- 
ing intermediate flora) and a subset of slides (n=172) was 
examined for the presence of fungal hyphae. Blood was collected 
for syphilis (Treponema pallidum) diagnosis and HSV-2 serology. 
ELISA was used to detect HSV-2 gG-2 IgG (HerpeSelect, Focus 
Diagnostics, USA). BD Macro-Vue Rapid Plasma Reagin (RPR) 
and haemagglutination tests (ImmuTrep TPHA, Omega 
Diagnostics, UK) were used to screen for T pallidum. 
 
Cytokine measurements 
CVLs (10 mL sterile saline) for cytokine measurements were col- 
lected, centrifuged and supernatants stored at −80°C.
25
 CVLs 
were not collected from menstruating participants. Blood was 
collected by venepuncture into Acid-Citrate-Dextrose (ACD) 
vacutainer tubes, plasma isolated and stored at −80°C. 
In an exploratory analysis, 42 cytokines were measured in 
CVLs from 227/242 women, and 13 cytokines were measured in 
plasma from 142/242 women. CVLs were prefiltered by centrifu- 
gation using 0.2 μm cellulose acetate filters (Sigma, USA). The 
concentrations of all 42 cytokines included in LINCOplex 
Human Cytokine and High Sensitivity Human Cytokine kits 
(LINCO Research, USA) were measured in CVLs. These included 
immunoregulatory cytokines (IL-10 and IL-1Ra), growth factors 
(vascular endothelial growth factor (VEGF), TGF-α, platelet- 
derived growth factor (PDGF)-AA, PDGF-AB/BB, FGF-2, epider- 
mal growth factor (EGF)), haematopoietic cytokines (IL-9, IL-7, 
IL-3, GM-CSF, G-CSF, FLT3 Ligand (FLT3L)), adaptive immune 
mediators (sIL-2Rα, sCD40L, IL-17, IL-15, IL-13, IL-5, IL-4, 
IL-2, IFN-γ), pro-inflammatory cytokines and chemokines 
(IFN-α, RANTES/CCL5, MIP-1α/CCL3, MIP-1β/CCL4, MDC/ 
CCL22, MCP-1/CCL2, MCP-3/CCL7, IP-10, IL-8/CXCL8, 
growth related oncogene (GRO) family (CXCL1-CXCL3), frac- 
talkine, eotaxin, TNF-β, TNF-α, IL-12p70, IL-12p40, IL-6, 
IL-1β, IL-1α). The lower limit of detection of these kits ranged 
between 0.01 and 27.65 pg/mL for each of the cytokines. Data 
was collected using a Bio-Plex Suspension Array Reader (Bio-Rad 
Laboratories) and a 5 PL regression formula was used to calculate 
cytokine concentrations from the standard curves (BIO-Plex 
manager V.4). Cytokine concentrations below the lower limit of 
detection were reported as the mid-point between the lowest 
concentrations measured and zero. 
 
Statistical analyses 
Statistical analyses were performed using GraphPad Prism 5 
(GraphPad Software, USA) and STATA V.10 (StataCorp, Texas, 
USA). Mann–Whitney U test was used for comparisons and 
Spearman Rank test for correlations. Logistic regression was used 
to assess associations between STIs/BVand log10-transformed cyto- 
kine concentrations, while adjusting for coinfections. p Values 
Basic science 
 
were adjusted using a false-discovery rate step-down procedure to 
reduce false positive results when multiple comparisons were 
made.
26
 Confirmatory factor analysis was used to explore under- 
lying associations between cytokines.
27
 Factor scores, which are 
linear combinations of concentrations of each cytokine in a factor, 
weighted according to their factor loadings, were generated for 
further analysis. Ingenuity Pathway Analysis was used to explore 
biological functions of the cytokines (Ingenuity Systems). 
Cytokine concentrations >2-fold above the median in the no STI/ 
BV group were considered upregulated. 
 
RESULTS 
A total of 227 HIV-uninfected women were included in this 
study to evaluate whether common STIs and BV were associated 
with specific changes in genital cytokine profiles in women at 
high risk of HIV  infection (table 1).
20 
The median age of these women was 36 years (range 18–58), 
and most (95%) reported having more than one casual sexual 
partner within the last 3 months. More than half the women had 
BV (53%; 120/227; Nugent score ≥7; table 1), 13% (30/227) had 
intermediate flora (Nugent score 4–6), and 30% (68/227) had a 
 
 
Table 1  Demographics, behavioural and clinical characteristics 
Demographic characteristics (n=227)                     n (%) 
Race (number of black women)                            224 (98.7) 
Median age in years (range)                              36 (18–58) 
Behavioural characteristics                             n/total (%) 
Women with multiple partners                            129/226 (57.1) 
Single women                                         17/226 (7.5) 
Married or in a stable relationship                          80/226 (35.4) 
Women with >1 casual sexual partner                      209/221 (94.6) 
Ever had anal sexual intercourse                           77/225 (34.2) 
Ever had oral sexual intercourse                           59/226 (26.1) 
Age at sexual debut (years; median (range))                  17 (12–33) 
Intravaginal substance use                                22/226 (9.7) 
Contraception                                        n/total (%) 
Condoms used as contraception                           133/226 (58.9) 
Injectable hormonal contraception                          63/226 (27.9) 
Oral contraception                                      5/226 (2.2) 
Intrauterine device                                      5/226 (2.2) 
Clinical and laboratory findings (n=227)                  n (%) 
No STI or bacterial vaginosis                              85 (37.4) 
Trichomonas vaginalis (PCR positive)                        47 (20.7) 
Chlamydia trachomatis (PCR positive)                       10 (4.4) 
Neisseria gonorrhoea (PCR positive)                        13 (5.7) 
Mycoplasma genitalium (PCR positive)                      3 (1.3) 
HSV-2 IgG                                            198 (87.2) 
HSV (PCR positive)                                      6 (2.6) 
Treponema pallidum (RPR>1:4, TPHA positive)                3 (1.3) 
Bacterial vaginosis (Nugent score >7)                       120 (52.9) 
Intermediate flora (Nugent score 4–6)                 68 (30.0) 
Any STI or bacterial vaginosis                             142 (62.6) 
Any STI (excluding bacterial vaginosis)                      68 (30.0) 
Multiple infections (including bacterial vaginosis)              49 (21.6) 
Vaginal discharge                                      34 (15.0) 
Genital ulceration                                      0 (0.0) 
HSV-2, herpes simplex virus type 2; RPR, rapid plasma reagin; STI, sexually 
transmitted infection; TPHA, Treponema Pallidum hemagglutination. 
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STI (excluding BV and HSV-2 serology). Of those seropositive for 
HSV-2 (198/227), only six had detectable HSV in their genital 
tracts and were considered to have reactivated HSV-2 infections, 
none had visible ulceration. Three women had RPR titres >1:4 
with a positive TPHA test, normally indicative of active syphilis 
but could indicate late-latent or treated syphilis. Three women 
were infected with M. genitalium. All women with syphilis or 
M. genitalium also had BV, therefore, cytokine changes in these 
women could not be evaluated in this study. Of women who had a 
STI or BV, only 27/141 (19%) had clinical signs of an infection.
20 
 
Genital cytokine concentrations were elevated in women 
with active STIs 
Of the common STIs evaluated in this study, women who had 
chlamydia (10/227) or gonorrhoea (13/227) had the highest 
CVL cytokine concentrations, despite only 3/10 women with 
chlamydia and 2/13 women with gonorrhoea having clinical 
signs of infection (figure 1;  see online supplementary figure S1). 
Concentrations of 17/42 cytokines, including proinflammatory 
cytokines (IL-1α, IL-1β, IL-6, IL-12p70, TNF-α), chemokines 
(IL-8, MIP-1β, RANTES), haematopoietic cytokines and growth 
factors (G-CSF, Flt3L, TGF-α), and adaptive mediators (IL-2, 
IL-4, IL-5, IL-13, IL-15, IL-17), were higher in CVLs from 
women with chlamydia compared with women who did not 
have a STI or BV (n=85), after adjusting for multiple compari- 
sons (figure 1). After adjusting for coinfections, BV and inject- 
able hormone contraceptive use using logistic regression, IL-1β, 
IL-6, TNF-α, IP-10, MDC, MIP-1α, MIP-1β, RANTES, G-CSF, 
EGF, FGF-2, PDGF-AA, PDGF-AB/BB, TGF-α, IL-4, IL-5, 
IL-13, IL-17 and IL-10 concentrations remained significantly 
associated with chlamydia infections. 
Women infected with gonorrhoea displayed a largely overlap- 
ping cytokine profile to women with chlamydia, with 11/17 of 
the same cytokines elevated in women with chlamydia also ele- 
vated in women with gonorrhoea (IL-1α, IL-1β, IL-12p70, 
TNF-α, RANTES, G-CSF, Flt3L, IL-2, IL-5, IL-15 and IL-17). 
In addition, certain unique cytokines were upregulated in 
women with gonorrhoea (TNF-β, eotaxin and VEGF; figure 1). 
Since the majority of women with gonorrhoea also had a coin- 
fection or BV (11/13), none of these cytokines remained signifi- 
cant after adjustment for coinfections, BV and injectable 
hormone contraceptive use. However, gonorrhoea was asso- 
ciated with high levels of inflammation overall, with a large 
cumulative β-coefficient (figure 2A). 
Although women with active HSV-2 infections (6/227) 
tended to have elevated CVL concentrations of several proin- 
flammatory cytokines, none was significantly higher than those 
found in women who did not have an infection, after adjusting 
for multiple comparisons and/or coinfections (figure 1). 
However, due to the small number of women who were shed- 
ding HSV-2, this analysis was underpowered to detect the 
changes in proinflammatory cytokine concentrations, particu- 
larly after accounting for multiple comparisons. Detection of 
HSV-2 antibodies in serum alone was not associated with 
changes in genital cytokine concentrations (data not shown). 
Despite being clinically implicated in vaginitis, trichomoniasis 
(in the absence of BV or coinfections; 13/227) was the least 
inflammatory infection in this study, with none of the cytokines 
elevated relative to women with no STI/BV after adjusting for 
multiple comparisons (figure 1;  see online supplementary figure 
S1). In a logistic regression analysis including all women with 
trichomoniasis (47/227), no cytokines were significantly asso- 
ciated with this infection after adjustment for coinfections and 
multiple comparisons (data not shown). 
 
Mixed genital cytokine profile in women with BV 
Certain proinflammatory cytokines (IL-1α, IL-1β and TNF-β) 
were significantly elevated in women who had BV in the 
absence of a coinfection (n=73), relative to women who had 
neither BV nor a STI (figure 1;  see online supplementary figure 
S1). However, women with BV simultaneously had lower con- 
centrations of several chemokines (IP-10, GRO, MDC and 
MIP-1α) and haematopoietic cytokines (IL-7 and GM-CSF), 
suggesting that cytokine changes associated with BV were 
complex. Cytokine concentrations in women with intermediate 
vaginal flora alone (n=18) did not differ from women who did 
not have a STI/BV (data not shown). 
A subset of Gram-stained slides (n=172) was examined for 
the presence of fungal hyphae. Women with visible fungal 
hyphae (n=19) had lower genital concentrations of IFN-α, IL-9, 
IL-15 and IL-17, after adjusting for STIs and BV using logistic 
regression, with IL-9 remaining significantly lower after adjust- 
ing for multiple comparisons. 
 
STIs did not influence cytokine concentrations in plasma 
Plasma cytokine concentrations did not differ in women with 
BV, or active C. trachomatis, N. gonorrhoeae, T. vaginalis, or 
HSV-2 infections compared to women who did not have a 
STI/BV. None of the cytokines measured in plasma correlated 
with those measured in CVLs from the same women (data not 
shown). 
 
Genital cytokines with similar biological functions clustered 
together 
Confirmatory factor analysis was used to group cytokines 
according to their primary roles in the immune response in 
order to reduce the complexity of the dataset and explore the 
relationships between functional groups of cytokines and STIs/ 
BV (see online supplementary table S1). Cytokines were 
grouped as proinflammatory (IL-1α, IL-1β, IL-6, IL-12p40, 
IL-12p70, TNF-α, TNF-β), chemokines (eotaxin, fractalkine, 
GRO, IL-8, IP-10, MCP-1, MCP-2, MIP-1α, MIP-1β, MDC, 
RANTES), haematopoeitic (FLT3L, G-CSF, GM-CSF, IL-3, IL-7, 
IL-9), growth factors (EGF, FGF-2, PDGF-AA, PDGF-AB/BB, 
TGF-α, VEGF) and adaptive mediators (IFN-γ, IL-2, IL-4, IL-5, 
IL-13, IL-15, IL-17, sCD40L, sIL-2Rα). Most of the cytokines 
(34/42) were significantly associated with the functional group 
to which they were assigned, as indicated by factor loadings 
>0.32 (which can be interpreted in a similar manner as correla- 
tions coefficients).
27
 This indicates that the concentrations of 
most cytokines within each functional classification correlated 
with one another, and are thus likely to be regulated by 
common underlying influences. 
All functional cytokine groups were positively associated with 
chlamydia after adjusting for coinfections, while all groups 
except the anti-inflammatory cytokine group were positively 
associated with gonorrhoea (figure 2B). In support of the mixed 
cytokine profile observed for BV (figure 1), the proinflammatory 
cytokine cluster was positively associated with BV, while the che- 
mokine cluster was inversely associated, after adjusting for coin- 
fections and multiple comparisons. 
 
Cytokines upregulated in women with STIs promote 
immune cell migration, activation, proliferation and 
differentiation 
The Ingenuity Knowledge Base (Ingenuity Systems) was used to 
explore the effects that cytokine changes in response to STIs 
and BV may have at the cellular level in the female genital tract 
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Figure 1 Fold change in cytokine concentrations in cervicovaginal lavage (CVL) from women who had a sexually transmitted infection (STI) or 
bacterial vaginosis (BV) relative to median concentrations in women who did not have an STI/BV. Several women who had chlamydia, gonorrhoea or 
herpes simplex virus type 2 (HSV-2) had other coinfections. For the analysis of BV or trichomoniasis, only women who had single infections were 
included. Mann–Whitney U test was used for comparisons and p values were adjusted for multiple comparisons using a false discovery rate 
step-down procedure. Cytokines that were significantly altered relative to women who did not have STIs or BV before adjusting for multiple 
comparisons are indicated by shaded bars (p<0.05). Cytokines that were upregulated or downregulated after adjustment are shown by solid grey 
bars (p<0.0012). 
 
(table 2). The cytokines assessed in this study primarily play 
roles in pathways associated with cellular trafficking, death, sur- 
vival, growth, proliferation, activation and differentiation. 
Chlamydia (in particular), gonorrhoea and HSV-2, were each 
associated with upregulation of the largest number of cytokines 
involved in these pathways, while BV and trichomoniasis were 
associated with few upregulated cytokines. Women with chla- 
mydia, gonorrhoea or HSV-2 had upregulated concentrations of 
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Figure 2 Relationships between cytokines and bacterial vaginosis (BV), trichomoniasis, chlamydia, gonorrhoea and active HSV-2 following 
adjustment for coinfections. (A) Cytokines were log10-transformed and standardised, and β-coefficients were calculated using logistic regression in 
order to adjust for coinfections. The β-coefficient, divided by the SE, for each of the 42 cytokines is represented in each stacked bar for each sexually 
transmitted infection (STI) and BV. A positive β-coefficient indicates that higher concentrations of the cytokine are associated with the STI or BV, 
while a negative β-coefficient indicates that the cytokine concentration is more likely to be lower in cervicovaginal lavage from women who had an 
STI or BV, relative to women who did not have an infection. Proinflammatory cytokines and chemokines are shown in shades of orange and red. 
Adaptive immune mediators are green, haematopoietic cytokines are yellow, growth factors are blue, and immunoregulatory IL-10 and IL-1Ra are 
black. (B) Associations between factor scores and each STI and BV. Factor scores for each function group were generated using confirmatory factor 
analysis. Dots indicate β-coefficients of logistic regression analyses, following adjustment for coinfections, error bars represent 95% CIs. Black dots 
indicate associations that were significant after adjusting for coinfections and multiple comparisons, grey dots indicate associations that fell away 
after adjusting for multiple comparisons. p Values were adjusted for multiple comparisons using a false discovery rate step-down procedure. HSV-2, 
Herpes simplex virus type 2. 
 
 
cytokines that mediate chemotaxis of T  cells, natural killer cells, 
phagocytes, monocytes, dendritic cells, neutrophils, eosinophils, 
granulocytes and endothelial cells. Cytokines involved in cellu- 
lar apoptosis, viability, activation, proliferation and differenti- 
ation were upregulated in women with chlamydia, gonorrhoea 
or HSV-2. These findings indicate that increases in the concen- 
trations of these cytokines in the genital tracts of women with 
chlamydia and, to a lesser extent, gonorrhoea and HSV-2, 
would likely result in the accumulation of highly activated and 
differentiated immune cells. 
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Table 2 Biological pathway analysis of cytokine functions 
 




Number of cytokines >2-fold upregulated (n (%)) 
Chlamydia      Gonorrhoea      HSV-2       Trichomoniasis      BV 
 
Cellular trafficking All cell types 35 28 (80) 23 (66) 12 (34) 4 (11) 2 (6) 
Leukocyte 31 24 (77) 20 (65) 11 (35) 4 (13) 2 (6) 
T cell 12 11 (92) 8 (67) 5 (42) 2 (17) 0 (0) 
NK cell 7 6 (86) 6 (86) 3 (43) 1 (14) 0 (0) 
Phagocyte 24 20 (83) 17 (71) 14 (58) 4 (17) 2 (8) 
Monocyte 18 15 (83) 13 (72) 9 (50) 3 (17) 1 (6) 
DC 10 7 (70) 6 (60) 5 (50) 2 (20) 1 (10) 
Neutrophil 13 12 (92) 9 (69) 8 (62) 1 (8) 2 (15) 
Granulocyte 19 15 (79) 13 (68) 9 (47) 3 (16) 2 (11) 
Eosinophil 13 11 (85) 9 (69) 6 (46) 2 (15) 1 (8) 
Endothelial 11 10 (91) 7 (64) 5 (45) 1 (9) 0 (0) 
Growth and proliferation All cell types 35 29 (83) 25 (71) 15 (43) 4 (11) 2 (6) 
Death and viability All cell types 33 26 (79) 21 (64) 13 (39) 4 (12) 2 (6) 
Activation All cell types 28 22 (79) 19 (68) 14 (50) 5 (18) 1 (4) 
Differentiation All cell types 27 20 (74) 17 (63) 12 (44) 3 (11) 2 (7) 
BV, bacterial vaginosis; DC, dendritic cell; HSV-2, herpes simplex virus type 2; NK, natural killer. 
 
DISCUSSION 
In women at high risk of HIV  infection, chlamydia and gonor- 
rhoea were associated with broadly elevated genital cytokine 
concentrations compared with women who did not have a STI 
or BV. Although few women were shedding HSV-2, several key 
cytokines with inflammatory functions were upregulated in 
these women compared with those with no STI or BV. By con- 
trast, BV was associated with a mixed inflammatory profile, with 
upregulated proinflammatory cytokine concentrations, but 
downregulated concentrations of chemokines and haematopoi- 
etic cytokines. While clear inflammatory cytokine signatures 
were found in genital secretions of women with BV and certain 
STIs, they did not have similar cytokine signatures in their 
plasma. No significant correlations were observed between 
plasma and genital cytokine concentrations, suggesting that 
inflammatory responses in the female genital tract are independ- 
ent of blood cytokine concentrations. This is likely because 
cytokines are locally produced in response to pathogen recogni- 
tion. Although certain STIs, in particular chlamydia and gonor- 
rhoea, were associated with high concentrations of cytokine 
biomarkers of genital inflammation, only 19% of women who 
had a STI/BV had clinical signs (3/10 and 2/13 women with 
chlamydia and gonorrhoea, respectively). As previously shown 
in this cohort, women with an STI but no clinical signs had 
similar cytokine profiles as women with clinical signs.
20
 
The reasons for the mixed cytokine expression profile in 
women with BV remain unclear, although Ryckman et al
17
 simi- 
larly reported, using a smaller cytokine panel, that women with 
BV had elevated proinflammatory IL-1α concentrations, but 
lower chemokine concentrations (IP-10 and MCP-1) than 
women with no BV. Others have demonstrated elevated genital 
IL-1β concentrations from women with BV compared with 








 Cytokine downregula- 
tion associated with BV may reflect a state of tolerance to abnor- 
mal vaginal microbes, which may be derived from normal gut 
microflora, may exist as a result of coevolution of these 
microbes with humans.
30
 These results demonstrate that BV 
induces changes in the genital cytokine milieu distinct from 
those that occur in response to STIs. 
T. vaginalis infections, which are associated with 









 were prevalent in this cohort of 
women (20.7%). Although several cytokines were higher in 
CVL from women with trichomoniasis compared with women 
without an infection, none was significant. A previous study 
similarly reported that women with chlamydia or gonorrhoea 
had increased endocervical CD4 T  cells than women with no 
STI, which was not observed in women with trichomoniasis.
5 
These findings suggest that asymptomatic trichomoniasis, 
perhaps involving low pathogen loads only detectable by PCR, 
are not necessarily inflammatory. Trichomoniasis, identified by 
culture, was associated with increased IL-8 concentrations in 







 also demonstrated that IFN-γ, TNF-α, IL-10 and 
IL-12 were upregulated in the genital secretions of women with 




showed that IL-10 was more often detectable in genital secretions 
from women with gonorrhoea, chlamydia or BV, but not tricho- 
moniasis, compared with women with no infection. Infection of 
cervical and vaginal cell lines with N. gonorrhoeae resulted in 
upregulated IL-1, IL-6 and IL-8 production.
6
 Contrary to these 
results, some studies have found no difference in cytokines in 









 compared with uninfected women. 
In this cohort, we previously reported that gonorrhoea, chla- 
mydia and M. genitalium infections and elevated genital concen- 
trations of IL-1β, IL-6, IL-8 and sCD40L were associated with 
increased HIV risk.
20
 Genital cytokine upregulation may increase 
HIV  risk by recruiting/activating HIV  target cells, reducing epithe- 
lial barrier integrity and activating NF-kB.
21
 
22–24 Many of the 
upgregulated cytokines in the CVLs from women with chlamydia, 
gonorrhoea or HSV-2 are involved in recruitment, activation, pro- 
liferation and differentiation of HIV  target cells. Increased genital 
concentrations of these cytokines could result in accumulation of 
activated/differentiated target cells for HIV infection. Women with 
BV are also at increased risk of HIV acquisition.
19
 Although che- 
mokine downregulation in the genital tracts of these women may 
result in reduced immune cell recruitment, upregulation of proin- 
flammatory cytokines may reduce the integrity of the epithelial 
barrier, activate HIV target cells that are already present, and 
promote HIV  replication by activating NF-κB. 
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This study has several limitations: relatively few women had 
gonnorhoea and chlamydia, possibly limiting our conclusions. 
Other factors may influence cytokine concentrations in the 
genital tract. While we showed that women with microscopically 
evident genital fungal hyphae had lower IFN-α, IL-9, IL-15 and 
IL-17 concentrations, and the relationships between cytokines 
and STIs/BV were not influenced by hormone contraceptive use, 
we have no information on semen exposure, antibiotic use and 
menstrual cycle phase, which may influence cytokine concentra- 
tions. The study was cross-sectional, so long-term implications 
of these profiles could not be addressed. Finally, this study was 
largely exploratory and observational, and mechanisms for cyto- 
kine differences require further investigation before an interven- 
tion can come from these data. 
Although chlamydia, gonorrhoea and M. genitalium infec- 
tions were associated with increased risk of HIV infection in 
this cohort, most of the women who had one or more of these 
STIs did not have a clinical sign.
20
 As a result, women with 
these infections would likely have remained untreated in settings 
where STIs are managed syndromically. This study highlights 
the urgent need for better strategies to manage asymptomatic 
STIs, as infections such as chlamydia, gonorrhoea and active 





▸  Chlamydia was associated with the highest genital cytokine 
levels, followed by gonorrhoea, herpes simplex virus type 2, 
trichomoniasis and bacterial vaginosis (BV). 
▸  Although women with chlamydia or gonorrhoea had very 
high genital cytokine biomarkers of inflammation, 
potentially putting them at risk of HIV infection, most lacked 
clinical signs. 
▸  Women with BV had a mixed genital cytokine profile, with 
upregulated proinflammatory cytokine concentrations, but 
also downregulated concentrations of chemokines and 
haematopoietic cytokines. 
▸  Genital infections did not cause changes in plasma cytokine 
concentrations, and genital and plasma cytokine 
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Supplementary Table 1 Factor loadings 
 
Biological functions (from CFA) Oblique groupings (from EFA) 
 
Cytokine Factor         Loading a        Factor        Loadinga 
 
IL-1α Pro-inflammatory 0.49 Factor 3 0.62 
IL-1β 0.81 Factor 3 0.89 
IL-6 0.70 Factor 3 0.57 
IL-12p40 0.16 Factor 2 0.82 
IL-12p70 0.66 Factor 4 0.68 
TNF-α 0.72 Factor 3 0.60 
TNF-β 0.23 Factor 1 0.51 
Eotaxin Chemokine 0.55 Factor 2 0.83 
Fractalkine 0.50 Factor 2 0.43 
GRO 0.72 Factor 5 0.73 
IL-8 0.52 Factor 3 0.66 
IP-10 0.73 Factor 5 0.79 
MCP-1 0.55 Factor 5 0.60 
MCP-3 0.29 Factor 4 -0.30 
MDC 0.66 Factor 5 0.78 
MIP-1α 0.63 Factor 2 0.78 
MIP-1β 0.43 Factor 1 0.73 
RANTES 0.21 Factor 3 0.39 
IFN-α Innate Factor 2 0.62 
FLT3L Hematopoietic 0.72 Factor 1 0.71 
G-CSF 0.55 Factor 3 0.43 
GM-CSF 0.36 Factor 4 0.68 
IL-3 0.53 Factor 2 0.56 
IL-7 0.27 Factor 4 0.69 
IL-9 0.71 Factor 1 0.91 
EGF Growth Factor 0.65 Factor 2 0.43 
FGF-2 0.74 Factor 2 0.76 
PDGF-AA 0.43 Factor 5 0.41 
PDGF-AB/BB 0.71 Factor 2 0.68 
TGF-α 0.54 Factor 1 0.60 
VEGF 0.26 Factor 1 0.41 
IFN-γ Adaptive -0.40 Factor 1 -0.57 
IL-2 0.61 Factor 4 0.53 
IL-4 0.54 Factor 4 0.58 
IL-5 0.36 Factor 4 0.66 
IL-13 0.52 Factor 4 0.40 
IL-15 0.66 Factor 1 0.83 
IL-17 0.72 Factor 1 0.86 
sCD40L 0.17 Factor 1 0.24 
sIL-2Rα 0.57 Factor 4 0.38 
IL-10 Anti-inflammatory 0.20 Factor 3 0.52 




A factor loading can be interpreted in a similar manner as a correlation coefficient. CFA: 
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Supplementary Figure 1. Cytokine concentrations in the genital tracts of women 
 
who did not have a sexually transmitted infection (STI) or bacterial vaginosis (BV) 
 
were compared to those of women who had BV (n=73), trichomoniasis (n=13), 
 
Mycoplasma genitalium (n=3), chlamydia (n=10), gonorrhoea (n=13), active HSV 
 
(detection of HSV in the genital tract by PCR accompanied by a positive HSV-2 IgG 
 
test; n=6) or active syphilis (n=3). Boxes indicate 25-75th percentiles; lines indicate 
 
medians; whiskers indicate 10-90th percentiles; dots indicate outliers. Several women 
 
who had M. genitalium, chlamydia, gonorrhoea, active HSV or active syphilis had 
 
other co-infections. For the analysis of BV or trichomoniasis, only women who had 
 
single infections were included. P-values were adjusted for multiple comparisons 
 
using a false discovery rate step-down procedure. Cytokines that were significantly 
 
altered relative to women who did not have an STI or BV before adjusting for 
 
multiple comparisons are indicated by shaded bars (p<0.05). Cytokines that were up- 
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Abstract 
Background: Prompt diagnosis of acute HIV infection (AHI) benefits the individual and provides opportunities for public 
health intervention. The aim of this study was to describe most common signs and symptoms of AHI, correlate these with 
early disease progression and develop a clinical algorithm to identify acute HIV cases in resource limited setting. 
Methods: 245 South African women at high-risk of HIV-1 were assessed for AHI and received monthly HIV-1 antibody and 
RNA testing. Signs and symptoms at first HIV-positive visit were compared to HIV-negative visits. Logistic regression 
identified clinical predictors of AHI. A model-based score was assigned to each predictor to create a risk score for every 
woman. 
Results: Twenty-eight women seroconverted after a total of 390 person-years of follow-up with an HIV incidence of 7.2/100 
person-years (95%CI 4.5–9.8). Fifty-seven percent reported $1 sign or symptom at the AHI visit. Factors predictive of AHI 
included age ,25 years (OR = 3.2; 1.4–7.1), rash (OR = 6.1; 2.4–15.4), sore throat (OR = 2.7; 1.0–7.6), weight loss (OR = 4.4; 1.5– 
13.4), genital ulcers (OR = 8.0; 1.6–39.5) and vaginal discharge (OR = 5.4; 1.6–18.4). A risk score of 2 correctly predicted AHI in 
50.0% of cases. The number of signs and symptoms correlated with higher HIV-1 RNA at diagnosis (r = 0.63; p,0.001). 
Conclusions: Accurate recognition of signs and symptoms of AHI is critical for early diagnosis of HIV infection. Our 
algorithm may assist in risk-stratifying individuals for AHI, especially in resource-limited settings where there is no routine 
testing for AHI. Independent validation of the algorithm on another cohort is needed to assess its utility further. Point-of- 
care antigen or viral load technology is required, however, to detect asymptomatic, antibody negative cases enabling early 
interventions and prevention of transmission. 
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The devastating toll of the HIV/AIDS epidemic on sub- 
Saharan Africa, with 67% of the estimated 33.3 million world- 
wide HIV infections in this region alone, is well recognized [1]. 
Individuals with acute HIV  infection (AHI) have been shown to be 
more infectious compared to individuals with chronic infection. 
Data from several cohorts provide estimates of HIV  transmission 
per coital act in sub-Saharan Africa, with dramatically higher 
transmission rates during acute and early, compared to latent or 
chronic infection [2–4]. One study modeling the impact of 
antiretroviral therapy (ART) on the HIV  epidemic estimated that 
38.4% of ongoing HIV transmissions are attributable to sexual 
contact with early HIV  index cases [5]. This is presumably due to 
several factors including very high plasma and genital tract HIV  
viral load [6–9]. Early identification of individuals in the acute/ 
early stage of infection would not only enable prompt intervention 
to prevent transmission to negative partners, but may also allow 
for earlier initiation of treatment. Data on the clinical benefits of 
ART in patients with acute HIV are conflicting [10–12]. 
Theoretical benefits of this intervention include potentially pre- 
serving immune function, reducing the pool of latently infected 
CD4 cells, thereby altering the virologic set point and delaying 
 






disease progression. These have to be weighed against side effects 
and patient readiness to start antiretrovirals [3,13–17]. 
Making the diagnosis of acute HIV  infection is challenging since 
the signs and symptoms of acute retroviral syndrome are non- 
specific. Of note, data on clinical characteristics of subtype C 
infection, particularly among women, are currently limited 
[18,19]. Days to weeks after acquisition, 40–90% of individuals 
develop signs and symptoms including a flu-like illness or 
mononucleosis-like syndrome [20]. The onset of symptoms 
coincides with viral replication and peak viremia [21–23]. During 
this window period, only HIV RNA can be detected in plasma 
until the appearance of p24 antigen and, subsequently, HIV  
antibodies. Laboratory-based fourth generation Ag/Ab combina- 
tion assays improve detection of acutely-infected individuals 
compared to third generation antibody assays. However, in 
resource limited, high prevalence settings, health services rely 
predominantly on point-of-care testing (POCT) and, disappoint- 
ingly, a recent evaluation found that the antigen component of the 
fourth generation DetermineH HIV-1/2 Ag/Ab Combo rapid test 
performed poorly in detecting acute infection [24]. Initiating RNA 
testing still requires clinician’s high index of suspicion and 
availability of resources. Thus, a clinical algorithm which 
prioritizes nucleic acid HIV  testing would be of benefit, especially 
in decentralized health care settings. 
The study, conducted by the Centre for the AIDS Programme 
of Research in South Africa (CAPRISA), was a prospective cohort 
study to examine the pathogenesis of acute HIV subtype C 
infection and to describe the immunologic, virologic and clinical 
characteristics of acute and early infection [25]. The purpose of 
the current analysis was (i) to describe the signs and symptoms of 
AHI in order to develop a diagnostic model for identifying cases 
with high probability of AHI which would allow interventions like 
targeted HIV-1 RNA or p24 antigen testing; (ii) to calculate 
sensitivity and specificity of the risk score to predict presence or 
absence of AHI; (iii) to correlate clinical signs and symptoms of 




Ethics approval for the study was obtained from the University 
of KwaZulu-Natal and the University of Cape Town. Written 
informed consent was obtained from all participants. 
 
Cohort 
Between August 2004 and May 2005, a cohort of 245 HIV- 
uninfected women at high risk of infection was recruited in 
Durban, South Africa [25]. Women were considered high-risk if 
they reported having more than three sexual partners in the past 3 
months or self-identified as sex workers. 
 
Study Evaluations and Definition of Acute HIV Infection 
Demographic and behavioural questionnaires were adminis- 
tered at enrollment. Women were evaluated at baseline and 
monthly thereafter with standardized interviews using a locally 
developed Clinical Evaluation Tool (CET) to screen for signs and 
symptoms associated with AHI. Interviews were performed by the 
research clinician who either spoke the local language or was 
assisted by a nurse who acted as an interpreter. Signs and 
symptoms screened for included: fever, fatigue, lethargy, night 
sweats, rash, headache, swollen lymph glands, sore throat, 
myalgia, any swollen joints, morning stiffness (joints), nausea, 
vomiting, diarrhoea, mucocutaneous ulceration, gingivitis, loss of 
appetite, reported weight loss, confusion, photophobia, neck 
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stiffness, retro-orbital pain and vaginal discharge. Women also 
underwent a physical examination to determine the presence or 
absence of fever (.38uC), measured weight loss, evidence of rash, 
lymphadenopathy, pharyngitis, thrush, mucocutaneous ulceration, 
conjunctivitis, hepatomegaly and splenomegaly. Whilst sexually 
transmitted infections (STIs) were managed syndromically, six 
monthly laboratory screening for STIs was performed as well. 
The CET was administered before the HIV status was 
established. HIV testing algorithm consisted of two rapid HIV-1 
antibody tests: the Determine HIV-1 test (Abbott Diagnostics, 
Johannesburg, South Africa) and the Capillus HIV-1/HIV-2 test 
(Trinity Biotech, USA). Discordant rapid antibody results were 
confirmed by HIV  enzyme immunoassay (EIA) (BEP 2000; Dade 
Behring, Marburg, Germany). A pooled plasma HIV-1 RNA 
(AMPLISCREEN
TM
 HIV-1 Tests, v1.5– Roche Diagnostics) was 
performed at enrollment and each visit subsequently, irrespective 
of antibody result. A primary pool containing 24 samples was used 
and if positive disaggregated into smaller secondary pools. 
Diagnosis of AHI was made if a woman had detectable plasma 
HIV  RNA level (using ,400 copies/mL lower limit of detection 
assay) and/or a positive HIV  antibody test following a previously 
documented negative test. Women presenting for unscheduled 
visits also completed a CET  and were tested for HIV  following the 
same algorithm. Participants underwent risk reduction counseling 
and were provided with male and female condoms at every visit. 
 
Data Analysis 
Signs and symptoms reported on the CET  at all HIV-negative 
visits and the AHI visit were used in the analysis. Prevalence of 
signs and symptoms at both the AHI and non-AHI visits was 
assessed. Weight before and after seroconversion was compared 
using a Wilcoxon signed rank test. A Pearson’s correlation 
coefficient was calculated to assess the strength of the linear 
relationship between the number of signs and symptoms and viral 
load, as well as CD4 count, measured at seroconversion, 6 and 12 
months post infection. Signs/symptoms at the AHI visit were 
compared to those captured on the CET at HIV-negative visits 
from both seroconverters and those who remained HIV  negative. 
To determine which signs/symptoms were associated with AHI, 
symptoms in women who seroconverted were compared with 
symptoms in women who remained HIV negative. Odds ratios 
(OR) for each of the signs/symptoms were calculated using 
a generalized estimating equation model, using a binomial 
distribution, accounting for multiple visits for the same participant. 
Two adjusted models were fitted to assess clinical factors predictive 
of AHI. Variables which were associated with AHI at p,0.15 in 
each of the models were then included in the final model, which 
was used to develop a model-based score to predict AHI. In 
addition to applying a risk score model to predict AHI, the 
absolute number of signs/symptoms was also assessed to de- 
termine association with AHI. Sensitivity, specificity and positive 
likelihood ratios (with 95% confidence intervals) for detecting AHI 
were calculated for different numbers of signs and symptoms. This 
was also repeated excluding POCT negative, RNA positive 
participants reflecting current clinical practice in South Africa 
where RNA testing is not part of the algorithm for HIV  diagnosis. 
All data analysis was performed using SAS version 9.2 (SAS 
Institute Inc., Cary). 
 
Results 
Demographic Characteristics of the Cohort 
Between August 2004 and May 2005, 775 high risk women 
were screened and 245 HIV uninfected women were enrolled 
 






and followed monthly for two years. The demographic and 
behavioural characteristics of the 245 women have been 
described in detail elsewhere [25] and are summarized in 
Table 1. Briefly, the median age of the participants was 36 
(interquartile range (IQR): 24–42) years, 41.2% had at least 11 
years of education, 58.8% reported using a condom at last sexual 
encounter, 13.9% and 35.0% indicated that they were never able 
to insist on condom use with casual and steady partners, 
respectively [26]. Most women (85.4%) reported having 2–5 
casual partners in the 3 months prior to enrollment and 78.8% 
were self-identified commercial sex workers. Of note, the 
prevalence of HIV among women screening for enrollment into 
the HIV negative cohort was 59.6% [25]. 
 
Signs and Symptoms in Acute HIV Infection 
The 245 HIV negative women had 4845 HIV negative visits, 
scheduled monthly, with a missed visit rate of 3.9%. The median 
time between visits was 28 days (IQR 28 - 34 days). Twenty-eight 
women seroconverted after a total of 390 person-years of follow-up 
with an HIV  incidence of 7.2/100 person-years (95%CI: 4.5–9.8). 
The frequency of signs/symptoms reported at AHI visit was 
higher than that reported at the HIV-negative visits (Table 2). The 
most prevalent signs/symptoms reported at AHI visit were loss of 
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throat (21.4% vs. 2.1%, p,0.001), fever (17.9% vs. 2.9%, 
p,0.001), arthralgia (17.9% vs. 2.9%, p,0.001), and reported 
weight loss (21.4% vs. 1.3%, p,0.001). Of note, of the 28 acute 
infections, 60.7% (n = 17) had confirmed (measured) weight loss in 
the preceding two weeks, with a median reduction of 2.0 kg (IQR 
1.3–2.6 kg). The median weight loss during seroconversion for all 
women with acute infection was 1.3 kg (IQR 0.0–2.2 kg; 
p = 0.025). 
Fifty-seven percent of participants with AHI reported at least 
one sign or symptom and the specificity and likelihood ratios 
increased with an increasing number of reported symptoms 
(Table 3). Participants with one to three signs/symptoms were 
more likely to have AHI compared to women with no signs/ 
symptoms (OR = 3.9; 95% CI: 1.6–9.2; p = 0.002); and presence 
of $4 signs/symptoms was strongly associated with AHI 
(OR = 17.3; 95% CI: 6.7–44.7; p,0.001). When excluding all 
POCT Ab negative, RNA positive AHI cases, the prevalence of 
signs/symptoms increased to 76.5% and the association with AHI 
was even stronger (1–3 symptoms: OR  = 10.3; 95% CI: 3.1–34.5, 
$4 symptoms: OR  = 36.9. 95% CI: 9.8–140). When comparing 
AHI and non-AHI visits among women who seroconverted, loss of 
appetite, fatigue, headache, rash and sore throat remained the 
most commonly reported symptoms. 
appetite (28.6% vs. 2.1% in HIV  uninfected, p,0.001), headache 
(25.0% vs. 5.7%, p,0.001), rash (25.0% vs. 2.9%, p,0.001), sore 
 
Table 1. Baseline demographic and behavioural characteristics of South African women at high risk of HIV acquisition stratified by 
HIV status [25]. 
 
Characteristic All %  (N) (N = 245) 
HIV negative %  (N) 
(N = 217) 
AHI
# cases %  (N) 
(N = 28) 
 
Age in years 
$25 73.5% (180) 75.6% (164) 57.1% (16) 
,25 26.5% (65) 24.4% (53) 42.9% (12) 
Relationship status 
No partner (single, widowed, divorced) 7.4% (18/244) 7.9% (17/216) 3.6% (1) 
One partner (stable or married) 35.7% (87/244) 37.5% (81/216) 21.4% (6) 
Many partners 57.0% (139/244) 54.6% (118/216) 75.0% (21) 
Number of casual partners in the last 3 months (baseline) 
0–1 5.0% (12/240) 4.7% (10/212) 7.1% (2) 
2–5 85.4% (205/240) 85.9% (182/212) 82.1% (23) 
.5 9.6% (23/240) 9.4% (20/212) 10.7% (3) 
Proportion of commercial sex workers 78.8% (193) 79.7% (173) 71.4% (20) 
Highest level of school completed 
Grade ,8 24.5% (60) 26.3% (57) 10.7% (3) 
Grade 8–10 34.3% (84) 32.3% (70) 50.0% (14) 
Grade 11–12 41.2% (101) 41.5% (90) 39.3% (11) 
Mean years sexually active (SD) 17.2 (10.38) 17.7 (10.35) 13.5 (10.08) 
Age at sexual debut 
,16 28.2% (69) 26.7% (58) 39.3% (11) 
$16 71.8% (176) 73.3% (159) 60.7% (17) 
Partner type at last sexual act (baseline) 
Steady Partner 75.9% (186) 77.9% (169) 60.7% (17) 
Casual Partner 24.1% (59) 22.1% (48) 39.3% (11) 
Proportion with condom use at last sex act 58.8% (144) 58.1% (126) 64.3% (18) 
# Acute HIV Infection. 
doi:10.1371/journal.pone.0062928.t001 
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Table 2. Signs and symptoms associated with acute HIV infection. 
 
 
Signs or symptoms 
Total cohort HIV negative 
visits 
N (%) (N = 4845) 
AHI cases N (%) 
(N = 28) 
*Unadjusted Odds 
Ratio 
(95% CI)               p-value     Sensitivity (%)   Specificity (%) 
 
Headache 277 (5.7) 7 (25.0) 5.5 (2.3–13.0) ,0.001 25.0 94.3 
Fever 140 (2.9) 5 (17.9) 7.3 (2.7–19.5) ,0.001 17.9 97.1 
Sore throat 100 (2.1) 6 (21.4) 12.9 (5.1–32.6) ,0.001 21.4 97.9 
Night sweats 119 (2.5) 3 (10.7) 4.8 (1.4–16.0) 0.012 10.7 97.5 
Fatigue 133 (2.7) 7 (25.0) 11.8 (4.9–28.3) ,0.001 25.0 97.3 
Swollen glands 280 (5.8) 3 (10.7) 2.0 (0.6–6.5) 0.275 10.7 94.2 
Rash 138 (2.8) 7 (25.0) 11.4 (4.8–27.2) ,0.001 25.0 97.2 
Loss of appetite 103 (2.1) 8 (28.6) 18.4 (7.9–42.8) ,0.001 28.6 97.9 
Weight loss 63 (1.3) 6 (21.4) 20.7 (8.1–52.8) ,0.001 21.4 98.7 
Nausea 80 (1.7) 5 (17.9) 12.9 (4.8–34.9) ,0.001 17.9 98.3 
Diarrhoea 102 (2.1) 4 (14.3) 7.8 (2.6–22.7) ,0.001 14.3 97.9 
Arthralgia 139 (2.9) 5 (17.9) 7.4 (2.8–19.6) ,0.001 17.9 97.1 
Myalgia 47 (1.0) 3 (10.7) 12.3 (3.6–42.0) ,0.001 10.7 99.0 
Lethargy 49 (1.0) 3 (10.7) 11.7 (3.4–40.2) ,0.001 10.7 99.0 
Oral ulcers 48 (1.0) 2 (7.1) 7.7 (1.8–33.3) 0.006 7.1 99.0 
Genital ulcers 8 (0.2) 2 (7.1) 46.5 (9.4–229.6) ,0.001 7.1 99.8 
Vaginal discharge 91 (1.9) 3 (10.7) 6.3 (1.9–21.1) 0.003 10.7 98.1 
*Odds Ratio adjusted for repeated measures. 
Note: Signs and symptoms reported with ,5% frequency in the AHI cases or p.0.15 were omitted. These included splenomegaly, anal ulcers, swollen joints, gingivitis, 
observed fever, aseptic meningitis, peripheral neuropathy, conjunctivitis, hepatomegaly, photophobia, parasthaesia, retro-orbital headache and neck stiffness. 
doi:10.1371/journal.pone.0062928.t002 
 
Factors Predictive of Acute HIV Infection 
In an adjusted model, six predictors of AHI were identified: age 
,25 years (OR = 3.2, 95% CI: 1.4–7.1), rash (OR 6.1, 95% CI: 
2.4–15.4), sore throat (OR 2.7, 95% CI: 1.0–7.6), loss of appetite 
(OR 4.7, 95% CI: 1.4–15.6), weight loss (OR 4.4, 95% CI: 1.5– 
13.4), vaginal discharge (OR: 5.4, 95% CI: 1.6–18.4) and genital 
ulcer (OR 8.0, 95% CI: 1.6–39.5) (Table 4). In this cohort, 
behavioural factors, including number of partners, condom use, 
 
Table 3. Sensitivity and Specificity for different number of 
signs and symptoms. 
 
Number of 
symptoms Sensitivity (%)  Specificity (%)  +LR (95% CI) 
All AHI cases included (N = 28) 
$1 57.1% 81.5% 3.09 (2.23–4.28) 
$2 42.9% 91.4% 4.98 (3.22–7.71) 
$3 32.1% 95.3% 6.86 (3.95–11.93) 
$4 25.0% 97.3% 9.11 (4.69–17.68) 
$5 25.0% 98.1% 13.31 (6.79–26.09) 
Excluding POCT* negative, RNA positive cases (N = 17) 
$1 76.5% 81.5% 4.13 (3.15–5.42) 
$2 58.8% 91.4% 6.82 (4.54–10.27) 
$3 41.2% 95.3% 8.76 (4.89–15.69) 
$4 29.4% 97.2% 10.65 (5.00–22.68) 
$5 29.4% 98.1% 15.68 (7.30–33.69) 
whether the partner was casual or steady, and educational level 
were not associated with AHI in the final model (data not shown). 
 
Signs and Symptoms According to HIV Diagnostic Test 
All participants had two POCTs and a viral load RNA performed 
at each visit. Positive results were followed up with a laboratory-based 
third generation ELISA test. Of the 28 women with AHI, 17 (60.7%) 
had positive POCTs including one participant with discordant 
POCTs, whileallwere HIVpositiveonRNAtesting(Table 5).Three- 
quarters of women (13/17; 76.5%) with positive or discordant 
POCTs were symptomatic compared to only one quarter with two 
negative POCTs at AHI (3/11; 27.3%, p = 0.019) who would have 
been identified with our clinical algorithm. However, it is important 
to note that, 8/28 women (28.6%) were POCT negative and 
experienced no signs or symptoms at the AHI visit and would 
therefore not have been identified by POCT testing or any clinical 
evaluation of AHI symptoms. 
 
Risk-score Model Predicting Acute HIV Infection 
The variables significantly associated with AHI in the adjusted 
analysis were used to construct a predictor risk score for AHI using 
the regression coefficients from the final adjusted model. The 
signs/symptoms in the model were weighted by the regression 
coefficients, rounded off to the nearest integer. Hence, the risk 
score algorithm was calculated as follows: 
 
Risk Score~2 if rashz1 if sore throatz2 if loss of appetite 
z1 if weight lossz2 if vaginal discharge 
z2 if genital ulcerz1 if agev25 years 
*POCT: point of care test. 
doi:10.1371/journal.pone.0062928.t003 
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Table 4. Unadjusted and adjusted analysis of signs and symptoms associated with acute HIV Infection. 
 
Predictor 
Unadjusted Odds Ratio 
(95% CI) 
Adjusted* Odds Ratio 
(95% CI) 





$25 1.0 1.0 1.0 
,25 2.77 (1.30–5.86) 2.60 (1.23–5.50) 3.15 (1.41–7.07) 
Symptoms and Signs 
Headache 5.50 (2.32–13.04) – – 
Fever 7.31 (2.74–19.50) – – 
Sore Throat 12.94 (5.14–32.61) 3.16 (1.01–9.83) 2.73 (0.99–7.56) 
Night Sweats 4.77 (1.42–16.00) – – 
Fatigue 11.81 (4.93–28.26) – – 
Swollen Glands 1.96 (0.59–6.52) – – 
Rash 11.37 (4.75–27.19) 5.42 (2.10–13.99) 6.07 (2.39–15.43) 
Loss of Appetite 18.42 (7.93–42.78) 4.91 (1.40–17.29) 4.72 (1.42–15.63) 
Weight Loss 20.70 (8.12–52.80) 3.50 (1.17–10.41) 4.43 (1.46–13.43) 
Nausea 12.95 (4.80–34.91) – – 
Diarrhoea 7.75 (2.64–22.74) – – 
Athralgia 7.36 (2.76–19.64) – – 
Myalgia 12.25 (3.58–41.98) – – 
Lethargy 11.74 (3.43–40.19) – – 
Oral Ulcers 7.69 (1.77–33.30) – – 
Genital Ulcers 46.51 (9.42–229.60) 8.11 (1.97–33.49) 7.95 (1.60–39.49) 
Vaginal Discharge 6.27 (1.86–21.13) 6.19 (1.73–22.15) 5.38 (1.57–18.40) 
*Model for behavioural and demographic factors adjusted for age in years, relationship status, education and age at sexual debut (data not shown), while model for 
symptoms and signs adjusted for sore throat, rash, loss of appetite, weight loss, genital ulcers and vaginal discharge. 
**Risk score model adjusting for age, sore throat, rash, loss of appetite, weight loss, genital ulcers and vaginal discharge. 
doi:10.1371/journal.pone.0062928.t004 
 
A risk score was calculated for each visit. The sensitivity and 
specificity of different cut-off scores were determined by compar- 
ing the risk score with the HIV status (HIV-1 RNA and/or 
antibody positive) of the participant at every visit. Simply RNA 
PCR testing every person with at least one symptom would yield 
a sensitivity of 57.1%. A risk score of at least 1 occurred at 28.0% 
of participant visits. Having a score of at least 1, that is, presenting 
with any of the risk score symptoms or being under 25 years of 
age, would identify 67.9% cases of AHI and positive predictive 
value (PPV) of the test would be low at 1.4%. Using this scoring 
system, a score of 2 could identify 50.0% of AHI cases by testing 
only 7.3% of participants, with a PPV of 3.9%. At a cut-off of 3, 
only 3.0% of participants would be tested to identify 39.3% of all 
AHI, with a PPV of 7.5%. 
 
Correlation of Number of Signs and Symptoms and 
Markers of HIV Disease Progression 
There was a significant positive correlation between the number 
of signs/symptoms and the HIV-1 plasma viral load at the AHI 
visit (correlation coefficient of 0.63, p = ,0.001) with participants 
who had a high viral load at seroconversion having a greater 
number of signs/symptoms. However, this trend did not persist, 
and no correlation was observed between the initial number of 
signs/symptoms and HIV-1 plasma viral loads at 6 or 12 months. 
There was no statistically significant correlation between the 
number of signs/symptoms and CD4 count at seroconversion 
(correlation coefficient of 0.16, p = 0.41). There was also no 
significant difference in the duration of signs/symptoms and self- 
reported severity of diarrhoea, skin rash, lethargy and pharyngitis 
(mild to severe) between women with AHI and HIV-negative 
women (data not shown). 
 
Discussion 
The period of acute HIV  infection contributes to a considerable 
proportion of transmission events and, therefore, identifying those 
who are acutely infected is of paramount importance in curbing 
the epidemic [20]. Accurate diagnosis of acute HIV infection 
includes use of molecular techniques like HIV RNA PCR 
detection which may either be expensive or not readily available 
in some settings. 
In this prospective cohort study of 245 high-risk women we 
identify clinical signs and symptoms predictive of acute subtype C 
infection. We present a screening algorithm which can be used to 
enhance detection of acute HIV infection in a resource-limited 
setting. Importantly, we report that younger age, rash, sore throat, 
loss of appetite, weight loss and vaginal discharge or genital ulcers 
were associated with AHI. A similar constellation of symptoms has 
been reported in other studies [27–32], although in our cohort 
none of the signs or symptoms had prevalence above 28.6%. In 
fact, fever, commonly reported in other studies, was found in only 
17.9% of our participants [27–32]. Most available data, however, 
pertains to predominantly male cohorts with subtype B infection. 
Data in the sub-Saharan African context is more limited 
[18,19,33], particularly among women with subtype C infection. 
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Table 5. Signs and symptoms according to HIV diagnostic test. 
 
HIV diagnostic testing N (%) of AHI cases (N = 28) N (%) with no symptoms  N (%) with any symptoms   p-value* 
POCT antibody positive or discordant 17 (60.7%) 4/17 (23.5%) 13/17 (76.5%) 0.0189 
POCT antibody negative 11 (39.3%) 8/11 (72.7%) 3/11 (27.3%) – 
*Fisher’s Exact test. 
doi:10.1371/journal.pone.0062928.t005 
 
Available literature on acute infection reports higher prevalence of 
symptoms than what was noted in our cohort. For example, in 
a prospective cohort of female sex workers in Kenya, 81% of 
women had at least one symptom, in comparison to only 57.1% in 
our cohort [18]. More recently, in a cross-sectional cohort of 
predominantly male adults presenting with fever in Mozambique, 
among those identified with acute infection, all had reported sore 
throat and 67% complained of a mononucleosis-like syndrome. 
The limitation of this particular study, however, was a small 
number of individuals with acute HIV infection and that the 
administration of the questionnaire a week after the diagnosis visit 
may have influenced the findings [34]. 
Our AHI cohort included individuals who were diagnosed by 
RNA testing alone potentially before a possible seroconversion 
illness could have manifested itself. Excluding these cases, the 
number of women who reported signs/symptoms was 76.5% 
similar to what has been previously reported [18,19]. Other 
contributing reasons for the observed difference may have been 
cultural or gender-specific characteristics in reporting signs/ 
symptoms, or differences in how HIV subtypes manifest disease 
[35]. In addition, the fact that our participants were not being 
evaluated in an STI  clinic or referred for a particular complaint, 
meant that they were probably less likely to report signs/ 
symptoms. It is therefore possible that if the clinical algorithm 
was applied to a primary health care facility or STI clinic, the 
sensitivity and specificity of the algorithm would improve, as well 
as its utility as part of an HIV  screening initiative in these settings. 
This study demonstrates that it is possible to create a model 
predictive of AHI in this population. RNA-PCR testing everyone 
with a risk cut-off of $1 (28.0% of participant visits), would allow 
for the identification of 67.9% of acutely-infected individuals. In 
contexts of limited resources, the cut-off score could be increased, 
thus reducing the number of tests done in order to identify acute 
infection. In our cohort, testing only women with a risk score of 
$2 would result in RNA-PCR testing of only 7.3% of participant 
visits, and half (50.0%) of all acute infections would be identified. 
The costs of these additional tests could be offset by the benefit of 
being able to intervene early in acutely-infected individuals, to 
initiate care and help prevent HIV  transmission during this high- 
risk period. 
Our algorithm did not yield as high a predictive value or 
sensitivity as the algorithm created from a cross-sectional 
assessment of individuals presenting at an STI clinic in Malawi. 
Powers et al, who included discordant POCT results in their 
model, were able to identify 95% of AHI cases by performing 
RNA or p24 testing in 40% of their population [19]. Apart from 
a difference in testing methodologies between the two studies, it is 
possible that the models were affected by differences in the 
population with higher overall prevalence of signs/symptoms such 
as genital ulcer disease in individuals presenting for diagnosis and 
treatment at an STI  clinic in the Malawi study. 
Many demographic factors such as number of sexual partners, 
age at sexual debut, education level and condom use were not 
significantly associated with AHI in our cohort. A possible 
explanation is that behavioural risk assessment was performed 
only at enrollment and thus, because of ongoing risk reduction 
counseling, it is possible that women modified their risk behaviour 
over the course of the study resulting in a decrease of HIV  
incidence over time [25]. Only age ,25 years was strongly 
predictive of acute HIV infection (OR 3.2). This finding reflects 
what has been reported in other studies that indicate a higher 
incidence of HIV  in younger women [36]. 
Availability of longitudinal follow-up data from the immediate 
post-seroconversion period, allowed us to demonstrate a correla- 
tion between the number of signs/symptoms and early HIV  RNA 
levels. While in our study this association did not persist beyond 
the early HIV infection period, previous studies found an 
association between the number, severity and duration of 
symptoms and higher viral load set-points in patients infected 
with subtype B virus [37–39]. For example, one cohort study with 
over 600 individuals found that HIV RNA levels remained 
persistently higher in symptomatic compared to asymptomatic 
patients highlighting the need to identify those individuals and 
ensure access to care [40]. Data from sub-Saharan Africa is limited 
but our findings differ from what has been reported in a cohort of 
women in Kenya where higher set-point viral load and more 
severe illness at acute HIV infection predicted faster disease 
progression [41,42]. 
Our study demonstrates that a considerable proportion of 
individuals (28.6%) neither test positive on conventional point-of- 
care testing nor report any symptoms when presenting to testing 
facilities with acute HIV  infection. This population provides a true 
challenge for the scientific community to develop reliable fourth 
generation Ag/Ab combination POCTs or low-cost point-of-care 
viral load technology. Although the DetermineH HIV-1/2 Ag/Ab 
Combo rapid test performed poorly in detecting acute infection in 
a recent trial [24] we hope that this is not the end of POCT Ag 
technology. Furthermore, several POCT viral load assays are 
currently being evaluated including the SAMBA (simple amplifi- 
cation based assay; Diagnostics Development Unit University of 
Cambridge) a semi quantitative test for using isothermal ampli- 
fication and visual detection by dipstick, the Liat TM Analyser, 
manufactured by IQuum (Marlborough, MA), is a real-time, 
battery operated, small, portable PCR kit providing quantitative 
results and the Alere NAT system (Alere Technologies, Stirling, 
UK). The hope would be that the implementation of this 
technology, primarily developed in order to monitor HIV  positive 
patients on ART, will also allow health care providers in less 
developed settings to test for AHI. 
The strengths of our study rest in the fact that this is 
a longitudinal cohort composed of women with subtype C 
infection which was conducted in a non-STI clinic setting and 
therefore may be more representative of the general population. 
The cohort design included clinical assessment at every visit which 
allowed comparison of signs/symptoms pre-seroconversion to AHI 
visit. Given the poor specificity of signs/symptoms and concurrent 
 






background of other illnesses, this systematic clinical assessment is 
an advantage of this study. In contrast to previous studies, all 
participants underwent antibody and RNA PCR testing at every 
visit allowing a detailed analysis of the characteristics of these tests 
and correlation with symptoms. 
Our study highlights the challenges associated with recognizing 
and diagnosing acute HIV  infection in a cohort of women at high 
risk of infection. Although signs/symptoms of AHI are non- 
specific and highly variable, it is possible to identify a large 
proportion of individuals who have acute or early HIV  infection if 
there is a high index of suspicion to consider the diagnosis and 
initiate appropriate testing. More advanced laboratory diagnostic 
tools offer promise of earlier detection of incident infections [21], 
but even then clinical judgement guiding prioritization of testing 
will remain critical, especially in resource-limited settings. Our risk 
score model based on several signs/symptoms most predictive of 
AHI may allow identification of women likely to be acutely 
infected with HIV and prioritize testing with RNA or newer 
generation assays, ultimately reducing cost of AHI diagnosis. 
Further independent validation of the model in different settings 
and larger sero-incidence cohorts would be important to assess the 
utility of the model in practice. In a setting where nucleic acid 
testing is not yet readily available, the ability to develop a checklist 
of signs/symptoms that would increase clinical suspicion of AHI 
would be of benefit for triaging of high-risk women and may lead 
to earlier detection of infection. 
A recent study by Powers and colleagues concluded that in 
order to have a large impact on decreasing HIV  prevalence, it is 
critical to identify and engage in care individuals in acute and early 
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stages of HIV infection [5]. Thus, rapid detection of incident 
infections is an important component of test-and-treat and other 
prevention strategies. Screening for AHI is, however, associated 
with substantial costs of using newer generation HIV  diagnostics 
and adds operational challenges [43]. Until rapid and cheap point- 
of-care assays which reliably detect HIV  RNA or p24 antigen are 
commercially available and deployable in resource-limited set- 
tings, detecting AHI will remain a challenge. In the meantime, 
a clinically relevant risk algorithm which would decrease the 
number of individuals needed to screen with laboratory tests to 
detect AHI, is critical. The window of opportunity to intervene is 
narrow but the potential to benefit the individual and prevent 
onward transmission is considerable. 
 
Acknowledgments 
We thank all the acute infection study participants who are making an 
important personal contribution to HIV  prevention research through their 
continued support and participation in our work. The scientific and 
supportive role of the whole CAPRISA 002 study and protocol team is 
gratefully acknowledged. The study team comprised of Dr Itua Iriogbe, Dr 
Saba Shembe, Nurse Nozipho Nhlabathi, Nurse Lindiwe Mpanza, 
Administrator Yoliswa Miya and Counselor Hlengiwe Shozi. 
 
Author Contributions 
Conceived and designed the experiments: KM MS FvL CW. Performed 
the experiments: KM FvL NN. Analyzed the data: KM LW AF NG. 




15. Koopman JS, Jacquez JA, Welch GW, Simon CP, Foxman B, et al. (1997) The 
role of early HIV  infection in the spread of HIV  through populations. J Acquir 
Immune Defic Syndr Hum Retrovirol 14: 249–258. 
16. Moir S, Buckner CM, Ho J, Wang W, Chen J, et al. (2010) B cells in early and 
chronic HIV  infection: evidence for preservation of immune function associated 
with early initiation of antiretroviral therapy. Blood 116: 5571–5579. 
17. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, et al. (2000) 
Immune control of HIV-1 after early treatment of acute infection. Nature 407: 
523–526. 
18. Lavreys L, Thompson ML, Martin HL, Jr., Mandaliya K,  Ndinya-Achola JO, et 
al. (2000) Primary human immunodeficiency virus type 1 infection: clinical 
manifestations among women in Mombasa, Kenya. Clin Infect Dis 30: 486–490. 
19. Powers KA, Miller WC, Pilcher CD, Mapanje C, Martinson FE, et al. (2007) 
Improved detection of acute HIV-1 infection in sub-Saharan Africa: de- 
velopment of a risk score algorithm. AIDS 21: 2237–2242. 
20. Kahn JO, Walker BD (1998) Acute human immunodeficiency virus type 1 
infection. N Engl J Med 339: 33–39. 
21. Cohen MS, Gay CL,  Busch MP, Hecht FM (2010) The detection of acute HIV 
infection. J Infect Dis 202 Suppl 2: S270–277. 
22. Lindback S, Thorstensson R, Karlsson AC, von Sydow M, Flamholc L, et al. 
(2000) Diagnosis of primary HIV-1 infection and duration of follow-up after 
HIV  exposure. Karolinska Institute Primary HIV  Infection Study Group. AIDS 
14: 2333–2339. 
23. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, et al. (2009) Induction of 
a striking systemic cytokine cascade prior to peak viremia in acute human 
immunodeficiency virus type 1 infection, in contrast to more modest and delayed 
responses in acute hepatitis B and C  virus infections. J Virol 83: 3719–3733. 
24. Rosenberg NE, Kamanga G, Phiri S, Nsona D, Pettifor A, et al. (2012) 
Detection of acute HIV  infection: a field evaluation of the determine(R) HIV-1/ 
2 Ag/Ab combo test. J Infect Dis 205: 528–534. 
25. van Loggerenberg F, Mlisana K ,  Williamson C, Auld SC, Morris L, et al. (2008) 
Establishing a cohort at high risk of HIV  infection in South Africa: challenges 
and experiences of the CAPRISA 002 acute infection study. PLoS ONE 3: 
e1954. 
26. Francois van Loggerenberg AAD, Magdalena E. Sobieszczyk, Lise Werner, 
Anneke Grobler, and Koleka Mlisana, for the CAPRISA 002 Acute Infection 
Study Team (2012) HIV prevention in high-risk women in South Africa: 
Condom use and the need for change. 
27. Kaufmann GR, Cunningham P, Zaunders J, Law M, Vizzard J, et al. (1999) 
Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV- 
1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T- 
 






lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV 
Infection Study Group. J Acquir Immune Defic Syndr 22: 437–444. 
28. Kaufmann GR, Duncombe C, Zaunders J, Cunningham P, Cooper D (1998) 
Primary HIV-1 infection: a review of clinical manifestations, immunologic and 
virologic changes. AIDS Patient Care STDS 12: 759–767. 
29. Lyles RH, Munoz A, Yamashita TE,  Bazmi H, Detels R,  et al. (2000) Natural 
history of human immunodeficiency virus type 1 viremia after seroconversion 
and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS 
Cohort Study. J Infect Dis 181: 872–880. 
30. Niu MT, Stein DS, Schnittman SM (1993) Primary human immunodeficiency 
virus type 1 infection: review of pathogenesis and early treatment intervention in 
humans and animal retrovirus infections. J Infect Dis 168: 1490–1501. 
31. Schacker T, Collier AC, Hughes J, Shea T, Corey L (1996) Clinical and 
epidemiologic features of primary HIV infection. Ann Intern Med 125: 257– 
264. 
32. Tindall B, Barker S, Donovan B, Barnes T, Roberts J, et al. (1988) 
Characterization of the acute clinical illness associated with human immuno- 
deficiency virus infection. Arch Intern Med 148: 945–949. 
33. Pilcher CD, Price MA, Hoffman IF, Galvin S, Martinson FE, et al. (2004) 
Frequent detection of acute primary HIV  infection in men in Malawi. AIDS 18: 
517–524. 
34. Serna-Bolea C, Munoz J, Almeida JM, Nhacolo A, Letang E, et al. (2010) High 
prevalence of symptomatic acute HIV infection in an outpatient ward in 
southern Mozambique: identification and follow-up. AIDS 24: 603–608. 
35. Ndung’u T, Sepako E, McLane MF, Chand F, Bedi K, et al. (2006) HIV-1 
subtype C  in vitro growth and coreceptor utilization. Virology 347: 247–260. 
Acute HIV Infection in African Women 
 
36. Welz T,  Hosegood V, Jaffar S, Batzing-Feigenbaum J, Herbst K,  et al. (2007) 
Continued very high prevalence of HIV infection in rural KwaZulu-Natal, 
South Africa: a population-based longitudinal study. AIDS 21: 1467–1472. 
37. Henrard DR, Daar E, Farzadegan H, Clark SJ, Phillips J, et al. (1995) Virologic 
and immunologic characterization of symptomatic and asymptomatic primary 
HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 9: 305–310. 
38. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, et al. (1996) 
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. 
Science 272: 1167–1170. 
39. Vanhems P, Hirschel B, Phillips AN, Cooper DA, Vizzard J, et al. (2000) 
Incubation time of acute human immunodeficiency virus (HIV) infection and 
duration of acute HIV infection are independent prognostic factors of 
progression to AIDS. J Infect Dis 182: 334–337. 
40. Ghosn J, Deveau C, Chaix ML, Goujard C, Galimand J, et al. (2010) Despite 
being highly diverse, immunovirological status strongly correlates with clinical 
symptoms during primary HIV-1 infection: a cross-sectional study based on 674 
patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother 
65: 741–748. 
41. Lavreys L, Baeten JM, Chohan V, McClelland RS, Hassan WM, et al. (2006) 
Higher set point plasma viral load and more-severe acute HIV  type 1 (HIV-1) 
illness predict mortality among high-risk HIV-1-infected African women. Clin 
Infect Dis 42: 1333–1339. 
42. Lavreys L, Baeten JM, Overbaugh J, Panteleeff DD, Chohan BH, et al. (2002) 
Virus load during primary Human Immunodeficiency Virus (HIV) type 1 
infection is related to the severity of acute HIV  illness in Kenyan women. Clin 
Infect Dis 35: 77–81. 
43. Cohen T,  Corbett EL  (2011) Test and treat in HIV: success could depend on 























































7.1 Genital Tract Inflammation During Early HIV-1 
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Genital Tract Inflammation During Early HIV-1 
Infection Predicts Higher Plasma Viral Load Set 
Point in Women 
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Background. The biggest challenge in human immunodeficiency virus type 1 (HIV-1) prevention in Africa is 
the high HIV-1 burden in young women. In macaques, proinflammatory cytokine production in the genital tract is 
necessary for target cell recruitment and establishment of simian immunodeficiency virus (SIV) infection following 
vaginal inoculation. The purpose of this study was to assess if genital inflammation during early HIV-1 infection 
predisposes women to rapid disease progression. 
Methods. Inflammatory cytokine concentrations were measured in cervicovaginal lavage (CVL) from 49 women 
6, 17, 30, and 55 weeks after HIV-1 infection and from 22 of these women before infection. Associations between 
genital inflammation and viral load set point and blood CD4 cell counts 12 months after infection were investigated. 
Results.  Elevated genital cytokine concentrations 6 and 17 weeks after HIV-1 infection were associated with 
higher viral load set points and, to a lesser extent, with CD4 depletion. CVL cytokine concentrations during early 
infection did not differ relative to preinfection but were elevated in women who had vaginal discharge, detectable 
HIV-1 RNA in their genital tracts, and lower blood CD4 counts. 
Conclusion.  Genital inflammation during early HIV-1 infection was associated with higher viral load set point 
and CD4 depletion, which are markers of rapid disease progression. Strategies aimed at reducing genital 




In sub-Saharan Africa, which has the highest prevalence 
of human immunodeficiency virus type 1 (HIV-1) 
worldwide, most new infections occur by sexual trans- 
mission to women [1]. The genital mucosa is the initial 
site of viral replication following vaginal transmission of 
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HIV-1 in women and simian immunodeficiency virus 
(SIV) in rhesus macaques [2, 3]. In macaques, vaginal 
inoculation with SIV is followed by proinflammatory 
cytokine production and recruitment of CD4
1
 T cells 
that are necessary for local viral expansion and dis- 
semination to the systemic compartment [4–6]. Proin- 
flammatory cytokine expression in the genital mucosa 
correlates with viral replication and approaches baseline 
as peak SIV viremia declines [6]. HIV-1 infection may 
likewise be accompanied by an early inflammatory cas- 
cade in the genital tract that is associated with viral 
replication in this compartment. HIV-1 has been shown 
to directly induce inflammatory cytokine production 
via Toll-like receptor 7 and 8 activation [7]. Elevated 
concentrations of inflammatory cytokines in turn may 
upregulate HIV-1 replication by recruiting and activat- 
ing target cells and through NF-jB activation [4, 8–11]. 
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Several studies have shown that cervicovaginal proin- 
flammatory cytokines are upregulated in women with early or 
chronic HIV-1 infection compared with HIV-uninfected 
women [10, 12–16]. However this upregulation may be attrib- 
uted to the high frequency of sexually transmitted infections 
(STIs) or bacterial vaginosis (BV) in these individuals rather 
than HIV-1 itself [17]. For example, BV was associated with 
increased concentrations of proinflammatory interleukin 
(IL)–1b, whereas chronic HIV-1 infection was not [18]. 
HIV-1 shedding, which is associated with STIs [19], may 
induce further inflammatory cytokine production. 
Plasma cytokine concentrations during early HIV-1 infection 
are predictive of plasma viral load set points and CD4 depletion 
[20], and treatment with cytokines such as IL-12p70 and IL-15 
during acute SIV infection is associated with altered disease 
course in macaques [21–23]. Several studies have suggested that 
cytokine responses in the genital tract during the early stages 
of HIV-1 infection may likewise be associated with disease 
progression. In macaques, induction of inflammatory cytokines 
and immune cell influx into the genital tract prior to vaginal SIV 
inoculation was associated with increased plasma viral load set 
points [24]. This suggests that preexisting genital inflammation 
in humans may similarly influence HIV-1 disease progression. 
Zara et al [14] demonstrated that upregulation of IL-1b in the 
genital tracts of HIV-1–infected women was associated with 
increased plasma viral loads. Recently, we reported that elevated 
proinflammatory cytokines in cervicovaginal lavage (CVL) cor- 
related with lower blood CD4
1
 T-cell counts during early HIV-1 
infection [15]. 
In this study, the relationships between genital cytokine 
concentrations during early HIV-1 infection and plasma viral 
load set point and blood CD4
1
 T-cell counts 12 months 
postinfection were investigated. 
 
MATERIALS  AND  METHODS  
 
Study Participants 
Forty-nine South African women recently infected with HIV-1 
subtype C were recruited as part of the CAPRISA Acute Infection 
Study [25]. Each woman provided informed consent and then 
attended regular evaluations of HIV-1 disease status. Time of 
infection was defined as the midpoint between the last HIV-1 
antibody negative test result and the first HIV-1 antibody posi- 
tive test result, or as 14 days prior to a positive RNA polymerase 
chain reaction (PCR) assay on the same day as a negative HIV-1 
enzyme immunoassay. This study was approved by the Uni- 




CVL samples were collected, as described elsewhere [15], at 
5 time points: 22 women were assessed preinfection (36 weeks 
preinfection, range, 2–92), 39 were assessed 6 weeks postinfection 
(range, 1–13), 32 were assessed at 17 weeks postinfection (range, 
14–23), 39 were assessed at 30 weeks postinfection (range, 
24–36), and 40 were assessed at 55 weeks postinfection 
(range, 50–62). Eighteen of the 22 women who were assessed 
preinfection had matching 6-week postinfection CVL sam- 
ples available. CVLs were prefiltered using 0.2 lm Costar 
Spin-X cellulose acetate filters (Sigma) and the supernatant 
was stored at 280°C. Concentrations of IL-1a, IL-1b, IL-2, 
IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-15, interferon 
(IFN)–a, eotaxin, fractalkine, granulocyte colony-stimulating 
factor (G-CSF), granulocyte macrophage (GM)–CSF, mono- 
cyte chemotactic protein 1, macrophage inflammatory protein 
(MIP)–1a, MIP-1b, MIP-3a, RANTES, soluble CD40 ligand 
(sCD40L), and tumor necrosis factor (TNF)–a were measured 
using Human Cytokine LINCOplex premixed kits (LINCO 
Research), Milliplex kits (Millipore), and enzyme-linked im- 
munosorbent assay (R&D Systems). The sensitivity of these kits 
ranged between 0.05 and 18.33 pg/mL. Multiplex data were 
collected using a Bio-Plex Suspension Array Reader (Bio-Rad 
Laboratories), and a 5 PL regression formula was used to calculate 
cytokine concentrations from the standard curves (Bio-Plex 
Manager software, version 4). Cytokine concentrations below the 
lower limit of detection were reported as the midpoint between 
the lowest concentration measured for each cytokine and zero. 
 
Clinical Characteristics 
Blood was collected by venipuncture into acetate citrate dextran 
vacutainer tubes. Absolute blood CD4
1
 T-cell counts were mea- 
sured using a FACSCalibur flow cytometer. Plasma HIV-1 RNA 
concentrations were quantified using the COBAS AMPLICOR 
HIV-1 Monitor v1.5 or COBAS Ampliprep/COBAS TaqMan 48 
Analyzer (Roche Diagnostics). CVL viral loads were determined 
using Nuclisens Easyq HIV-1 (version 1.2). As viral load set 
point after 3 months postinfection is predictive of time to AIDS 
[26], the average viral load measurement of 3 consecutive visits 
overlying 12 months postinfection (range, 37–69) was used to 
assess disease progression. Additionally, associations between 
cytokines and (1) average CD4
1
 T-cell measurements of the 
same 3 visits and (2) CD4
1
 T-cell loss between preinfection and 
12 months postinfection were investigated. 
Participants were screened for Chlamydia trachomatis, Neisseria 
gonorrhoeae, and herpes simplex virus type 2 (HSV-2) in cervical 
swab samples by PCR and Trichomonas vaginalis by Diamond’s 
culture and PCR. Agents of BV were assessed by Gram staining. 
 
Statistical Analyses 
Statistical analyses were performed using GraphPad Prism 
software, version 5 (GraphPad) and Stata, version 10 (Stata- 
Corp). Distribution of variables was assessed by Shapiro-Wilk 
and Shapiro-Francia tests. The v2 test was used to compare 
proportions. Mann-Whitney U and Wilcoxon signed-rank tests 
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were used for unmatched and matched comparisons, re- 
spectively. Spearman rank test was used for correlations. The 
relationships between cytokine concentrations and markers of 
disease progression were evaluated using multivariate linear 
regression. Variables were log-transformed, and cytokines were 
standardized to allow for direct comparison of b-coefficients. 
Mixed-effects logistic regression was used to assess the change 
in HIV-1 shedding over time. P values ,.05 were considered 
significant. P values were adjusted using false discovery rate 
step-down procedure in order to reduce false-positive results 




Forty-nine women recently infected with HIV-1 were recruited 
and followed longitudinally. Their median age was 24 years 
(range, 18–59). Most women (98%) were unmarried, 20% had 
multiple partners, and 32% reported using injectable hormonal 
contraceptives. The median CD4
1
 T-cell count and viral load 
measurements at 6 weeks postinfection were 524 cells/lL and 
56 500 copies/mL, respectively (Table 1). The median CD4
1 
T-cell loss during the first 12 months of HIV-1 infection was 
486 cells/lL, while the median set-point viral load was 39 783 
copies/mL. STIs and BV were prevalent in this cohort, both 
pre– and post HIV-1 infection. 
Cytokine Concentrations in the Genital Tract of Women Recently 
Infected With HIV-1 Were Not Significantly Elevated Compared 
With Preinfection 
The concentrations of 22 cytokines in CVL from women 
prior to HIV-1 infection (median, 36 weeks preinfection) were 
compared with those of the same women during early HIV-1 
infection (median, 6 weeks postinfection) for whom samples at 
both time points were available (n 5 18). In matched samples, 
TNF-a and eotaxin concentrations were higher in CVLs from 
early HIV-1 infection compared with preinfection, whereas 
MIP-3a concentrations were lower (P , .05; Figure 1A). 
However, these changes were not significant after adjustment for 
multiple comparisons. Furthermore, in an unmatched analysis 
including all women who had either preinfection samples 
(n 5 22) or 6-week postinfection samples available (n 5 39), 
only MIP-3a concentrations were lower in postinfection CVLs, 
before adjusting for multiple comparisons. These data indicate 
that, in contrast to previous reports that have compared genital 
cytokine concentrations in HIV-1 infected women to unmatched 
HIV-uninfected women [10, 12–16], the women in this study 
did not have significantly altered CVL cytokine concentrations 
during early HIV-1 infection relative to preinfection samples 
from women who later became infected with HIV-1. 
Interestingly, the concentrations of 7 of 22 cytokines mea- 
sured in CVLs correlated between pre– and post HIV-1 infection 
(Figure 1B). MIP-1a and sCD40L remained significantly cor- 
related after adjusting for multiple comparisons. Following 
evaluation of cytokine concentrations in longitudinal samples 
(17, 30, and 55 weeks postinfection), it was found that 11 of 20 
cytokines correlated between at least 3 of the 5 time points. After 
adjusting for multiple comparisons, IL-1a, IL-b, IL-6, IL-8, 
MIP-1a, G-CSF, and GM-CSF were significantly correlated 
across $3 time points. These findings suggest that the relative 
degrees of cervicovaginal inflammation in individual women 




Table 1. Clinical Characteristics of Study Participants 
CD4
1 T-Cell Counts (Cells/lL) Cells/lL, Median (IQR) No. 
Preinfection CD41 T-cell count 975 (860–1149) 22 
Six-week postinfection CD41 T-cell count 524 (379–685) 48 
CD41 T-cell count set point (average of 3 visits overlying 12 months postinfection) 408 (339–551) 46 
CD4
1 T-cell loss (preinfection minus 12-month postinfection CD41 T-cell count) 486 (254–653) 22 
Plasma viral loads (copies/mL) Copies/mL, Median (IQR) No. 
Six-week postinfection plasma viral load 56 500 (14 200–370 500) 49 
Plasma viral load set point (average of 3 visits overlying 12-months postinfection) 39 783 (7248–102 208) 46 
 
Sexually transmitted infections Preinfection, 
No./Total (%) 
Early infection, 
No./Total (%)  
Prevalence of active STIs (women with laboratory-diagnosed STIa) 8/22 (36.3) 17/44 (38.6) 
Bacterial vaginosis (women with Gram stain positive for BV) 15/22 (68.2) 34/44 (77.4) 
Vaginal discharge (women with visible discharge) 3/22 (13.7) 8/49 (16.3) 
Genital ulcer (women with visible genital ulcer[s]) 0/22 (0) 6/49 (12.2) 
 





Participants with multiple transmitted variants 4/45 (8.9) 7/45 (15.6) 
Abbreviations: BV, bacterial vaginosis; HIV-1, human immunodeficiency virus type 1; IQR, interquartile range; STI, sexually transmitted infection. 
a Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, herpes simplex virus type 2. 
 










































Figure 1. Comparison of cervicovaginal lavage (CVL) cytokine concen- 
trations in women (n 5 18) before infection (median, 36 weeks preinfection) 
and during early human immunodeficiency virus type 1 (HIV-1) infection 
(median, 6 weeks postinfection). A, Fold changes in cytokine concentrations 
following HIV-1 infection are shown as box-and-whisker plots; error bars 
indicate the range. Wilcoxon signed-rank test was used to compare cytokine 
concentrations in CVL from the same women pre– and post HIV-1-infection. 
Changes in cytokine concentrations that were significant before adjusting for 
multiple comparisons and are indicated by gray bars (P , .05). B, Spearman 
correlations between cytokine concentrations measured in pre- and 
postinfection CVL. MIP-1b was no longer correlated between time points 
following exclusion of outliers. Gray dots indicate cytokines that correlated 
significantly before adjusting for multiple comparisons (P ,.05). Black dots 
indicate cytokines that remained significantly correlated after adjustment 
(P , .0023). G-CSF, granulocyte colony-stimulating factor; GM-CSF, 
granulocyte macrophage-colony stimulating factor; IFN, interferon; 
IL, interleukin; MCP, monocyte chemotactic protein; MIP, macrophage in- 
flammatory protein; sCD40L, soluble CD40 ligand; TNF, tumor necrosis factor. 
Genital Tract Inflammation During Early HIV-1 Infection Was Not 
Associated With Multivariant HIV-1 Transmission 
Abrahams et al [29] have reported that in this cohort of women, 
22% were infected with .1 HIV-1 genetic variant. To investigate 
the relationship between genital tract inflammation and trans- 
mission of multiple HIV-1 variants, cytokine concentrations at 
6 weeks postinfection were compared in women with multiple 
(n 5 10) or single (n 5 25) transmitted variants. No differences 
in cervicovaginal cytokines were found between women infected 
with multiple or single variants (data not shown), suggesting 
that genital inflammation was not associated with the break in 
HIV-1 transmission bottleneck in this cohort. 
 
Cervicovaginal Inflammation During Early HIV-1 Infection Was 
Associated With STIs 
Cytokine concentrations in CVL from women with early HIV-1 
infection (6 weeks postinfection) who tested positive for $1 STI 
or had symptoms of STIs were compared with those of women 
who did not have an STI or BV (Figure 2). Women who had $1 
active STI (C. trachomatis, N. gonorrhoeae, T. vaginalis, or HSV-2; 
n 5 14) tended to have elevated cytokine concentrations; 
however, these changes were not significant after adjusting for 
multiple comparisons. Abnormal vaginal discharge, which may 
be caused by other factors in addition to STIs, including BV, 
Candida albicans, allergic reaction, irritation, or physiologic 
changes [28], was associated with elevated concentrations of 
proinflammatory IL-1a, IL-1b, IL-12p40, eotaxin, MIP-1a, 
and T-cell homeostatic IL-15, after adjustment for multiple 
comparisons. 
 
Genital Tract Inflammation During HIV-1 Infection Was 
Associated With HIV-1 Shedding 
HIV-1 viral loads were measured in CVL samples collected at 
6, 17, 30, and 55 weeks postinfection as an indicator of HIV-1 
shedding. CVL viral loads and proportions of women with de- 
tectable HIV-1 RNA did not differ significantly between time 
points (Figure 3). CVL viral loads did not correlate between time 
points, indicating that different women were shedding HIV-1 at 
different times. Cytokine concentrations in CVL correlated with 
CVL viral loads at all time points, and women who had de- 
tectable HIV-1 RNA in their genital tracts had higher cytokine 
concentrations than did women who were not shedding HIV-1 
(Table 2). Preinfection cytokine concentrations did not differ 
between women who were shedding and women who were not 
shedding HIV-1 6 weeks postinfection. Additionally, lower 
blood CD4 counts and/or higher plasma viral loads were asso- 
ciated with CVL viral loads at each time point. The prevalence of 
STIs did not differ between women with detectable HIV-1 RNA 
levels in their genital tracts [3 of 7 (42.9%)] and women who 
were not shedding [11 of 31 (35.5%)]. Furthermore, there were 
no significant differences in occurrence of BV, vaginal discharge, 
and genital ulcers in women shedding HIV-1 compared with 
women who were not shedding. 
 

















































Figure 2. Fold change in cytokine concentrations in cervicovaginal 
lavage (CVL) samples from women who had $1 sexually transmitted 
infection (STI) or bacterial vaginosis (BV) compared with the median 
concentrations in women who did not have an STI. Cytokine concentrations 
were measured in CVL samples from women infected with human 
immunodeficiency virus type 1 (HIV-1) (median, 6 weeks postinfection) 
who had no STI (n 5 7), women who had visible vaginal discharge (n 5 7) 
or genital ulceration (n 5 4), women who had $1 laboratory-diagnosed 
active STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas 
vaginalis, or herpes simplex virus type 2 [HSV-2]; n 5 14) and women who 
Elevated Genital Tract Cytokine Concentrations During Early 
HIV-1 Infection Correlated With Lower Blood CD41 T-Cell Counts 
We have previously reported that cervicovaginal IL-1b, IL-6, 
and IL-8 concentrations during early HIV-1 infection were as- 
sociated with lower blood CD4
1
 T-cell counts at these early time 
points [15]. In this study, it was similarly found that higher 
concentrations of IL-6 (q 5 20.455, adjusted P 5 .030), TNF-a 
(q 5 20.498, adjusted P 5 .017), RANTES (q 5 20.460, ad- 
justed P 5 .026), and IL-10 (q 5 20.503, adjusted P 5 .027) in 
CVL correlated with lower blood CD4 counts during early HIV-1 
infection. Only weak associations between 17-, 30-, and 55-week 
cytokine concentrations and concurrent CD4 cell counts were 
found, and these were not significant after adjusting for multiple 
comparisons, indicating that the relationship was restricted to 
early HIV-1 infection. 
Despite finding a significant correlation between (1) plasma 
viral load and HIV-1 shedding and (2) genital inflammation and 
HIV-1 shedding, few associations were found between genital 
cytokine concentrations and plasma viral loads measured at the 
same time points. This suggests that changes in inflammatory 
cytokine production in the genital tract during early HIV-1 
infection are largely independent of systemic viral load. 
 
Cervicovaginal Inflammation During Early HIV-1 Infection Was 
Associated With CD41 T-Cell Depletion During the First Year 
of Infection 
To determine whether genital cytokine concentrations during 
HIV-1 infection were associated with disease progression, as- 
sociations between cytokines and (1) average blood CD4 counts 
measured at 3 consecutive visits overlying 12 months post- 
infection and (2) CD4 loss between preinfection and 12 months 
postinfection were investigated. Although higher concentrations 
of several cytokines at multiple time points were associated with 
lower CD4 counts 12 months postinfection before adjusting for 
multiple comparisons, only GM-CSF concentrations 6 weeks 
postinfection remained significantly associated after adjustment 
(Figure 4A). No significant relationship between preinfection 
cytokine concentrations and CD4 counts 12 months post- 
infection was found, although relatively few CVL samples (22 
of 49) from preinfection time points were available for this 
analysis. 
Blood CD4 counts and plasma viral loads during early HIV-1 
infection were also associated with 12 month postinfection CD4 
counts (b 5 .70 [95% CI, .46 to .95] and b 5 2.07 [95% 
 
 
Figure 2 continued. had BV (n 5 16). Mann-Whitney U test was used to 
compare cytokine concentrations in CVL from women with STIs, BV, or 
symptoms to women with no STIs and/or BV. Fold changes in cytokine 
concentrations are shown as box-and-whisker plots; error bars indicate 
the range. Gray bars indicate cytokines that were significantly different 
before adjusting for multiple comparisons (P , .05). Stars indicate 
cytokines that remained significant after adjustment (P , .0023). 
 
 
















Figure 3.  Human immunodeficiency virus type (HIV-1) RNA concentrations in cervicovaginal lavage (CVL) at 6, 17, 30, and 55 weeks postinfection. A, 
HIV-1 viral loads in CVL from each woman are indicated by gray dots. Lines connect RNA concentrations in CVL from the same women at different time 
points. No significant Spearman correlations were found between HIV-1 RNA levels at each time point, indicating that different women were shedding at 
each time point. B, Proportion of women who had detectable HIV-1 RNA at each time point. Mixed-effects logistic regression was used to determine 
whether the proportion of women shedding HIV-1 at 17, 30, and 55 weeks postinfection differed relative to 6 weeks postinfection; eb indicates the 
change in number of women shedding at each time point relative to 6 weeks postinfection (reference time point). No significant differences were found. 
 
 
CI, –.12 to –.02], respectively). HIV-1 disease status could 
predispose individuals to higher incidence of STIs and genital 
shedding of HIV-1 [30, 31], thereby exacerbating genital in- 
flammation, which would therefore be indirectly rather than 
directly associated with disease progression. Multivariate re- 
gression was thus used to adjust for CD4 counts and viral loads 
measured at the same time points as cytokine concentrations. 
Again, there was a strong trend toward an association between 
higher cytokine concentrations and lower 12-month CD4 counts. 
Finally, associations between preinfection (n 5 22) and 6-week 
postinfection (n 5 18) cytokine levels and blood CD4
1
 T-cell 
loss during the first 12 months of HIV-1 infection were in- 
vestigated in a subset of women for whom preinfection CD4 
count measurements were available. CD4 depletion during the 
first year of infection was associated with higher preinfection 
cervicovaginal concentrations of RANTES (q 5 0.46, P 5 .03) 
and 6-week postinfection concentrations of IL-1b (q 5 0.53, 
P 5 .02) and GM-CSF (q 5 0.62, P 5 .006). However, these 
associations were not upheld after adjusting for multiple 
comparisons, which may be due to the relatively small sample 
sizes available for this analysis. 
 
Genital Inflammation During Early HIV-1 Infection Was 
Associated With Higher Viral Load Set Point 
It was found that the concentrations of several inflammatory 
and T-cell homeostatic cytokines in CVL during early HIV-1 
infection (6 and 17 weeks postinfection) were associated with 
higher plasma viral load set point (Figure 4B), even though these 
cytokines did not correlate with viral loads measured at the same 
time points as cytokine measurements. No associations between 
cytokine concentrations at later time points postinfection 
(30 and 55 weeks postinfection) and viral load set point were 
significant after adjusting for multiple comparisons. Addi- 
tionally, although cytokine concentrations did not differ be- 
tween preinfection and early infection time points, no 
significant associations between preinfection cytokine concen- 
trations and viral load set point were found. Elevated GM-CSF, 
IL-1b, IL-12p70, and IL-15 concentrations at 6 weeks post- 
infection and GM-CSF, IL-1b, IL-10, IL-6, RANTES, MIP- 
1b, and IL-2 concentrations 17 weeks postinfection were 
associated with higher viral load set point. Following ad- 
justment for CD4 counts and viral loads measured at the 
same time points as cytokine measurements, elevated GM- 
CSF concentrations 6 weeks postinfection remained signifi- 
cantly associated with higher viral load set point. This suggests 
that the relationship between this inflammatory cytokine and 
disease progression is at least partly independent of early infection 




Previous studies have shown that women with early and chronic 
HIV-1 infection have elevated genital inflammatory cytokine 
concentrations relative to unmatched HIV-uninfected women 
[10, 12–16]. This study is the first to compare cytokine con- 
centrations in cervicovaginal samples from the same women 
preinfection and during early HIV-1 infection. It was found that 
inflammatory cytokine levels preinfection were correlated with 
those postinfection and in fact were not significantly elevated 
shortly following HIV-1 infection (6 weeks postinfection). 
However, genital cytokine concentrations were higher in women 
who had vaginal discharge and in women who were shedding 
HIV-1 in their genital secretions. In addition, cytokine 
concentrations were elevated in women who had lower blood 
 
Genital Inflammation and HIV Disease d JID 2012:205 (15 January) d 199 
104 
 
Blood CD4   T-cell count     20.485       (.002)        20.305        (.090)         20.428        (.007)        20.047       (.782) 
Table 2. Spearman Rank Correlations Between CVL HIV-1 RNA Concentrations and Blood CD4 Counts, Plasma Viral Loads, and CVL 
Cytokine Concentrations 
 
6 Weeks Postinfection 17 Weeks Postinfection 30 Weeks Postinfection 55 Weeks Postinfection 
q (P Value) q (P Value) q (P Value) q (P Value) 
1 
Plasma viral load 0.430 (.006) 0.533 (.002) 0.314 (.055) 0.371 (.022) 
IL-1a 0.236 (.147) 0.154 (.401) 0.260 (.114) 0.337 (.039)a 
IL-1b 0.355 (.026)a 0.478 (.006)b 0.207 (.212) 0.513 (.001)b 
IL-6 0.427 (.007)a 0.446 (.011)b 0.261 (.113) 0.338 (.038)a 
IL-12p40 0.159 (.333) 0.211 (.247) 0.294 (.073) 0.175 (.293) 
IL-12p70 0.325 (.044) 0.204 (.263) 0.177 (.287) 0.027 (.873) 
TNF-a 0.388 (.015)a 0.382 (.031)a 0.415 (.010)a 0.309 (.059) 
Eotaxin 0.216 (.186) 0.227 (.211) 20.038 (.821) 0.473 (.003)b 
Fractalkine 0.163 (.321) 0.405 (.022)a 20.186 (.264) 0.331 (.042)a 
IL-8 0.323 (.045) 0.279 (.122) 0.393 (.015)a 0.437 (.006)b 
MCP-1 0.419 (.008)a 0.487 (.005)b 0.099 (.555) 0.432 (.007)b 
MIP-1a 0.155 (.345) 0.385 (.030)a 0.059 (.726) 0.128 (.445) 
MIP-1b 0.186 (.258) 0.570 (.001)b 0.087 (.604) 0.314 (.055) 
RANTES 0.490 (.002)a 0.531 (.002)b 0.267 (.106) 0.549 (.0004)b 
G-CSF 0.310 (.055) 0.457 (.009)b 0.198 (.234) 0.379 (.019)a 
GM-CSF 0.090 (.585) 0.537 (.002)b 0.315 (.054) 0.077 (.645) 
MIP-3a 0.226 (.207) ND ND ND 
IFN-a 0.212 (.201) ND ND ND 
IL-10 0.378 (.018)a 0.247 (.173) 0.038 (.821) 20.160 (.336) 
IL-2 0.385 (.015)a 0.534 (.002)b 0.137 (.413) 20.134 (.421) 
IL-7 0.260 (.110) 0.119 (.517) 0.126 (.450) 20.057 (.736) 
IL-15 0.382 (.016)a 0.220 (.226) 0.375 (.020)a 20.013 (.939) 
sCD40L 0.331 (.040)a 0.309 (.085) 0.218 (.188) 0.123 (.462) 
Significant associations are shown in bold (P , .05). Associations that were significant after adjusting for multiple comparisons are underlined. 
Abbreviations: CVL, cervicovaginal lavage; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; HIV -1, 
human immunodeficiency virus type 1; IFN, interferon; IL, interleukin; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; ND, not done; 
sCD40L, soluble CD40 ligand; TNF, tumor necrosis factor. 
a Cytokine concentration significantly higher in women who had detectable HIV-1 RNA in their genital tracts compared with women who had undetectable HIV-1 
RNA concentrations (P , .05). 






 T-cell counts 6 weeks postinfection [15]. Elevated cer- 
vicovaginal cytokines during early HIV-1 infection (6 and 
17 weeks postinfection) were associated with higher plasma 
viral load set point, which is predictive of time to AIDS [26]. 
Additionally, higher GM-CSF concentrations 6 weeks post- 
infection were associated with lower CD4 counts 12 months 
postinfection. 
When genital cytokine concentrations were compared in the 
same women preinfection and at several time points during the 
first year of HIV-1 infection, some women maintained higher 
levels of genital inflammation over time, while others had 
consistently low cytokine concentrations. STI prevalence did not 
differ between pre– and post HIV-1 infection; thus, the cause of 
sustained inflammation may be STI recurrence. Mitchell et al 
[18] demonstrated that genital inflammatory cytokines were 
not elevated in chronically HIV-1 infected women relative to 
uninfected women but rather were associated with BV. The 
higher frequency of STIs in HIV-1 infected women compared 
with uninfected women [17]  may account for previous findings 
that genital inflammatory cytokines are higher in women with 
early HIV-1 infection. It is possible that elevated genital in- 
flammatory cytokine responses, similar to those reported 
shortly after SIV infection of macaques [6], may have subsided 
by 6 weeks postinfection. Alternatively, cervicovaginal in- 
flammatory cytokine concentrations may increase over time 
during HIV-1 infection and may thus be higher in chronically 
infected women relative to those with early infection [12]. 
Genital HIV-1 RNA concentrations correlated not only with 
higher levels of genital inflammation but also with lower blood 
CD4 counts and higher plasma viral loads at the same time 
points. Although these findings may suggest that high systemic 
viral loads drive HIV-1 shedding, which in turn induces genital 
 









































Figure 4. Linear regression was used to assess relationships between cytokine concentrations in cervicovaginal lavage (CVL) from women 6 weeks 
(n 5 37) and 17 (n 5 31) weeks postinfection and average blood CD4 counts of 3 consecutive visits overlying the 12-month postinfection time point 
(A ) and viral load set points (B ). Viral loads, CD4 counts, and cytokine concentrations were log-transformed, and cytokine concentrations were 
standardized to allow for direct comparison between b-coefficients. b-Coefficients that were generated by univariate regression are indicated by circles 
and show the relationship between each cytokine and 12-month CD4 counts or viral load set points. b-Coefficients that indicate the relationships 
between cytokine concentrations and 12-month CD4 counts or viral load set points, following adjustment for CD4 counts and viral loads at the 
same visits as cytokine measurements using multivariate regression, are represented by triangles. Error bars indicate 95% confidence intervals. 
Cytokines were ranked according to the strength of their associations with 12-month CD4 counts or viral load set point. Significant associations 
are shown in blue (P , .05). Associations that were significant after adjusting for multiple comparisons are shown in red. G-CSF, granulocyte 
colony-stimulating factor; GM-CSF, granulocyte macrophage-colony stimulating factor; IFN, interferon; IL, interleukin; MCP, monocyte chemotactic 




inflammation, which is thus indirectly associated with disease 
progression, shedding during early HIV-1 infection was not 
associated with 12-month CD4 counts or viral load set point. 
Additionally, genital inflammation during early HIV-1 
infection was only weakly associated with concurrent plasma 
viral load before adjusting for multiple comparisons but was 
strongly associated with plasma viral loads at subsequent time 
points. It was also found that, although CVL cytokine levels 
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correlated positively over time, different women were shedding 
at different time points during HIV-1 infection. Therefore, 
shedding was not the cause of sustained cervicovaginal in- 
flammation that was observed in this cohort, and genital in- 
flammation may rather facilitate HIV-1 shedding in individuals 
who have high plasma viral loads by recruiting HIV-1-infected 
cells to the genital tract and by promoting viral replication. 
It was found that elevated CVL cytokine concentrations 
6 weeks postinfection were associated with lower blood CD4 
counts at the same time point. Blood CD4 depletion may reflect 
CD4 depletion in the genital tract. This would contribute to 
genital inflammation by inducing T-cell homeostatic cytokine 
production [32], which in turn induces inflammatory cytokine 
production [33, 34]. In support, T-cell homeostatic cytokines 
IL-2 and IL-15 were inversely associated with blood CD4 counts 
before adjusting for multiple comparisons. Therefore, STIs and 
other factors that are associated with vaginal discharge are likely 
to be major contributors to cervicovaginal inflammation during 
early HIV-1 infection, with inflammation exacerbated by HIV-1 
replication in the genital tract and the homeostatic response to 
CD4 depletion. A recent macaque study demonstrated the im- 
portance of proinflammatory cytokine production in the genital 
tract in establishment of productive SIV infection following 
vaginal inoculation [4]. Wang et al [24] further showed that 
induction of inflammatory cytokine responses in the genital 
tracts of macaques prior to vaginal inoculation with SIV was 
associated with increased plasma viral load set point, suggesting 
that genital cytokine concentrations at the time of infection may 
influence disease progression. Similar to macaque studies, it was 
found in this study that higher levels of cervicovaginal proin- 
flammatory and T-cell homeostatic cytokines during early HIV-1 
infection were associated with more rapid HIV-1 disease pro- 
gression. Additionally, the findings of this study suggest that 
the association between genital inflammation during early in- 
fection and disease progression is partly independent of blood 
CD4 counts and plasma viral loads measured at the same time 
points as cytokine concentrations. Although the earliest time 
point included in this study (6 weeks postinfection) was past 
viral dissemination to blood, preinfection genital cytokine 
concentrations correlated with those measured during the 
first year of HIV-1 infection. Therefore, genital inflammation 
6 weeks postinfection may reflect inflammation at the time of 
infection. Although preinfection genital inflammation may be 
associated with HIV-1 disease progression, this could not be 
investigated here as the number of women for whom pre- 
infection samples were available was small (22 of 49 women). 
Cytokine concentrations measured 6 weeks postinfection (range, 
1–13) may, however, be a closer representation of the level of 
genital inflammation present at the time of HIV-1 infection 
than were preinfection cytokine concentrations that were mea- 
sured 36 weeks prior to infection (range, 2–92). Higher concen- 
trations of cervicovaginal inflammatory cytokines at the time of 
HIV-1 transmission may favor disease progression by recruiting 
and activating CD4
1
 T cells for HIV-1 infection and directly 
promoting viral replication [4, 9–11]. These findings suggest that 
the inflammatory environment in the genital tracts of women who 
become infected with HIV-1 through sexual transmission may 
influence disease outcome and that strategies to reduce genital 
inflammation may slow disease progression. 
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Background. Whereas human immunodeficiency virus (HIV) subtype B–infected individuals generally progress 
to AIDS within 8–10 years, limited data exist for other clades, especially from Africa. We investigated rates of HIV 
disease progression of clade C–infected South African women. 
Methods. Prospective seroincidence cohorts in KwaZulu-Natal were assessed for acute HIV infection monthly 
(n = 245) or every 3 months (n = 594) for up to 4 years. Rapid disease progression was defined as CD4 decline to 
<350 cells/µL by 2 years postinfection. Serial clinical and laboratory assessments were compared using survival 
analysis and logistic regression models. 
Results. Sixty-two women were identified at a median of 42 days postinfection (interquartile range, 34–59), con- 
tributing 282 person-years of follow-up. Mean CD4 count dropped by 39.6% at 3 months and 46.7% at 6 months 
postinfection in women with preinfection measurements. CD4 decline to <350 cells/µL occurred in 31%, 44%, and 
55% of women at 1, 2, and 3 years postinfection, respectively, and to <500 cells/µL in 69%, 79%, and 81% at equiv- 
alent timepoints. Predictors of rapid progression were CD4 count at 3 months postinfection (hazard ratio [HR], 2.07; 
95% confidence interval [CI], 1.31–3.28; P = .002), setpoint viral load (HR, 3.82; 95% CI, 1.51–9.67; P = .005), and 
hepatitis B coinfection (HR, 4.54; 95% CI, 1.31–15.69; P = .017). Conversely, presence of any of HLAB*1302, B*27, 
B*57, B*5801, or B*8101 alleles predicted non–rapid progression (HR, 0.19; 95% CI, .05–.74; P = .016). 
Conclusions. Nearly half of subtype C–infected women progressed to a CD4 count <350 cells/µL within 2 years 
of infection. Implementing 2013 World Health Organization treatment guidelines (CD4 count <500 cells/µL) would 
require most individuals to start antiretroviral therapy within 1 year of HIV infection. 
Keywords. HIV disease progression; acute HIV infection; subtype C; viral load; women. 
 
Human immunodeficiency virus (HIV) disease pro- 
gression is highly variable between individuals and pop- 
ulations and is determined by genetic, immunologic, 
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T-cell decline has been recognized as one of the 
major markers of the rate of HIV disease progression. 
Once CD4 counts drop below 200 cells/µL, the risk of 
opportunistic infections and death increases dramati- 
cally. In addition to CD4 decline, disease progres- 
sion can be defined by time to antiretroviral therapy 
(ART) initiation, diagnosis of AIDS-defining illnesses, 
or death. Whereas the majority of HIV-infected indi- 
viduals (70%–80%) fall into an intermediate category, 
rapid progression and long-term nonprogression repre- 
sent extreme phenotypes with respect to CD4 decline 
[4]. In addition, the infecting subtype can have a signifi- 
cant impact on the rate of CD4 decline [5, 6]. This has 
been best defined for clades A and D in East Africa, 
 



















































where studies demonstrated a shorter median time to AIDS 
in subtype D–infected individuals than in subtype A– 
infected individuals [7–9]. Studies from sub-Saharan Africa 
suggest faster disease progression in subtype C–infected indi- 
viduals [10, 11], despite observations that subtype C may repli- 
cate less efficiently than subtype B [12]. 
A major immunologic predictor of progression is the level of 
host immune activation, which predicts rates of CD4 decline 
more accurately than plasma viral load (VL) [13]. African pop- 
ulations have reportedly higher levels of immune activation 
than US populations, possibly linked to a higher burden of 
comorbidities and micronutrient deficiencies [14, 15]. Indirect 
immune activation caused by microbial translocation and loss 
of gut-associated CD4 cells has also been demonstrated in 
HIV rapid progressors [16]. Another major host predictor of 
disease progression is the human leukocyte antigen (HLA) 
background. HLA-B35, B8, B45, and B53 have been associated 
with rapid progression, whereas HLA-B57 and B27 are more 
common in slow progressors [11, 17–19]. 
Results from mostly subtype B–infected cohorts suggest that 
rapid progression is uncommon, with only about 5% of individ- 
uals progressing from acute HIV infection to AIDS within 3 
years [20, 21]. However, there are limited data on disease pro- 
gression in other subtypes, especially from prospective African 
cohorts infected with subtype C. This study describes HIV type 
1 (HIV-1) disease progression in South African women and 





Between August 2004 and May 2005, a cohort of HIV-uninfected 
women at high risk of HIV acquisition was enrolled into the Cen- 
tre for the AIDS Programme of Research in South Africa (CAP- 
RISA) 002 Acute Infection Study, recruited at 2 sites within the 
province of KwaZulu-Natal in South Africa—an urban site in 
Durban and a rural site in Vulindlela. The aim of the study was 
to describe immunologic, virologic, and clinical characteristics of 
HIV-1 subtype C acute infection and investigate the natural his- 
tory of HIV-1 subtype C infection [22]. Women aged ≥18 years 
who self-reported as sex workers or having >3 sexual partners 
within the last 3 months were screened. Those testing HIV neg- 
ative were offered enrollment and followed for up to 4 years, 
with monthly testing to identify acute HIV infections [23]. In 
addition, women were also recruited from a rural family plan- 
ning and sexually transmitted infection (STI) clinics in Durban 
[24] with quarterly HIV testing and follow-up. Written in- 
formed consent was obtained from all participants, and ethical 
approval for the study was granted by the University of KwaZu- 
lu-Natal (E013/04), University of Cape Town (025/2004), and 
University of the Witwatersrand (M040202). 
HIV Testing and Time of Infection 
HIV diagnosis was based on antibody and/or nucleic acid 
detection. Two point-of-care antibody tests were used, the 
third-generation Determine (Abbott Laboratories, Abbott Park, 
Illinois) and Capillus (Trinity Biotech, Jamestown, New York). 
An HIV enzyme-linked immunosorbent assay was performed 
to confirm HIV diagnosis using the HIV enzyme immunoassay 
BEP 2000 (Dade Behring, Marburg, Germany). HIV reverse 
transcription polymerase chain reaction (RT-PCR) testing was 
performed at every testing with antibody-negative results. 
COBAS Amplicor version 1.5 RT-PCR testing (Roche Diagnos- 
tics, Rotkreuz, Switzerland) was performed using a pooling 
strategy of 24 samples per pool [25, 26]. Time of infection 
was estimated as the midpoint between last antibody-negative 
and first antibody-positive test or 14 days before a positive 
RT-PCR result for those diagnosed preseroconversion. 
Once HIV diagnosis was confirmed, women were enrolled into 
the acute HIV infection cohort. The visit structure was divided into 
3 phases: weekly to fortnightly visits up to 3 months postinfection 
(acute infection), monthly visits from 3 to 12 months (early in- 
fection), and quarterly visits thereafter (established infection) 
until ART initiation. Samples for immunologic, virologic, and 
clinical parameters were collected, and VL and CD4 counts 
(FACSCalibur Flow Cytometer, BD Biosciences, San Jose, 
California) were measured at each visit. Screening for STIs 
with multiplex PCR testing and Gram stain for bacterial vaginosis 
were performed at enrollment and every 6 months thereafter [27]. 
Women with positive results were recalled for treatment or referred 
to the nearest clinic. Any other STIs were treated syndromically 
on presentation according to South African National Guidelines. 
High-resolution HLA typing was performed on all partici- 
pants. DNA was extracted from either peripheral blood mono- 
nuclear cells or granulocytes using the Pel-Freez DNA Isolation 
kit. HLA-A, -B, and -C typing was performed by sequencing of 
exons 2, 3, and 4 using Atria AlleleSeqr kits (Abbott), and data 
were analyzed using Assign-SBT 3.5 (Conexio Genomics). Any 
ambiguities resulting from either polymorphisms outside the 
sequenced exons or identical heterozygote combinations were 
resolved using sequence-specific primers. 
 
Statistical Analysis 
Basic descriptive statistics were used to summarize frequencies 
and timing of the first occurrences of clinical signs and symp- 
toms. Linear mixed models were used to estimate the CD4 
slope within 12 months of HIV infection. Kaplan–Meier anal- 
yses were carried out using estimated time of infection to 
endpoints of CD4 counts of <200, <350, and <500 cells/µL. 
Stratified analyses using 3- and 6-month postinfection VL (<5 
and ≥5 log copies/mL) were also performed. Whereas rapid 
disease progression is currently defined as ≥2 CD4 measure- 
ments <350 cells/µL within 3 years of seroconversion [28], we 
 



















































Days postinfection at enrollment , median (IQR)         42 (34–59)           42 (30–59)           46 (34–60)            .804 






Characteristic All (N = 62) (n = 27) Progressors (n = 35)       P Value 
 
a 
Age, y, median (IQR) 25 (21–33) 27 (23–36) 24 (21–33) .163 
Urban 74.2% (46) 85.2% (23) 65.7% (23) .142 
Completed high school 29.0% (18) 29.6% (8) 28.6% (10) 1.000 
Marital status 
Married or stable partner 71.0% (44) 59.3% (16) 80.0% (28) .240 
Many partners 16.1% (10) 22.2% (6) 11.4% (4) 
No partners 12.9% (8) 18.5% (5) 8.6% (3) 
No. of sexual partners in last 3 mo prior to HIV infectiona 
0–1 68.3% (41) 55.6% (15) 78.8% (26) .093 
≥2 31.7% (19)  44.4% (12) 21.2% (7) 
Commercial sex workers 32.3% (20) 33.3% (9) 31.4% (11) 1.000 
Condom used at last sex act 56.5% (35) 59.3% (16) 54.3% (19) .798 
Ever had anal sex 14.5% (9) 22.2% (6) 8.6% (3) .160 
History of tuberculosis 8.1% (5) 3.7% (1) 11.4% (4) .376 
BMI
a
, median (IQR) 26.6 (23.5–31.8) 26.8 (23.9–32.1) 26.4 (22.7–31.3) .287 
CD4 counta, mean (SD) 520 (193.61) 413 (128.95) 603 (195.88) <.001 
Log viral loada, median (SD) 4.62 (0.92) 4.96 (0.84) 4.36 (0.90) .009 
Bacterial vaginosisa 73.3% (44/60) 66.7% (18/27) 78.8% (26/33) .382 
Any STIa,b 44.3% (27/61) 40.7% (11/27) 47.1% (16/34) .796 
HSV-2 Ab positivea 91.9% (57) 92.6% (25) 91.4% (32) 1.000 
HBcAb positivea 50.0% (31) 59.3% (16) 42.9% (15) .306 
Data are presented as % (No.) unless otherwise specified. 
Abbreviations: Ab, antibody; BMI, body mass index; HBcAb, hepatitis B core antibody; HIV, human immunodeficiency virus; HSV-2, herpes simplex virus type 2; 
IQR, interquartile range; SD, standard deviation; STI, sexually transmitted infection. 
a Measured at enrollment into acute HIV infection cohort. 
b Any sexually transmitted disease, defined as testing positive for Treponema pallidum, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, 
Mycoplasma genitalium, or HSV-2 polymerase chain reaction. 
 
conservatively defined it as 2 consecutive CD4 counts <350 cells/ 
µL between 6 months (to exclude seroconversion decline) and 24 
months postinfection. Non–rapid progressors (NRPs) were those 
maintaining a CD4 count >350 cells/µL beyond 24 months. Base- 
line differences between rapid progressors (RPs) and NRPs were 
assessed by Wilcoxon rank-sum and Fisher exact tests. Cox pro- 
portional hazards regression modeling was used to assess predic- 
tors of rapid progression. Participants who did not progress 
rapidly were censored at their last follow-up visit or 24 months 
postinfection, whichever came first. Predictors in the unadjusted 
model with P values <.20, or deemed important, were included in 
the adjusted model. Statistical analysis was performed using SAS 
software, version 9.3 (SAS Institute Inc., Cary, North Carolina); 




Baseline Characteristics of the Cohort 
Of the 245 HIV-negative women followed up monthly for 
4 years, 35 (14.3%) acquired HIV. The 594 HIV-negative 
women followed quarterly from seroincidence cohorts yielded 
39 HIV seroconversions; 27 of these women consented to fur- 
ther follow-up. HIV incidence rates were similar between co- 
horts (6.5/100 person-years [95% confidence interval {CI}, 
4.6–8.9] for the N = 594 women and 7.2/100 person-years 
[95% CI, 4.5–9.8] for the N = 245 women) [29], and the cohorts 
had minimal influence on progression rates (hazard ratio [HR], 
0.61 [95% CI, .29–1.32]; P = .209). Of the 62 HIV infections, 
17 (27%) were diagnosed before seroconversion. The median 
time from estimated date of infection to first HIV-positive 
sample was 42 days (interquartile range [IQR], 34–59 days). 
Demographic, behavioral, and clinical characteristics of these 
women are summarized in Table 1. The median age at HIV in- 
fection was 25 years (IQR, 21–33 years), and most women 
(71.0%) were either married or had a stable partner. At enroll- 
ment into the acute HIV infection cohort, STIs were common 
(44.3%), and most women (91.9%) were seropositive for herpes 
simplex virus type 2 (HSV-2). The overall mean CD4 count at 
this first postseroconversion timepoint was 520 cells/µL. This 
was significantly lower than the preinfection CD4 counts 
 

















































































Figure 1.  Superimposed Kaplan–Meier graphs of time to CD4 count <200, <350, and <500 cells/µL since estimated date of infection. Abbreviations: CI, 
confidence interval; IR, incidence rate; PY, person-years. 
 
 
(mean CD4 count, 993 cells/µL available for 25 of 62 women; 
P < .001). The CD4 counts differed significantly between RPs 
and NRPs (413 vs 603 cells/µL; P < .001; Table 1) at first post- 
seroconversion with a mean log VL of 4.62 log copies/mL 
(SD = 0.92) and higher levels in RPs than NRPs (4.96 vs 4.36 
log copies/mL; P = .009). 
 
Prospective Analysis 
A total of 282 person-years of ART-naive follow-up amongst 
participants not yet initiated on ART were observed, including 
a median of 33 CD4 count or VL measurements (range, 3–45) 
per participant. In the first 2 years of HIV infection, the median 
number of CD4 count measures for RP and NRP participants 
was 19 (IQR, 16–20) and 19 (IQR, 18–20), respectively. At 
the time of analysis, 17 of 62 women remained ART-naive 
and were an estimated 6.4 years postinfection (IQR, 5.9–7.1 
years) at their last follow-up visit. Of the remainder, 37 initiated 
ART, 5 died (2 HIV-related deaths), 2 were lost to follow-up 
( prior to ART initiation), and 1 declined study participation. 
Almost one-third (30.6%) reached a CD4 count of <350 cells/ 
µL within 6–12 months of infection, 43.5% within 24 months, 
and 54.8% within 36 months postinfection (Figure 1). Increas- 
ing the treatment threshold to CD4 count <500 cells/µL, in 
keeping with the 2013 consolidated World Health Organiza- 
tion (WHO) guidelines [30], would have resulted in 69.4% 
of women qualifying for treatment within 6–12 months post- 
infection, 79.0% within 24 months, and 80.6% within 36 
months. 
Rapid progressors lost 11.5 CD4
+
 cells/µL per month in the 
first year of infection, compared with NRPs who lost 6.1 CD4
+
 
cells/µL (P = .019). For the 25 women with available preinfection 
CD4 counts (mean, 993 cells/µL), this count dropped by 39.6% 
(SD, 20.25%) at 3 months and 46.7% (SD, 22.04%) at 6 months 
postinfection. Rapid progressors experienced a larger CD4 drop 
during acute infection (48.2% vs 30.2% from preinfection to se- 
roconversion; P = .023). There were no significant differences in 
 

























































































the preinfection CD4 counts between RPs and NRPs (mean CD4 
count, 960 cells/µL and 1029 cells/µL, respectively; P = .649) 
(Supplementary Figure 1). These data suggest that severe deple- 
tion of CD4 T cells in early infection is highly predictive of 
subsequent disease progression. 
 
Plasma Viral Loads as a Predictor of Rapid Disease Progression 
The mean of the first available VL in this cohort (including the 
available preseroconversion RT-PCR results) was 4.83 log cop- 
ies/mL (SD, 1.10), at a median of 31 days postinfection (IQR, 
14–58 days), likely representing the decline following peak vire- 
mia. Mean VL dropped to 4.26 (SD, 0.91) and 4.20 (SD, 0.95) 
log copies/mL at 6 and 12 months, respectively, representing 
setpoint viremia. Viral loads were significantly higher in RPs 
than in NRPs, with a mean VL at 3 months postinfection of 
4.86 log copies/mL (SD, 0.62) compared with 4.13 log copies/ 
mL (SD, 0.86; P < .001). 
To further determine the impact of VL on disease progres- 
sion, we compared CD4 decline in participants with high VL, 
using a cutoff of 5 log copies/mL. Participants with higher VL 
at 3 months postinfection were more likely to reach a CD4 
count <350 cells/µL sooner (log-rank P < .001), compared 
with women with lower VL. At 24 months postinfection, 77% 
of those who had high VL at 3 months reached the endpoint, 
compared with 35% of the lower VL group. The median time 
to endpoint for those with high VL was 6.7 months from infec- 
tion compared with 34.6 months with a low VL (Figure 2). Sim- 
ilar results were obtained for VL at 6 months postinfection. The 
data for a CD4 count endpoint of <500 cells/µL were even more 
dramatic, with the probability of reaching the endpoint by 2 
 






































































Figure 3.  Time to first episode of clinical conditions from acute human immunodeficiency virus infection experienced by study participants. Circles 
represent participants and when they experienced the first episode of the corresponding clinical condition. 
 
 
years postinfection for those with high and low VL, reaching 
0.93 and 0.75, respectively. 
 
Timing of Clinical Conditions From Acute Infection 
The timing of the first presentation of clinical events during the 
acute phase and subsequent course of HIV infection is shown in 
Figure 3. Almost all participants experienced lymphadenopathy 
(98.4%), and many presented with upper respiratory tract infec- 
tion (38.7%), vaginal discharge (87.1%), and genital ulcer dis- 
ease (19.4%) during acute HIV infection. Whereas women 
presented with fungal infection and nonspecific skin rashes 
throughout the disease course, other infections such as shingles, 
lower respiratory tract infections, and tuberculosis were diag- 
nosed later during HIV infection. Aside from 2 participants 
who died of HIV-related diseases (tuberculosis and cryptococ- 
cal meningitis), there were no other AIDS-defining diagnoses in 
the cohort. Of 41 participants, who became eligible and were 
referred for ART during the study, 37 have so far initiated ART. 
 
Predictors of Rapid HIV Disease Progression 
In the unadjusted analysis, associations were noted between 
rapid progression and not having a regular partner (HR, 3.03 
[95% CI, 1.07–8.53]; P = .036), having ≥2 sexual partners in 
the 3 months prior to infection (HR, 2.06 [95% CI, .96–4.41]; 
P = .063), and being enrolled at the urban site (HR, 2.47 [95% 
CI, .85–7.14]; P = .096). CD4 count decline from pre–HIV in- 
fection (HR, 1.56 [95% CI, 1.12–2.17 per 10% decrease]; 
P = .008) and incident hepatitis B infection during the first 6 
months (HR, 8.98 [95% CI, 2.21–36.47]; P = .002) were also 
predictive of rapid disease progression. Notably, in the 3 cases 
of incident hepatitis B infection identified between HIV acqui- 
sition and 6 months postinfection, all rapidly progressed to a 
CD4 count <350 cells/µL. No associations were observed for 
age, education, sex worker status, or clinical data including a 
history of tuberculosis, body mass index, an abnormal full 
blood count result, or STIs at enrollment into the acute HIV in- 
fection cohort (Table 2). 
Overall, the best independent predictors of CD4 decline and 
rapid disease progression were CD4 count at 3 months (HR, 
2.07 [95% CI, 1.31–3.28 per 100 cells/µL decrease]; P = .002), 
VL during early infection (HR, 3.82 [95% CI, 1.51–9.67 per 
1-log increase]; P = .005), and hepatitis B infection at the time 
of HIV infection (HR, 4.54 [95% CI, 1.31–15.69]; P = .017). 
Conversely, the best predictors of non–rapid progression were 
any of the previously described protective HLA genotypes 
(B*1302, B*27, B*57, B*5801, B*8101), with an HR of 0.19 




The rate of HIV disease progression is highly variable, with im- 
portant implications for both clinical disease management and 
program planning. Previous studies have estimated that rapid 
HIV progression is relatively uncommon, using definitions of 
CD4 decline within 3 years [31]. Here, we show that nearly 
half of the clade C–infected women met our conservative defi- 
nition of rapid disease progression (CD4 decline to <350 cells/ 
 



















































Table 2. Predictors of Rapid Disease Progression Defined as CD4 Count <350 Cells/µL Within 2 Years of Infection 
 
Unadjusted Analysis Adjusted Analysisa 














Demographic and behavioral characteristics 
Age (per 5 y increase) 1.03 (.85–1.24) .761 0.82 (.55–1.21) .317 
Completed high school No 19/44 1.0 (Ref) 
Yes 8/18 1.09 (.48–2.49) .840 
 
Marital status Married or stable 16/44         1.0 (Ref)                  1.0 (Ref) 
partner 
Many partners 6/10 2.05 (.80–5.25) .135 0.19 (.03–1.42) .105 
No partner 5/8 3.03 (1.07–8.53) .036 0.22 (.03–1.64) .139 
Site Rural 4/16 1.0 (Ref) 1.0 (Ref) 
Urban 23/46 2.47 (.85–7.14) .096 2.09 (.41–10.63) .374 
No. of sexual partners in last 3 m 0–1 15/41 1.0 (Ref) 1.0 (Ref) 
≥2 12/19 2.06 (.96–4.41) .063 4.21 (.70–25.35) .117 
Condom at last sex act Yes 16/35 1.0 (Ref) 
No 11/27 0.84 (.39–1.82) .666 
Sex worker No 18/42 1.0 (Ref) 
Yes 9/20 1.07 (.48–2.39) .864 
Ever had anal sex No 21/53 1.0 (Ref) 1.0 (Ref) 
Yes 6/9 1.93 (.78–4.79) .157 0.91 (.23–3.57) .894 
Routine clinical and laboratory assessment 
 
Personal or family history of 
hypertension or diabetes 
No                        15/34         1.0 (Ref) 
 
Yes 12/28 0.93 (.44–1.99) .858 
Creatinine count at 3 mo postinfection 0.96 (.91–1.01) .087 0.97 (.91–1.04) .369 
History of tuberculosis No 26/57 1.0 (Ref) 
Yes 1/5 0.40 (.05–2.97) .373 
BMI at enrollment, kg/m
2 0.99 (.94–1.05) .823 
Hemoglobin at 3 mo, g/dL ≥12 15/31 1.0 (Ref) 
<12 12/31 0.72 (.33–1.53) .387 
Neutrophil count at 3 mo, ×10
9
/L ≥2.5 13/29 1.0 (Ref) 
<2.5 14/32 1.03 (.49–2.20) .932 
Platelets at 3 mo, ×10
9
/L 1.00 (.99–1.00) .692 
Elevated liver function tests at 3 mob No 22/51 1.0 (Ref) 
Yes 5/11 1.00 (.38–2.65) .993 
CD4
+ count decline from baseline 
(by 10% decrease) 
CD4
+ count at 3 mo (by 100 cells/µL 
decrease) 
Log viral load at 3 mo 
1.56 (1.12–2.17)   .008 
1.98 (1.43–2.74)  <.001 2.07 (1.31–3.28)   .002 
2.77 (1.63–4.70)  <.001 3.82 (1.51–9.67)   .005 
(by 1 log increase) 
Any STIc at enrollment No 16/34 1.0 (Ref) 
Yes 11/27 0.58 (.38–1.78) .621 
HBcAb status at enrollment Negative 11/31 1.0 (Ref) 1.0 (Ref) 
Positive 16/31 1.52 (.70–3.27) .287 4.54 (1.31–15.69) .017 
HBcAb status at 6 mo Remained negative 7/24 1.0 (Ref) 
Baseline positive 14/27 2.10 (.85–5.22) .109 
























































Table 2 continued. 
 
Unadjusted Analysis Adjusted Analysisa 















Protective HLA-B typesd No 24/47 1.0 (Ref) 1.0 (Ref) 
Yes 3/15 0.30 (.09–.99) .048 0.19 (.05–.74) .016 
Harmful HLA-B typesd No 18/43 1.0 (Ref) 
Yes 9/19 1.04 (.47–2.32) .922 
Abbreviations: BMI, body mass index; CI, confidence interval; HBcAb, hepatitis B core antibody; HLA, human leukocyte antigen; HR, hazard ratio; Ref, reference; 
STI, sexually transmitted infection. 
a Due to missing data, the adjusted analysis was performed on a total of 55 participants, with 26 events of rapid disease progression. 
b Elevated liver function tests defined as having alanine aminotransferase level >35 IU/L and/or aspartate aminotransferase level >35 IU/L. 
c Any sexually transmitted disease, defined as testing positive for Treponema pallidum, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, 
Mycoplasma genitalium, or herpes simplex virus type 2 polymerase chain reaction. 
d Protective HLA-B types are B*1302, B*27, B*57, B*5801, B*8101. Harmful HLA-B types are B*1801, B*35, B*5802. 
 
 
µL within 2 years of HIV-1 infection). Similar findings have 
been reported from Argentina where 26% of untreated acute 
HIV infections showed clinical or immunological progression 
within 12 months of infection [32]. The high proportion of 
women experiencing rapid disease progression suggests that 
this may be the dominant phenotype in the natural history of 
HIV-1 disease in our setting. This finding supports the argu- 
ment of starting ART early, especially in settings where the 
risk of coinfections such as tuberculosis is high. The 2013 
WHO guidelines suggest starting ART at a CD4 count of 
<500 cells/µL [30]. Here, we showed that nearly three-quarters 
of HIV-infected individuals will reach this threshold within 1 
year of infection. 
Preinfection CD4 counts in this population were similar to 
those in developed countries, with no association between prein- 
fection CD4 counts and disease progression rate. A striking find- 
ing in this study is the magnitude of CD4 cell depletion during 
acute HIV infection, with nearly half of preinfection CD4 cells 
lost within the first 6 months of HIV infection. We observed 
very little CD4 cell rebound after acute infection, in contrast to 
the modest and transient loss described in most published studies. 
The rate of CD4 cell loss in the rapid progressors is higher than 
that observed in other HIV-1 subtype C–infected cohorts [5]. 
We have previously shown in this cohort that the magnitude 
or breadth of T-cell recognition across the expressed genome at 
3 months had no association with viral setpoint at 12 months 
[33] and that recognition of more conserved epitopes in Gag 
tended to associate with slow disease progression in the first 
year of infection. This was in parallel with the accumulation 
of less differentiated Gag-specific CD8
+
 T memory cells by 6– 
9 months postinfection in individuals with lower viral setpoints 
[34]. It appeared that the higher setpoint induced a greater level 
of immune activation, which resulted in high T-cell turnover 
being directly proportional to the level of viremia [13, 35]. 
This study confirms the direct association of high VL with 
rapid CD4
+
 cell loss, which, in turn, is related to levels of 
T-cell activation [36]. Collectively, these data suggest that recog- 
nition of class I HLA–restricted variant epitopes and the late 
stage of CD8
+
 memory differentiation are concentrated in 
women with rapid disease progression. We have previously 
shown that the frequency of conserved HLA-B restricted epi- 
topes is more abundant in non–rapid progressors [37]. 
The long-term follow-up of this cohort enabled us to describe 
the trajectory of clinical signs and symptoms occurring in these 
women. STIs (genital ulcers and discharge) were common dur- 
ing early infection, whereas other infections such as varicella 
and tuberculosis occurred later. This is likely because the former 
are co-transmitted, or are the result of reduced mucosal barrier 
function as a result of CD4 loss, whereas the latter require more 
advanced immunodeficiency. Although this cohort showed 
rapid immunologic progression, there was little evidence of se- 
vere clinical disease or early AIDS-defining illnesses within the 
first 3 years of infection [32], compared with what has been ob- 
served in other cohorts. The most likely reason for this was the 
close follow-up of participants and prompt ART initiation prior 
to onset of AIDS. 
A limitation of this acute HIV-infected cohort is the relatively 
small sample size, albeit comparable to similar cohorts, and our 
findings may therefore not be generalizable outside our setting. 
Because this was a female cohort, caution would need to be ex- 
ercised when extrapolating these results on disease progression 
to the male population. 
The rapid progression observed in this cohort provides 
additional motivation to implement earlier ART initiation. 
 



















































Although this may present economic and operational challenges, 
the fact that half of individuals need ART in the first year of HIV 
infection provides compelling data for continued treatment roll- 
out. Long-term ART use will bring challenges of adherence and 
potential development of drug resistance, and require more 
health system strengthening to manage HIV as a chronic illness. 
Despite the challenges, this study suggests that earlier treatment 
initiation carries many benefits, including the potential for major 
impact on individual health by increasing survival and on public 
health by preventing transmission. The concept of “test and 
treat” might even be more pertinent in KwaZulu-Natal in 
South Africa, where we show that rapid disease progression in 
women is disturbingly common. Given the new WHO guidelines 
of ART initiation at a CD4 count of ≤500 cells/µL, more effort 
should be placed into diagnosing acute HIV infection to ensure 
that the large proportion of women requiring treatment within 
the first year of infection are not missed. 
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Supplementary Figure 1: Loess smoothing graphs and 95% confidence intervals of viral load and CD4 count in the first 24 months 


















Chapter 9:  Conclusions 
 
This dissertation described clinical, mucosal and systemic features associated with 
HIV infection and their relationship to disease progression in a population of women 
at high-risk for HIV infection. STIs and associated genital tract inflammatory 
cytokines were found to increase risk for HIV infection and only 12.4% of women 
who had a laboratory diagnosed STI presented with symptoms or had any clinical 
signs detected by the clinician. . Elevated cytokine signatures of genital inflammation 
were observed in both the symptomatic and asymptomatic women, signifying a 
similar risk for HIV infection. Of the STIs evaluated, the presence of Neisseria 
gonorrhoea in this cohort was the strongest predictor of subsequently becoming HIV 
infected. 
 
The HIV incidence in this cohort was 7.2/100 person-years (95%CI 4.5–9.8). In those 
women who became infected with HIV, 57% presented with at least one sign or 
symptom at seroconversion and the specificity and likelihood ratios increased with 
increasing number of reported symptoms. The most prevalent signs and symptoms 
reported at acute HIV infection visit were loss of appetite, headache, rash, sore throat, 
fever, arthralgia and reported weight loss. A risk score algorithm to enhance diagnosis 
of acute HIV infection was developed, using the variables significantly associated 
with AHI (rash, sore throat, weight loss, genital ulcers, vaginal discharge and age <25 
years).  
 
Genital tract inflammation around the time of acute HIV infection, CD4+ T cell  
count at 3 months post-infection (p = 0.002), viral load set-point  (p = 0.005) and 
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hepatitis B infection (p = 0.017) were found to influence the rate of disease 
progression . Most importantly, this study showed that almost a third of women who 
became infected, progressed to CD4+ T cell counts below 350 cells/ul within 6 
months of infection and over half were eligible for HAART within 2 years of 
infection. These findings of high rates of rapid disease progression in South African 
women highlights the importance of active identification of acute HIV infected 
individuals and subsequent care and early treatment initiation. The economic 
implications as well as the operational challenges associated with addressing these 
findings, especially in the current WHO recommendation of ART initiation at 500 
cells/ul, demand appropriate strategies for individual and public health benefits.  
 
9.1 Women at high-risk for HIV infection: A prospective cohort study  
A cohort of HIV-uninfected women was established in Durban, South Africa, in order 
to investigate clinical, immunological and virological factors that may play a role in 
HIV acquisition and disease progression in this population of high HIV prevalence 
(van Loggerenberg, Mlisana et al., 2008; 2012).  This cohort comprised 245 women 
who were 18 years or older (median age of 34 years), of whom more than 75% self-
identified as sex workers, had a high level of HIV/AIDS knowledge, and more than 
half reported regular condom use. It was interesting to note that choice to use 
condoms at their last sexual act varied depending on whether they were having sex 
with steady versus casual partners (57.0% versus 64.4%, p = 0.36), although their 
perceived ability to choose to use condoms was significantly lower with steady 
partners compared to casual partners (van Loggerenberg, Mlisana et al., 2012). In this 
cohort of high-risk HIV-uninfected women, the retention rate after 2 years of monthly 
follow-up visits was an acceptable 86.1%, with 28 new HIV-1 infections being 
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observed during 390 person-years of follow-up, resulting in an HIV incidence rate of 
7.2 (95% CI 4.5-9.8) per 100 person-years (van Loggerenberg, Mlisana et al., 2008). 
Having such intensive clinical follow-up from pre-infection time points, through to 
acute HIV infection and establishment of chronic phase of infection and determining 
viral set-point in the same individuals enabled very detailed laboratory studies in 
subsequent chapters on factors associated with increased risk for HIV infection, the 
natural history of HIV-1 subtype C infection across the spectrum ranging from acute 
to chronic phases of infection, and the high rate of rapid disease progression. 
9.2 Poor performance of syndromic management of STIs in settings of high 
risk for HIV infection  
Women with a laboratory-diagnosed STIs were at 3-fold increased risk of HIV 
infection. Chlamydia, gonorrhoea and M. genitalium, were each associated with 
increased risk of HIV acquisition, with gonorrhoea associated with highest risk 
(almost 5-fold). These findings confirm those of previous studies that have 
demonstrated associations between these STIs and HIV acquisition risk [1-3]. 
Although several studies have shown BV to be  associated with increased risk of HIV 
infection [4], it was interesting that no increased association was observed in this  
cohort study. It is possible that the sample size in this study and the high rates of co-
infections with other inflammatory STIs may have masked this phenomenon. The 
emerging microbiome research studies to identify and characterize the human vaginal 
microbial populations will hopefully aid in further determining the relationship of BV 
and HIV acquisition. Additionally, although genital ulcerative STIs have been found 
to be associated with increased HIV acquisition [5, 6], we found that women with 
clinical signs of STIs, including abnormal vaginal discharge and genital ulcers, were 
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not more susceptible to HIV-infection, although only a small proportion of women 
presented with ulcers in this study. 
Of the STIs assessed, chlamydia and gonorrhoea (which were both associated with 
increased HIV acquisition risk) were found to be the most inflammatory in this study, 
as indicated by up-regulated concentrations of multiple pro-inflammatory cytokines 
and chemokines. Trichomoniasis and HSV-2 reactivation were less inflammatory and 
BV was associated with up-regulated pro-inflammatory cytokines, but down-
regulated chemokines. Elevated genital inflammatory cytokines, including IL-1β, IL-
6, IL-8 and sCD40L, were also associated with increased risk of HIV acquisition. It 
has been suggested that inflammatory cytokine and chemokine up-regulation in the 
female genital tract may increase HIV acquisition risk by recruiting and activating 
HIV target cells, reducing epithelial barrier integrity and activating NF-kB.[[7-9] 
Although this suggests that underlying genital tract inflammation may be a biological 
mechanism for HIV transmission in women with STIs, it is also possible that the 
relationship between elevated inflammation and risk of HIV infection observed in this 
study was indirect. 
Despite the fact that some of the STIs were associated with high concentrations of 
inflammatory markers, most women with these infections did not have clinical signs. 
Importantly, genital tract inflammatory cytokine concentrations were similarly 
elevated in women who had symptomatic and asymptomatic laboratory-diagnosed 
STIs, relative to women who had no STIs, bacterial vaginosis, or symptoms. 
Although the prevalence and incidence of laboratory-diagnosed STIs in this cohort 
were high, only 12.3% of women who tested positive for at least one STI had visible 
clinical signs. As a result, 87.7% of STIs in this cohort of women, who were at high 
risk of HIV acquisition, would have been left untreated in a syndromic management 
125 
 
setting such as South Africa. The findings that clinically evident and syndromically 
managed STIs declined during follow-up while the prevalence of laboratory-
diagnosed STI remained relatively high confirms that syndromic management does 
not address subclinical STI infections, which may contribute to genital inflammation 
and risk of HIV infection. 
This study highlights the urgent need for better strategies to manage women with 
asymptomatic STIs, as infections such as chlamydia and gonorrhoea were found to 
have significantly elevated laboratory markers of genital inflammation, irrespective of 
absence of symptoms. This has important implications not only for HIV prevention 
strategies, but also for complications that are associated with untreated inflammatory 
STIs, including pelvic inflammatory diseases, ectopic pregnancy, and infertility [10]. 
The burden of asymptomatic STIs highlights the need for laboratory screening of, at 
least high risk populations; which would include men who have sex with men 
(MSMs), female sex-workers (FSWs), young adults in high HIV prevalence 
communities. Howell et al, has described enormous cost saving estimates and 
prevention of related morbidities associated with STI screening of young women in 
the USA, using the CDC criteria [11]. In South Africa, syndromic management of 
STIs alone, has been estimated to have attributed a  6.6% (3.3 – 10.3%) reduction of 
adult HIV incidence between 1994 and 2004 when syndromic management coverage 
was about 52% [3].  The public health gains that would be realised with national 
screening of high risk populations in SA would therefore far outweigh the cost 
thereof.  
Healthcare systems should include regular screening for STIs by means of laboratory 
testing in these groups rather than relying on symptoms only. The increased 
diagnostic power of PCR technology and the related potential to impact the risk of 
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HIV acquisition could outweigh its high costs. This strategy would lead to treatment 
of greater number of individuals with STIs, reducing prevalence and incidence. 
Another diagnostic approach in under-resourced areas would be to explore point-of-
care STI testing as an alternative to laboratory testing. Some of these point-of-care 
tests have proven to be sensitive diagnostic tools in clinical trials and would offer 
significant benefits in poorly resource settings with absent or limited access to larger 
STI  diagnostic  laboratories [12, 13]. Mathematical modelling of point of care testing 
for C. trachomatis and N. gonorrhoeae amongst just sex-workers in Sub-Saharan 
Africa, China and South-East Asia estimates that >16.5 mil new gonococcal and 
chlamydia infections as well as >212 000 HIV infections could be prevented over a 4 
year period by availability of such diagnostic tests and more than 4 million disability-
adjusted life years could be saved. There is a definite need to ensure that STIs are 
diagnosed in a timely fashion and managed comprehensively by educating individuals 
at risk for transmission and acquisition on how to reduce the risk; early recognition of 
signs and symptoms of infections; improving health seeking behaviour in 
asymptomatic and symptomatic individuals; effective management of those 
symptomatic individuals seeking care and effective management of sexual partners to 
include education and treatment. 
9.3 Challenges to diagnosis of acute HIV infection 
Being able to diagnosis acute HIV infection rapidly has broad benefits to both the 
individual and community so defining an algorithm to identify acute HIV infection 
(AHI) cases in resource limited settings would be enormously useful. Accurate 
recognition of signs and symptoms of acute HIV infection is critical for enhancing 
early diagnosis of HIV infection. Chapter 6 reported that 57% of all women reported 
at least one sign or symptom of AHI at the study visit post HIV infection. The factors 
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that were strongly predictive (from highest to lowest) of AHI were genital ulceration 
and vaginal discharge; skin rash, losing weight, younger age, or having a sore throat. 
These variables significantly predicted AHI and were used to construct a predictor 
risk score for AHI the regression coefficients from the final adjusted model (Mlisana 
et al., 2013). The signs and or symptoms in the model were weighted by the 
regression coefficients with the final risk score algorithm calculated as follows:  
Risk Score = 2 [skin rash] + 1 [sore throat] + 2 [loss of appetite] + 1 [weight] loss] + 
2 [vaginal discharge] + 2 [genital ulcer] + 1 [age <25 years] 
A proposed risk score of 2 correctly predicted AHI in 57% of cases, with the number 
of signs and symptoms correlating with higher plasma HIV-1 RNA at the time of 
diagnosis.  This algorithm enabled risk-stratifying of individuals for AHI especially in 
resource-limited settings where no or limited testing for AHI exists.  Although this 
panel of clinical symptoms or signs has been associated with AHI in several studies 
[14-16], HIV incidence in those studies was far less than 7.2/100 person-years seen in 
our cohort. Our study was the first to focus on HIV -1 subtype C infection in women, 
in South Africa. Whether these findings or such a scoring algorithm can be 
generalised to men presenting with AHI needs further exploring. 
 
 
9.4 Factors influencing rate of disease progression 
Sixty-two women were identified at a median of 42 days post-infection (interquartile 
range, 34–59), contributing 282 person-years of follow-up. Mean CD4 count dropped 
by 39.6% at 3 months and 46.7% at 6 months post-infection in women with pre-
infection measurements. CD4 decline to <350 cells/μl occurred in 31%, 44%, and 
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55% of women at 1, 2, and 3 years post-infection, respectively, and to <500 cells/μl in 
69%, 79%, and 81% at equivalent time points. Predictors of rapid progression were 
CD4 count at 3 months post infection, set point viral load, and hepatitis B co-
infection. Conversely, presence of any of HLAB*1302, B*27, B*57, B*5801, or 
B*8101 alleles predicted non–rapid progression. Nearly half of subtype C–infected 
women progressed to a CD4 count <350 cells/μl within 2 years of infection. 
Implementing 2013 World Health Organization treatment guidelines (CD4 count 
<500 cells/μl) would require most individuals to start antiretroviral therapy within 1 
year of HIV infection. A meta-analysis of trends in prognostic markers of HIV 
disease progression confirmed an increase in virulence of the virus over the epidemic 
course [17]. This analysis showed that a CD4+ T-cell trend of −4.93 cells/µl per year 
and viral RNA of 0.013 log10 copies/ml per year  reflect a loss of CD4+ T-cells of 
148 cells/µl and an increase of 0.39 log10 copies/ml RNA over the 30-year period of 
the HIV epidemic[17]. 
9.5 Limitations and Strengths of this study 
The small sample size of the cohort is the main limitation of this study and this was 
conducted in women and so limits the generalizability of the conclusions to other 
populations. However, it is still one of the first acute HIV infection cohorts in a 
subtype C HIV-1 infected population.  The socio-behavioural data collection relied on 
self-report and was therefore subject to reporting and recall bias. However, in an 
attempt to minimize reporting bias, the questions were constructed to be neutral and 
participants were assured of confidentiality. An independent validation of the acute 
HIV infection diagnostic algorithm on another cohort would be needed to further 
assess its utility. Point-of-care antigen or viral load technology is required to detect 
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asymptomatic, antibody negative cases enabling early interventions and prevention of 
transmission. 
This study presented the first prospective cohort to be assembled in southern Africa 
for a comprehensive analysis of the behavioural, clinical and immunological 
characteristics associated with acute HIV infection. The longitudinal design allowed 
for long follow up and therefore understanding of the natural history of HIV infection. 
This has led to a better understanding of risk factors for HIV acquisition; subtype-C 
pathogenesis and disease progression. It is one of the few cohorts with pre-HIV 
infection, seroconversion as well as post-infection data on a significant percentage of 
the studied population. 
9.6  Final conclusion 
This work highlights key points with regards to HIV-1 subtype C infections in South 
African women. 
 The feasibility of establishing cohorts of high risk HIV-1 uninfected women 
with high retention rates and intensive follow-up could be established, 
notwithstanding the challenges with screening and recruitment in high 
prevalence settings. A major contribution of this cohort was the follow-up of 
HIV uninfected to AHI to established infection.  Such cohorts are critical for 
understanding host and viral dynamics for HIV prevention, treatment and 
vaccine research. 
 Sexually transmitted infections, whether symptomatic or not, increase the risk 
of HIV acquisition and transmission. The burden of asymptomatic STIs needs 
to be urgently addressed by screening high risk populations as well as 
130 
 
identifying simple and affordable point-of-care tests especially for gonococcal 
and chlamydial infections. 
 Genital inflammation in females, occurs in asymptomatic sexually transmitted 
infections as well, with similar consequences of HIV risk. Chlamydia 
trachomatis infection was associated with the highest genital cytokine levels, 
followed by Neisseria gonorrhoea, HSV-2, Trichomonas vaginalis and 
bacterial vaginosis. 
 Acute HIV seroconversion syndrome is seen in a significant percentage of 
individuals in resource limited countries, and therefore, clinicians need to have 
an increased index of suspicion to identify these. Further studies are needed to 
evaluate the proposed clinical scoring algorithm for use in poorly resourced 
regions with high prevalence of HIV to identify acute infections. 
 Genital inflammation during early HIV-1 infection was associated with higher 
viral load set-point and CD4 depletion. CD4 counts at 3 months post-infection, 
viral load set-point and Hepatitis B co-infection were predictors of rapid 
progression in this cohort. Nearly half of these subtype C infected women 
progressed to a CD4 count <350 within 2 years of infection and with the 
imminent increase of ART initiation at <500 cells/µL, following WHO 
recommendations, will see the majority of South African women requiring 
ART within 1 year of HIV infection. 
 
Additional important questions that are raised by these findings, that provide avenues 
for future research to include: 
 The role of the genital microbiome in shaping inflammatory cytokine 
signatures and contributing to HIV acquisition risk; 
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• A clearer understanding of why certain genital tract infections are associated 
with specific cytokine signatures and how such signatures relate to 
susceptibility to HIV acquisition; 
• Whether these cytokine signatures could be used in developing alternative 
rapid diagnostic assays for STI diagnosis, particularly in high risk 
asymptomatic patients.  
 It is important that future research should determine the impact of improved 
STI diagnosis and treatment on HIV acquisition and transmission as well as 
the impact of early antiretroviral therapy on clinical outcomes in HIV subtype 
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